0002014596-25-000022.txt : 20250507 0002014596-25-000022.hdr.sgml : 20250507 20250507164901 ACCESSION NUMBER: 0002014596-25-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Concentra Group Holdings Parent, Inc. CENTRAL INDEX KEY: 0002014596 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 301006613 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-42188 FILM NUMBER: 25922232 BUSINESS ADDRESS: STREET 1: C/O SELECT MEDICAL CORPORATION STREET 2: 5080 SPECTRUM DRIVE, SUITE 1200W CITY: ADDISON STATE: TX ZIP: 75001 BUSINESS PHONE: (972) 364-8000 MAIL ADDRESS: STREET 1: C/O SELECT MEDICAL CORPORATION STREET 2: 5080 SPECTRUM DRIVE, SUITE 1200W CITY: ADDISON STATE: TX ZIP: 75001 10-Q 1 cghp-20250331.htm 10-Q cghp-20250331
0002014596false12/312025Q1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharescghp:health_centercghp:statecghp:cliniccghp:less_than_wholly_owned_subsidiaryxbrli:purecghp:patientcghp:class_action_lawsuitcghp:segmentcghp:hospital00020145962025-01-012025-03-3100020145962025-04-3000020145962025-03-3100020145962024-12-3100020145962024-01-012024-03-310002014596us-gaap:RelatedPartyMember2025-01-012025-03-310002014596us-gaap:RelatedPartyMember2024-01-012024-03-310002014596us-gaap:CommonStockMember2024-12-310002014596us-gaap:AdditionalPaidInCapitalMember2024-12-310002014596us-gaap:RetainedEarningsMember2024-12-310002014596us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310002014596us-gaap:ParentMember2024-12-310002014596us-gaap:NoncontrollingInterestMember2024-12-310002014596us-gaap:RetainedEarningsMember2025-01-012025-03-310002014596us-gaap:ParentMember2025-01-012025-03-310002014596us-gaap:NoncontrollingInterestMember2025-01-012025-03-310002014596us-gaap:CommonStockMember2025-01-012025-03-310002014596us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310002014596us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002014596us-gaap:CommonStockMember2025-03-310002014596us-gaap:AdditionalPaidInCapitalMember2025-03-310002014596us-gaap:RetainedEarningsMember2025-03-310002014596us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310002014596us-gaap:ParentMember2025-03-310002014596us-gaap:NoncontrollingInterestMember2025-03-310002014596us-gaap:MemberUnitsMember2023-12-310002014596us-gaap:RetainedEarningsMember2023-12-310002014596us-gaap:ParentMember2023-12-310002014596us-gaap:NoncontrollingInterestMember2023-12-3100020145962023-12-310002014596us-gaap:RetainedEarningsMember2024-01-012024-03-310002014596us-gaap:ParentMember2024-01-012024-03-310002014596us-gaap:NoncontrollingInterestMember2024-01-012024-03-310002014596us-gaap:MemberUnitsMember2024-01-012024-03-310002014596us-gaap:CommonStockMember2024-01-012024-03-310002014596us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310002014596us-gaap:CommonStockMember2024-03-310002014596us-gaap:AdditionalPaidInCapitalMember2024-03-310002014596us-gaap:RetainedEarningsMember2024-03-310002014596us-gaap:ParentMember2024-03-310002014596us-gaap:NoncontrollingInterestMember2024-03-3100020145962024-03-310002014596us-gaap:NonrelatedPartyMember2025-01-012025-03-310002014596us-gaap:NonrelatedPartyMember2024-01-012024-03-310002014596cghp:OccupationalHealthCentersMember2025-03-310002014596cghp:OnsiteHealthClinicsMember2025-03-310002014596cghp:ConcentraGroupHoldingsParentMembercghp:SelectMedicalCorporationMember2024-11-252024-11-250002014596us-gaap:SwapMember2025-01-012025-03-310002014596cghp:CollarMember2025-01-012025-03-310002014596us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310002014596us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310002014596us-gaap:RelatedPartyMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310002014596us-gaap:RelatedPartyMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310002014596cghp:A6.875SeniorNotesDueJuly152032Memberus-gaap:SeniorNotesMember2025-03-310002014596us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-03-310002014596cghp:TermLoanMemberus-gaap:SecuredDebtMember2025-03-310002014596us-gaap:NotesPayableOtherPayablesMember2025-03-310002014596cghp:A6.875SeniorNotesDueJuly152032Memberus-gaap:SeniorNotesMember2024-12-310002014596cghp:TermLoanMemberus-gaap:SecuredDebtMember2024-12-310002014596us-gaap:NotesPayableOtherPayablesMember2024-12-310002014596us-gaap:SecuredDebtMember2024-07-260002014596us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-07-260002014596us-gaap:StandbyLettersOfCreditMemberus-gaap:LineOfCreditMember2024-07-260002014596cghp:ConcentraRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-03-012025-03-310002014596cghp:ConcentraRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-02-280002014596cghp:ConcentraRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-03-310002014596cghp:ConcentraRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-02-282025-02-280002014596cghp:ConcentraTermLoanMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2025-03-012025-03-310002014596cghp:ConcentraTermLoanMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2025-03-310002014596cghp:ConcentraRevolvingCreditFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2025-02-282025-02-280002014596cghp:ConcentraRevolvingCreditFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2025-03-012025-03-310002014596cghp:ConcentraRevolvingCreditFacilityMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2025-03-310002014596cghp:ConcentraCreditFacilitiesMemberus-gaap:LineOfCreditMember2024-07-262024-07-260002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherCurrentAssetsMember2025-03-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherCurrentAssetsMember2025-03-310002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherCurrentAssetsMember2024-12-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherCurrentAssetsMember2024-12-310002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2025-03-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2025-03-310002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:SwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherCurrentLiabilitiesMember2025-03-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherCurrentLiabilitiesMember2025-03-310002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherCurrentLiabilitiesMember2024-12-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherCurrentLiabilitiesMember2024-12-310002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherNoncurrentLiabilitiesMember2025-03-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherNoncurrentLiabilitiesMember2025-03-310002014596us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310002014596us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310002014596us-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Membercghp:CollarMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LineOfCreditMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LineOfCreditMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LineOfCreditMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LineOfCreditMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310002014596cghp:OccupationalHealthCenterWorkersCompensationMember2025-01-012025-03-310002014596cghp:OccupationalHealthCenterWorkersCompensationMember2024-01-012024-03-310002014596cghp:OccupationalHealthCenterEmployerServicesMember2025-01-012025-03-310002014596cghp:OccupationalHealthCenterEmployerServicesMember2024-01-012024-03-310002014596cghp:OccupationalHealthCenterConsumerHealthMember2025-01-012025-03-310002014596cghp:OccupationalHealthCenterConsumerHealthMember2024-01-012024-03-310002014596cghp:OccupationalHealthCenterOtherMember2025-01-012025-03-310002014596cghp:OccupationalHealthCenterOtherMember2024-01-012024-03-310002014596cghp:OccupationalHealthCenterMember2025-01-012025-03-310002014596cghp:OccupationalHealthCenterMember2024-01-012024-03-310002014596cghp:OnsiteHealthClinicsMember2025-01-012025-03-310002014596cghp:OnsiteHealthClinicsMember2024-01-012024-03-310002014596cghp:OtherBusinessesMember2025-01-012025-03-310002014596cghp:OtherBusinessesMember2024-01-012024-03-310002014596us-gaap:ProfessionalMalpracticeLiabilityMember2025-01-012025-03-3100020145962024-02-2900020145962025-03-012025-03-310002014596cghp:ReportableSegmentMember2025-01-012025-03-310002014596cghp:ReportableSegmentMember2024-01-012024-03-310002014596us-gaap:RelatedPartyMembercghp:ReportableSegmentMember2025-01-012025-03-310002014596us-gaap:RelatedPartyMembercghp:ReportableSegmentMember2024-01-012024-03-310002014596cghp:NovaAcquisitionMember2025-03-012025-03-010002014596cghp:NovaMedicalCentersMember2025-03-012025-03-010002014596cghp:NovaMedicalCentersMember2025-03-0100020145962025-03-012025-03-0100020145962025-03-010002014596cghp:NovaAcquisitionMember2025-03-010002014596cghp:NovaAcquisitionMember2025-03-012025-03-310002014596cghp:NovaAcquisitionMember2025-01-012025-03-310002014596cghp:NovaAcquisitionMember2024-01-012024-03-310002014596us-gaap:SwapMember2025-03-310002014596cghp:CollarMember2025-03-310002014596us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310002014596us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-03-310002014596us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-03-310002014596us-gaap:SwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002014596cghp:CollarMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002014596us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002014596us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002014596cghp:OnsiteInnovationsAcquisitionMemberus-gaap:SubsequentEventMember2025-04-182025-04-180002014596us-gaap:SubsequentEventMembercghp:OnsiteInnovationsMember2025-04-182025-04-180002014596us-gaap:SubsequentEventMembercghp:OnsiteInnovationsMember2025-04-180002014596us-gaap:SubsequentEventMember2025-04-182025-04-180002014596us-gaap:SubsequentEventMember2025-05-062025-05-06


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Quarterly Period Ended March 31, 2025
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from              to              
Commission file numbers: 001-42188
 
CONCENTRA GROUP HOLDINGS PARENT, INC.
(Exact name of Registrant as specified in its Charter)
Delaware30-1006613
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number)
 
5080 Spectrum Drive, Suite 1200W
Addison, TX 75001
(Address of Principal Executive Offices and Zip code)
(972) 364-8000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCONNew York Stock Exchange
(NYSE)
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒  No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).   Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☐
 Emerging Growth Company☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒
As of April 30, 2025, Concentra Group Holdings Parent, Inc. had outstanding 128,171,952 shares of common stock.
Unless the context indicates otherwise, any reference in this report to “Concentra” refers to Concentra Group Holdings Parent, Inc. and its subsidiaries. References to the “Company,” “we,” “us,” and “our” refer collectively to Concentra and its subsidiaries.



TABLE OF CONTENTS
 

Page
   
 
 
 
 
 
   


PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CONCENTRA GROUP HOLDINGS PARENT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except par value and share data)

March 31, 2025December 31, 2024
ASSETS 
Current assets: 
Cash$52,109 $183,255 
Accounts receivable258,128 217,719 
Prepaid income taxes1,392 1,544 
Other current assets39,960 34,689 
Total current assets351,589 437,207 
Operating lease right-of-use assets463,032 435,595 
Property and equipment, net207,271 197,930 
Goodwill1,444,563 1,234,707 
Other identifiable intangible assets, net249,788 204,725 
Other assets12,995 11,000 
Total assets$2,729,238 $2,521,164 
LIABILITIES AND EQUITY 
Current liabilities: 
Current operating lease liabilities$96,301 $75,442 
Current portion of long-term debt and notes payable15,758 10,093 
Accounts payable35,188 19,752 
Dividends payable
8,010 — 
Accrued and other liabilities165,134 201,899 
Total current liabilities320,391 307,186 
Non-current operating lease liabilities405,914 396,914 
Long-term debt, net of current portion1,618,473 1,468,917 
Non-current deferred tax liability24,362 25,380 
Other non-current liabilities29,037 24,043 
Total liabilities2,398,177 2,222,440 
Commitments and contingencies (Note 12)
Redeemable non-controlling interests18,609 18,013 
Stockholders’ equity: 
Common stock, $0.01 par value, 700,000,000 shares authorized, 128,171,952 and 128,125,952 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively
1,282 1,281 
Capital in excess of par263,105 260,837 
Retained earnings44,454 13,553 
Accumulated other comprehensive loss
(1,722)— 
Total stockholders’ equity307,119 275,671 
Non-controlling interests5,333 5,040 
Total equity312,452 280,711 
Total liabilities and equity$2,729,238 $2,521,164 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3


CONCENTRA GROUP HOLDINGS PARENT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands)
 For the Three Months Ended March 31,
 20252024
Revenue$500,752 $467,598 
Costs and expenses:
Cost of services, exclusive of depreciation and amortization357,101 336,990 
General and administrative, exclusive of depreciation and amortization(1)
46,713 36,909 
Depreciation and amortization16,619 18,485 
Total costs and expenses420,433 392,384 
Other operating income— 284 
Income from operations80,319 75,498 
Other income and expense:
Loss on early retirement of debt(875)— 
Interest expense(25,548)(111)
Interest expense on related party debt— (9,971)
Income before income taxes53,896 65,416 
Income tax expense13,254 15,137 
Net income40,642 50,279 
Less: net income attributable to non-controlling interests1,731 1,323 
Net income attributable to the Company$38,911 $48,956 
Earnings per common share (Note 10):
Basic and diluted$0.30 $0.47 
____________________________________________
(1)    Includes transaction services agreement fees of $3.7 million for the three months ended March 31, 2025, and shared service fees from a related party of $3.8 million for the three months ended March 31, 2024. See Note 11—“Relationship with Select”, for additional information.

The accompanying notes are an integral part of these condensed consolidated financial statements.
4

CONCENTRA GROUP HOLDINGS PARENT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(in thousands)
 For the Three Months Ended March 31,
 20252024
Net income
$40,642 $50,279 
Other comprehensive loss, net of tax:
Loss on derivatives
(1,808)— 
Reclassification adjustment for gains included in net income
86 — 
Net change, net of tax benefit of $574 for the three months ended March 31, 2025
(1,722)— 
Comprehensive income
38,920 50,279 
Less: comprehensive income attributable to non-controlling interests
1,731 1,323 
Comprehensive income attributable to the Company
$37,189 $48,956 

The accompanying notes are an integral part of these condensed consolidated financial statements.
5

CONCENTRA GROUP HOLDINGS PARENT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(in thousands, except per share amounts)

For the Three Months Ended March 31, 2025
 Common Stock IssuedCommon Stock Par ValueCapital in excess of parRetained
Earnings
Accumulated Other Comprehensive Loss
Total Stockholders’ EquityNon-controlling
Interests		Total
Equity
Balance at December 31, 2024128,126 $1,281 $260,837 $13,553 $— $275,671 $5,040 $280,711 
Net income attributable to the Company38,911 38,911 38,911 
Net income attributable to non-controlling interests— 293 293 
Cash dividends declared for common shareholders ($0.0625 per share)
(8,010)(8,010)(8,010)
Issuance of restricted stock46 1 (1)— — 
Stock compensation expense2,269 2,269 2,269 
Other comprehensive loss
(1,722)(1,722)(1,722)
Balance at March 31, 2025
128,172 $1,282 $263,105 $44,454 $(1,722)$307,119 $5,333 $312,452 

For the Three Months Ended March 31, 2024
 Total Members’ UnitsMembers’ Contributed CapitalCommon Stock IssuedCommon Stock Par ValueCapital in excess of parRetained
Earnings		Total Stockholders’ EquityNon-controlling
Interests		Total
Equity
Balance at December 31, 2023447,081 $470,303 — $— $— $685,293 $1,155,596 $5,366 $1,160,962 
Net income attributable to the Company48,956 48,956 48,956 
Net income attributable to non-controlling interests— 270 270 
Distribution to Parent(6,891)(6,891)(6,891)
Distributions to and purchases of non-controlling interests— (369)(369)
Redemption value adjustment on non-controlling interests(1,901)(1,901)(1,901)
Conversion of LLC to Corporation and impact of reverse stock split(447,081)(463,412)104,094 1,041 462,371 — — 
Balance at March 31, 2024
— $— 104,094 $1,041 $462,371 $732,348 $1,195,760 $5,267 $1,201,027 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

CONCENTRA GROUP HOLDINGS PARENT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands)

 For the Three Months Ended March 31,
 20252024
Operating activities  
Net income$40,642 $50,279 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization16,619 18,485 
Loss on extinguishment of debt
51 — 
(Gain) loss on sale of assets
(1)43 
Stock compensation expense2,269 166 
Amortization of debt discount and issuance costs976 — 
Deferred income taxes(1,028)(2,521)
Other11 12 
Changes in operating assets and liabilities, net of effects of business combinations:  
Accounts receivable(21,145)(13,505)
Other current assets(2,753)(7,315)
Other assets902 722 
Accounts payable and accrued liabilities(24,844)(1,744)
Net cash provided by operating activities11,699 44,622 
Investing activities  
Business combinations, net of cash acquired(279,018)(5,144)
Purchases of property and equipment(15,732)(17,231)
Proceeds from sale of assets1 23 
Net cash used in investing activities(294,749)(22,352)
Financing activities  
Borrowings on revolving facilities50,000 — 
Borrowings from related party revolving promissory note— 10,000 
Payments on related party revolving promissory note— (10,000)
Proceeds from term loans, net of issuance costs948,848 — 
Payments on term loans(847,875)— 
Borrowings of other debt6,468 6,618 
Principal payments on other debt(4,695)(2,276)
Distributions to and purchases of non-controlling interests(842)(1,543)
Distributions to Select
— (6,891)
Net cash provided by (used in) financing activities
151,904 (4,092)
Net (decrease) increase in cash
(131,146)18,178 
Cash at beginning of period183,255 31,374 
Cash at end of period$52,109 $49,552 
Supplemental information  
Cash paid for interest$38,137 $9,958 
Cash (refund received) paid for taxes$(48)$34 

The accompanying notes are an integral part of these condensed consolidated financial statements.
7

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1.    Organization
Concentra Group Holdings Parent, Inc., a Delaware corporation, conducts substantially all of its business through Concentra Health Services, Inc. (“CHSI”) and its subsidiaries. As the context may require, the “Company,” “we,” “our” or similar words in this report refer collectively to Concentra and its subsidiaries.
The Company is the largest provider of occupational health services in the United States based on number of locations. As of March 31, 2025, we operated 627 stand-alone occupational health centers in 41 states and 160 onsite health clinics at employer worksites in 36 states. The Company provides a diverse and comprehensive array of occupational health services, including workers’ compensation and employers services, and consumer health services.
2.    Accounting Policies
Basis of Presentation and Consolidation
The Company operated as part of Select Medical Corporation (“Select”) until Select made a special stock distribution of 104,093,503 shares of the Company’s common stock to Select’s stockholders (the “Distribution”) on November 25, 2024. The Company’s consolidated financial statements prior to the Distribution have been prepared from Select’s historical accounting records and derived from the condensed consolidated financial statements of Select to present the Company as if it had been operating on a standalone basis. The unaudited condensed consolidated financial statements of the Company as of March 31, 2025, and for the three months ended March 31, 2025 and 2024, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods.
The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the full fiscal year ended December 31, 2025. These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (File No. 001-42188).
The condensed consolidated financial statements include the assets, liabilities, revenue, and expenses based on our legal entity structure as well as direct and indirect costs that are attributable to our operations. Indirect costs are the costs of support functions that are partially provided on a centralized basis by Select and its affiliates, which include finance, human resources, benefits administration, procurement support, information technology, legal, corporate governance and other professional services. Indirect costs were allocated to the Company, prior to the IPO, for the purposes of preparing the consolidated financial statements based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method, primarily based on headcount or other allocation methodologies that are considered to be a reasonable reflection of the utilization of services provided or the benefit received by the Company during the periods presented, depending on the nature of the services received. Subsequent to the IPO, the support services provided by Select have been billed to the Company pursuant to a transitional services agreement, as further described in Note 11—“Relationship with Select”.
The income tax amounts in these condensed consolidated financial statements prior to the Distribution have been calculated based on a separate return methodology and are presented as if our income gave rise to separate federal and state consolidated income tax return filing obligations in the respective jurisdictions in which we operate. Adjustments to income tax expense resulting from the application of the separate return methodology, as compared to tax obligations determined by the Company’s inclusion in Select’s consolidated income tax provision, were assumed to be immediately settled with Select through contributed capital/capital in excess of par as reflected on the condensed consolidated balance sheets, and reflected as a (distribution)/contribution to Select on the condensed consolidated statements of changes in stockholders’/members’ equity and the condensed consolidated statements of cash flows within financing activities.
8

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
The condensed consolidated financial statements include the accounts of the Company and the subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions within the Company are eliminated in consolidation. Transactions between the Company and Select have been included in these condensed consolidated financial statements. The transactions with Select are settled in cash, other than the assumed income tax settlement noted above, and are reflected within the condensed consolidated statement of cash flows as an operating or financing activity determined by the nature of the transaction.
Derivatives and Hedging
The Company is exposed to certain risks relating to its ongoing financial arrangements. The primary risk managed using derivative instruments is to reduce variability in interest cash flows on its variable-rate debt. Interest rate swaps and collars are entered into to manage interest rate risk associated with the Company’s variable-rate debt. As a matter of policy, we do not use highly leveraged derivative instruments, nor do we use financial instruments for speculative purposes.
ASC 815 requires entities to recognize all derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship.
Our designated derivative contracts include interest rate swap and collar agreements, which effectively modify the Company’s exposure to interest rate risk by converting the Company’s floating-rate debt to a fixed-rate basis (for interest rate swap arrangements) and capping and flooring the interest rates (for collar arrangements) for the next three years, thus reducing the impact of interest-rate changes on future interest expense. These agreements involve the receipt of floating-rate amounts in exchange of fixed-rate interest payments and the application of cap and floor rates over the term of the agreements without an exchange of the underlying principal amount.
Our derivatives are designated as cash flow hedges and qualify for hedge accounting treatment. Gains or losses on cash flow hedges are deferred as a component of accumulated other comprehensive income or losses and reclassified into earnings at the time the hedged item affects earnings, presented in the same income statement line item as the underlying hedged item (i.e., in “interest expense” when the hedged transactions are interest cash flows associated with floating-rate debt).
To qualify for hedge accounting, a specified level of hedge effectiveness between the hedging instrument and the hedged item must be achieved at inception and maintained throughout the hedged period. We formally document our risk management objectives, our strategies for undertaking the hedge transactions, the nature of and relationships between the hedging instruments and hedged items, and the method for assessing hedge effectiveness. Additionally, for qualified hedges of forecasted transactions, we specifically identify the significant characteristics and expected terms of the forecasted transactions.
If it becomes probable that a forecasted transaction will not occur, previously deferred gains and losses related to those forecasted transactions would be recognized in earnings in the current period.
Recent Accounting Guidance Not Yet Adopted
Income Taxes
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.
The ASU is effective for the Company’s annual financial statements for the year ended December 31, 2025. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have on the disclosures in our consolidated financial statements.
Expense Disaggregation
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which is intended to improve the disclosures of expenses by providing more
9

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
detailed information about the types of expenses in commonly presented expense captions. The ASU requires entities to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption; as well as a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendment also requires disclosure of the total amount of selling expense and, in annual reporting periods, an entity’s definition of selling expenses.
The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2024-03 will have on the disclosures in our consolidated financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.
3.    Redeemable Non-Controlling Interests
The Company’s redeemable non-controlling interests are comprised of membership interests held by equity holders other than the Company in five less than wholly-owned subsidiaries. These shares are subject to redemption rights. The changes in redeemable non-controlling interests are as follows:
20252024
(in thousands)
Balance as of January 1$18,013 $16,477 
Net income attributable to redeemable non-controlling interests1,438 1,053 
Distributions to redeemable non-controlling interests
(842)(1,174)
Redemption value adjustment on redeemable non-controlling interests— 1,901 
Balance as of March 31$18,609 $18,257 
4.    Variable Interest Entities
Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices that directly employ physicians and from exercising control over medical decisions by physicians. In these states, the Company enters into long-term management agreements with affiliated professional medical groups (referred to as “Managed PCs”) that are owned by licensed physicians which, in turn, employ or contract with physicians who provide professional medical services in its occupational health centers. The Company also enters into a stock transfer restriction agreement with the respective equity holders, which provide for the Company to direct the transfer of ownership of the Managed PCs to other licensed physicians at any time. The long-term management agreements provide for various administrative and management services to be provided by the Company to the Managed PCs, including, but not limited to, billing and collections, accounting, non-physician personnel, supplies, security and maintenance, and insurance. The Company has the right to receive income as an ongoing management fee, and effectively absorbs all of the residual interests of the Managed PCs. Based on the provisions of the management and stock transfer agreements, the Managed PCs are variable interest entities for which the Company is the primary beneficiary and consolidates the Managed PCs under the variable interest entity model. There are no restrictions on the use of the assets of the Managed PCs or on the settlement of its liabilities. Additionally, the Company fully indemnifies the licensed physician owners from all claims, demands, costs, damages, losses, liabilities, and other amounts arising from the ownership and operation of the medical practices, excluding gross negligence.
As of March 31, 2025, and December 31, 2024, the total assets of the Company’s variable interest entities were $235.3 million and $213.9 million, respectively, and are principally comprised of accounts receivable. As of March 31, 2025, and December 31, 2024, the total liabilities of the Company’s variable interest entities were $51.8 million and $57.5 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of $180.9 million and $157.0 million as of March 31, 2025, and December 31, 2024, respectively. These intercompany balances are eliminated in consolidation.
10

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
5.    Leases
The Company’s total lease cost is as follows:
Three Months Ended March 31,
20252024
(in thousands)
Operating lease cost$27,317 $24,790 
Finance lease cost:
Amortization of right-of-use assets58 211 
Interest on lease liabilities(2)55 
Variable lease cost5,615 5,256 
Total lease cost$32,988 $30,312 
6.     Long-Term Debt
As of March 31, 2025, the Company’s long-term debt is as follows:
 Principal OutstandingUnamortized Premium (Discount)Unamortized Issuance CostsCarrying Value
(in thousands)
6.875% senior notes
$650,000 $— $(11,533)$638,467 
Credit facilities:
Revolving Credit Facility
50,000 — — 50,000 
Term Loan
950,000 (956)(12,126)936,918 
Other debt(1)
8,846 — — 8,846 
Total debt$1,658,846 $(956)$(23,659)$1,634,231 
____________________________________________
(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.
As of March 31, 2025, principal maturities of the Company’s long-term debt and notes payable are as follows:
 20252026202720282029ThereafterTotal
(in thousands)
6.875% senior notes
$— $— $— $— $— $650,000 $650,000 
Credit facilities:
Revolving Credit Facility
— — — — 50,000 — 50,000 
Term Loan
7,125 9,500 9,500 9,500 9,500 904,875 950,000 
Other debt, including finance leases5,369 1,311 467 483 151 1,065 8,846 
Total debt$12,494 $10,811 $9,967 $9,983 $59,651 $1,555,940 $1,658,846 
11

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
As of December 31, 2024, the Company’s long-term debt and notes payable are as follows:
 Principal OutstandingUnamortized Premium (Discount)Unamortized Issuance CostsCarrying Value
(in thousands)
6.875% senior notes
$650,000 $— $(11,925)$638,075 
Credit facilities:
Term Loan
847,875 (995)(11,468)835,412 
Other debt(1)
5,523 — — 5,523 
Total debt$1,503,398 $(995)$(23,393)$1,479,010 
____________________________________________
(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.
Credit Facilities
On July 26, 2024, Concentra Health Services, Inc. (“CHSI”), a wholly-owned subsidiary of Concentra, entered into a senior secured credit agreement (the “Credit Agreement”) that provides for an $850.0 million term loan (the “Term Loan”), and a $400.0 million revolving credit facility, including a $75.0 million sublimit for the issuance of standby letters of credit (the “Revolving Credit Facility” and, together with the Term Loan, the “Credit Facilities”). In March 2025, the Company completed an amendment to the Credit Agreement to increase our Revolving Credit Facility by $50.0 million from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid. In addition, the amendment to the Credit Agreement also added new debt through an incremental term loan of $102.1 million, which provides an updated Term Loan of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including 25-basis point step down at a net leverage ratio of ≤3.25x.
At March 31, 2025, the Company had $386.4 million of availability under its Revolving Credit Facility after giving effect to $50.0 million of borrowings under the Revolving Credit Facility and $13.6 million of outstanding letters of credit.
The Credit Facilities require CHSI to maintain a leverage ratio (as defined in the Credit Agreement), which is tested quarterly and currently must not be greater than 6.50 to 1.00. As of March 31, 2025, the Company was in compliance with all debt covenants.
7.    Accrued and Other Liabilities
The following table sets forth the components of accrued and other liabilities on the condensed consolidated balance sheets:
March 31, 2025December 31, 2024
(in thousands)
Accrued payroll$42,999 $75,657 
Accrued vacation43,909 43,647 
Accrued interest9,695 21,849 
Accrued other52,003 58,396 
Income taxes payable16,528 2,350 
Accrued and other liabilities$165,134 $201,899 
12

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
8.    Fair Value of Financial Instruments
Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:
•Level 1 – inputs are based upon quoted prices for identical instruments in active markets.
•Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.
•Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.
The Company’s derivative instruments are based on quotes from the market makers that derive fair values from market data, and therefore, are classified as Level 2.

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the Credit Facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the Concentra senior notes is based on quoted market prices. The carrying value of the Company’s other debt, as disclosed in Note 6—“Long-Term Debt”, approximates fair value.

We did not have any Level 3 financial assets or liabilities in any period presented.

The fair values and the levels within the fair value hierarchy of financial instruments recorded on the condensed consolidated balance sheets were (in thousands):
March 31, 2025December 31, 2024
Financial InstrumentLevel
Balance Sheet Classification
Carrying ValueFair ValueCarrying ValueFair Value
Derivatives designated as hedging instruments(in thousands)
Swap contracts
Level 2
Other current assets
$347 $347 $— $— 
Swap contractsLevel 2Non-current liability(1,759)(1,759)— — 
Total swap contracts
(1,412)(1,412)— — 
Collar contractsLevel 2Current liability(121)(121)— — 
Collar contractsLevel 2
Non-current liability
(763)(763)— — 
Total collar contracts
(884)(884)
Total fair value
$(2,296)$(2,296)$— $— 
6.875% senior notes
Level 2$638,467 $657,150 $638,075 $660,972 
Credit facilities:
Revolving Credit Facility
Level 2$50,000 $49,465 $— $— 
Term LoanLevel 2$936,918 $947,625 $835,412 $853,174 
The Company’s other financial instruments, which primarily consist of cash, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.
13

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
9.    Revenue
The following table disaggregates the Company’s revenue for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
(in thousands)
Occupational health centers:
Workers’ compensation$302,107 $279,866 
Employer services160,140 150,735 
Consumer health8,611 8,326 
Other occupational health center revenue2,064 2,145 
Total occupational health center revenue472,922 441,072 
Onsite health clinics16,550 15,857 
Other11,280 10,669 
Total revenue$500,752 $467,598 
10.    Earnings per Share
As of March 31, 2025, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the three months ended March 31, 2025, the Company applied the two-class method because its unvested restricted shares were participating securities.
As of March 31, 2024, the Company’s capital structure consists of common stock and there were no participating shares or securities outstanding.
The following table sets forth the net income attributable to the Company, its shares, and its participating shares:
Basic and Diluted EPS
Three Months Ended March 31,
20252024
(in thousands)
Net income$40,642 $50,279 
Less: net income attributable to non-controlling interests
1,731 1,323 
Net income attributable to the Company38,911 48,956 
Less: distributed and undistributed income attributable to participating securities
455 — 
Distributed and undistributed income attributable to common shares
$38,456 $48,956 
The following table set forth the computation of EPS. For the three months ended March 31, 2025, the Company applied the two-class method.
Three Months Ended March 31, 2025
Three Months Ended March 31, 2024
Net Income Attributable to the Company
Shares(1)
Basic and Diluted EPSNet Income Attributable to the Company
Shares(1)
Basic and Diluted EPS
(in thousands, except for per share amounts)
Common shares$38,456 126,647 $0.30 $48,956 104,094 $0.47 
Participating securities
455 1,500 $0.30 — — $— 
Total Company
$38,911 $48,956 
____________________________________________
(1)    Represents the weighted average shares outstanding during the period.
14

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
11.    Relationship with Select
On November 25, 2024, Concentra became a fully independent company upon the completion of the Distribution and Select ceased to be a related party on that date. The Company continues to have material agreements with Select, including a separation agreement, a transition services agreement, a tax matters agreement and an employee matters agreement.
Shared Services Agreement and Transition Services Agreement
The Company pays Select a fee for the shared support functions provided on a centralized basis by Select and its affiliates. Prior to the IPO, the shared services fee was governed by a shared services agreement between the Company and Select which was reassessed and adjusted annually. The transition services agreement, which became effective concurrent with the IPO, now provides the framework for the services provided by Select and the applicable fee for such services. For the three months ended March 31, 2025, the transaction services agreement fees were $3.7 million, and for the three months ended March 31, 2024, the shared service fees from a related party were $3.8 million.
12.    Commitments and Contingencies
Litigation
The Company is a party to various legal actions, proceedings, and claims, and regulatory and other governmental audits and investigations in the ordinary course of its business, including, but not limited to, legal actions and claims alleging professional malpractice, general liability for property damage, personal and bodily injury, violations of federal and state employment laws, often in the form of wage and hour class action lawsuits, and liability for data breaches. Many of these actions involve large claims and significant defense costs and sometimes, as in the case of wage and hour class actions, are not covered by insurance. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties.
To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating. The Company currently maintains insurance coverages under a combination of policies with a total annual per claim aggregate limit of $29.0 million for professional malpractice liability insurance and general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. In addition, the Company purchases additional primary care limits in certain patient compensation fund states, including Indiana, Kansas, Louisiana, Nebraska, Pennsylvania and Wisconsin. The Company also maintains additional types of liability insurance covering claims that, due to their nature or amount, are not covered by or not fully covered by the applicable professional malpractice and general liability insurance policies, including workers compensation, property and casualty, directors and officers, cyber liability, and employment practices liability insurance coverages. Our insurance policies generally are silent with respect to punitive damages so coverage is available to the extent insurable under the law of any applicable jurisdiction, and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities.
California Department of Insurance Investigation. On February 5, 2024, the Company received a subpoena from the California Department of Insurance relating to an investigation under the California Insurance Frauds Prevention Act, Cal. Ins. Code § 1871.7 et seq., which allows a whistleblower to file a false claims lawsuit based on the submission of false or fraudulent claims to insurance companies. The subpoena seeks documentation relating mainly to the Company’s billing and coding for physical therapy claims submitted to commercial insurers and workers’ compensation carriers located or doing business in California. The Company has produced data and other documents requested by the California Department of Insurance and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.
Perry Johnson & Associates, Inc. Data Breach. On November 10, 2023, Perry Johnson & Associates, Inc., a third-party vendor of health information technology solutions that provides medical transcription services (“PJ&A”), notified CHSI that certain information related to particular Concentra patients was potentially affected by a cybersecurity event. In February 2024,
15

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Concentra sent notices to almost four million patients who may have been impacted by the data breach. During the first quarter of 2024, Concentra became aware of six putative class action lawsuits filed against PJ&A and Concentra related to the data breach. Five of the putative class action lawsuits have been transferred to the U.S. District Court for the Eastern District of New York and consolidated with the one class action lawsuit pending there. Plaintiffs filed a Consolidated Class Action Complaint on August 19, 2024 against PJ&A, Concentra, Select Medical Holdings Corporation and other unrelated defendants under the caption In re Perry Johnson & Associates Medical Transcription Data Security Breach Litigation (“Consolidated Complaint”). The Consolidated Complaint alleges that the plaintiffs have suffered injuries and damages under theories of negligence, breach of contract, and failure to comply with statutory duties, including duties under HIPAA, FTC guidelines and industry standards, and various state consumer protection and deceptive trade practice laws. In March 2025, pursuant to a Case Management Order (“Court Order”), five of the named plaintiffs in the Consolidated Complaint filed an amended Direct-Filed Class Action Complaint in the U.S. District Court for the Eastern District of New York. Pursuant to this Court Order, the Direct-Filed Class Action Complaint will be remanded to the United States District Court for the Northern District of Texas after the conclusion of pretrial proceedings. The Company is working with its cybersecurity risk insurance policy carrier and does not believe that the data breach or the lawsuits will have a material impact on its operations or financial performance. However, at this time, the Company is unable to predict the timing and outcome of these matters.
Physical Therapy Billing. In 2021, Select Medical Corporation (“Select”), the former parent of the Company, received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services (“HHS”), is investigating Select in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, et seq. The letter specified that the investigation relates to Select’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from Select. Although the DOJ’s initial requests involved Select’s outpatient therapy clinics, in 2022 and 2023, the DOJ sought and the Company produced additional data and documents relating to the physical therapy services furnished by the Company. In May 2024, by order of the U.S. District Court for the Middle District of Florida, a qui tam lawsuit that is related to the DOJ’s investigation was unsealed after the U.S. filed a notice declining to intervene in the case. The lawsuit, filed in May 2021 and amended in October 2021, was brought by Kathleen Kane, a physical therapist formerly employed in Select’s outpatient division, against Select Medical Corporation, Select Physical Therapy Holdings, Inc. and Select Employment Services, Inc., but does not name the Company as a defendant. The amended complaint alleges that the defendants billed Federally funded health programs for one-on-one therapy services when group therapy was performed or overbilled for one-on-one therapy services, billed for unreimbursable unskilled physical therapy services, and submitted claims containing signatures of therapists who did not provide the billed services. The Company is fully cooperating on this investigation, but at this time, is unable to predict the timing and outcome of this matter.
13.    Segment Information
Our business is organized into three operating segments based primarily on the type or location of occupational health services provided: (i) occupational health centers, (ii) onsite health clinics, and (iii) other businesses. All three operating segments are aggregated into a single reportable segment in our consolidated financial statements based on similar services provided, service delivery process involved, target customers, and similar economic characteristics. Across our operating segments, we offer a diverse and comprehensive array of services, which includes workers’ compensation, employer services and consumer health. Our patients are generally employed by our main customers - employers across the United States.
Occupational health services are focused on the diagnosis and treatment of work-related injuries and illnesses (workers’ compensation services) and employer services such as examinations, physicals, tests and screenings, vaccinations, and a range of consulting services designed to protect employees from workplace hazards.
The chief operating decision maker (“CODM”) is our Chief Executive Officer. The CODM uses Segment Adjusted EBITDA in the annual budgeting and forecasting process, in the review of budget-to-actual and prior year variances to make decisions about the allocation of operating and capital resources, and to establish management’s compensation.
16

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
The following table is representative of the significant categories, including significant expenses, regularly provided to the CODM when managing the Company’s single reporting segment.
Three Months Ended March 31,
20252024
(in thousands)
Revenue$500,752 $467,598 
Expenses:(1)
Personnel expenses
281,658 268,372 
Facility expenses
48,382 43,805 
Other expenses
68,053 59,279 
Total segment expenses398,093 371,456 
Segment Adjusted EBITDA$102,659 $96,142 
Total assets$2,729,238 $2,366,162 
Purchases of property and equipment$15,732 $17,231 
Depreciation and amortization$16,619 $18,485 
____________________________________________
(1)    Includes transaction services agreement fees of $3.7 million and shared services fees from a related party $3.8 million for the three months ended March 31, 2025 and 2024, respectively. See Note 11—“Relationship with Select”, for additional information.
Segment Adjusted EBITDA is calculated as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.
The following table reconciles Segment Adjusted EBITDA to income before income taxes for the periods indicated.
 Three Months Ended March 31,
 20252024
(in thousands)
Segment Adjusted EBITDA
$102,659 $96,142 
Interest expense(25,548)(111)
Interest expense on related party debt
— (9,971)
Loss on early retirement of debt
(875)— 
Stock compensation expense
(2,269)(166)
Depreciation and amortization
(16,619)(18,485)
Separation transaction costs(1)
(315)(1,993)
Nova acquisition costs
(3,137)— 
Income before income taxes
$53,896 $65,416 
____________________________________________
(1)    Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations.
17

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
14.    Acquisitions
Nova Acquisition
Effective March 1, 2025, the Company acquired Nova Medical Centers (“Nova”). CHSI entered into an equity purchase agreement to acquire all of the outstanding membership interests for a purchase price of approximately $265 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. We financed the transaction using a combination of $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.
Nova operates 67 occupational health centers in five states, providing workers’ compensation injury care services, physical therapy, drug and alcohol screening, and pre-employment physicals as part of their full suite of occupational health services. The acquisition enabled the Company to expand to more than 775 occupational health centers and onsite health clinics at employer worksites in 42 states.
The Nova acquisition met the definition of a business pursuant to Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, and the acquisition was accounted for as a business combination under the acquisition method of accounting. The Company allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary estimated fair values. The fair values are based on inputs that are unobservable in the market and therefore represent Level 3 inputs.
The Company is in the process of completing its assessment of the acquisition-date fair values of the assets acquired and liabilities assumed and determining the estimated useful lives of long-lived assets and finite-lived intangible assets; therefore, the values set forth are subject to adjustment during the measurement period. The amount of these potential adjustments could be significant. The Company expects to complete its purchase price allocation activities by December 31, 2025.
Pursuant to ASC Topic 810, Consolidation, certain Nova affiliated entities were determined to be a variable interest entity, and the Company was determined to be their primary beneficiary. As a result, the Company obtained a controlling financial interest and Nova has been consolidated into the Company's financial results.
The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):
Identifiable tangible assets
$45,667 
Identifiable intangible assets
38,471 
Goodwill
205,633 
Total assets
289,771 
Total liabilities
24,600 
Consideration given
$265,171 

The preliminary estimate for goodwill of $205.6 million has been recognized for the business combination, representing the excess of the consideration given over the fair value of identifiable net assets acquired. The value of goodwill is derived from Nova’s future earnings potential and its assembled workforce. The amount of goodwill is expected to be deductible for tax purposes.

For the period March 1, 2025 through March 31, 2025, Nova had total revenue and net income of $11.2 million and $1.2 million, respectively, which was included in the condensed consolidated financial statements.

Pro Forma Results

The following unaudited consolidated pro forma financial results combine the historical results of Nova and the Company to present the results as if the Nova acquisition had occurred on January 1, 2024. The pro forma information is presented for illustration purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition occurred on that date, nor is it indicative of future results.
18

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Three Months Ended March 31,
20252024
(unaudited)
(in thousands)
Total revenue$522,111 $499,991 
Net income attributable to the Company
$43,400 $50,935 

The pro forma financial information is based on the preliminary allocation of the purchase price of the Nova acquisition and is therefore subject to adjustment upon finalizing the purchase price allocation, as described above, during the measurement period. The net income tax impact was calculated at the effective tax rate, as Nova had been a subsidiary of the Company as of January 1, 2024.

Pro forma results were adjusted to exclude acquisition-related expenses incurred by the Company that are directly attributable to the transaction. These excluded costs primarily consist of legal, advisory, and transaction-related compensation expenses that are nonrecurring in nature and not reflective of the ongoing operations of the combined business.

15.    Derivative Instruments

The Company uses derivative instruments to manage its exposure to variable-rate debt indexed to 1-month Term SOFR, issued under its Tranche B-1 Term Loans drawn from the Company’s Credit Agreement.

Derivative

Certain information related to our derivatives contracts is presented below (in thousands):
Effective DateNotional AmountFixed RateCapFloorIndexActual Termination Date
Swap contracts3/3/2025$300,000 3.829 %USD-SOFR rate2/29/2028
Collar contracts3/3/2025$300,000 — 4.500 %3.001 %USD-SOFR rate2/29/2028
Cash Flow Hedge Coverage

The Company has entered into interest rate swap and collar agreements designated as cash flow hedges. These agreements are used to manage interest rate risk associated with a portion of the Company’s floating-rate debt for periods not exceeding the next three years.

Deferred Hedging Gains and Losses on Cash Flow Hedges

Based on our valuation at March 31, 2025 and assuming market rates remain constant through contract maturities, we expect transfers to earnings of the existing gains or losses reported in accumulated other comprehensive income on interest rate cash flow hedges during the next 12 months to correspond to the current and non-current assets and liabilities portion of the derivative as disclosed in Note 8—“Fair Value of Financial Instruments”.
19

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Derivative Impact on the Statements of Comprehensive Income

The following table presents the pre-tax amounts of derivative gains or losses deferred into accumulated other comprehensive income and the income statement line item that will be affected when reclassified to earnings (in thousands):

Accumulated Other Comprehensive Income Component (OCI)Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging InstrumentsLocation of Gains/(Losses) When Reclassified to Net Income/(Loss)
Three Months Ended March 31, 2025
Cash flow hedges:
Swap contracts$(1,412)Interest expense
Collar contracts(884)Interest expense
Total (losses)/gains recognized in statements of comprehensive income
$(2,296)

Derivative Impact on the Statements of Income

The following tables present the pre-tax amounts of derivative gains or (losses) recorded to earnings and the affected income statement line items (in thousands):
Three Months Ended March 31, 2025
Interest expense
Total amounts presented in the condensed consolidated statements of income in which the following effects were recorded
Gains/(losses) related to derivatives designated as hedging instruments:
Cash flow hedges(1):
Swap contracts
$115 
Collar contracts(2)
— 
Total gains/(losses) recognized in statements of income$115 
____________________________________________
(1)    Represents the pre-tax amounts of derivative gains/(losses) reclassified from accumulated other comprehensive income to earnings.
(2)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, there are no payments required to be exchanged under this agreement.
16.    Accumulated Other Comprehensive Income
The components of, and changes in, accumulated other comprehensive income, net of tax, were as follows (in thousands):

Net Cash Flow
Hedge Adjustments
Balance as of December 31, 2024$— 
Net deferred (losses)/gains on cash flow hedges
(1,808)
Net deferred gains/(losses) on cash flow hedges reclassified to net income
86 
Balance as of March 31, 2025$(1,722)



20

CONCENTRA GROUP HOLDINGS PARENT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
The gross amount and related tax benefit/(expense) recorded in, and associated with, each component of other comprehensive income were as follows (in thousands):

Three Months Ended March 31, 2025
Before Tax AmountTaxNet of Tax Amount
Net deferred (losses)/gains on cash flow hedges
$(2,411)$603 $(1,808)
Net deferred gains/(losses) on cash flow hedges reclassified to net income
$115 $(29)$86 
The amounts reclassified from accumulated other comprehensive income were as follows (in thousands):

Accumulated Other Comprehensive Income (OCI) ComponentReclassified from Accumulated OCI to Earnings for the Three Months Ended March 31, 2025Affected Line Item in the Statements of Income
Gains/(losses) on cash flow hedges:
Swap contract$115 Interest expense
Collar contract(1)
—Interest expense
Gains/(losses) on hedges before income taxes
$115 
Income tax expense(29)
Gains on hedges$86 
____________________________________________
(1)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, no amounts have been reclassified from OCI to earnings.
17.    Subsequent Events
Equity Purchase Agreement
On April 18, 2025, CHSI entered into an equity purchase agreement with Pivot Occupational Health, LLC to acquire all of the outstanding equity interests of Onsite Innovations, LLC (“Pivot Onsite Innovations”). The transaction values Pivot Onsite Innovations at $55 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. The transaction is expected to close in the second quarter of 2025 and is subject to customary closing conditions set forth in the purchase agreement.
CHSI currently expects to finance the transaction using a combination of cash on hand and available borrowing capacity under its existing Revolving Credit Facility.
Pivot Onsite Innovations operates approximately 200 onsite health clinics at employer locations in over 40 states, providing occupational health, wellness, prevention, and performance services. When combined with Concentra’s current onsite health clinic footprint, the acquisition will enable the Company to expand to more than 350 onsite health clinics at employer worksites.
Dividend
On May 6, 2025, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable May 29, 2025, to stockholders of record as of the close of business on May 20, 2025.
21

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.
Forward-Looking Statements
This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development activities; regulatory approvals; market position; market size and opportunity; expenditures; and the effects of the Separation on our business.
Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to risks, uncertainties and changes that are difficult to predict and many of which are outside of our control. You should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements. You are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include:
•The frequency of work-related injuries and illnesses;
•The adverse changes to our relationships with employer customers, third-party payors, workers’ compensation provider networks or employer services networks;
•Changes to regulations, new interpretations of existing regulations, or violations of regulations;
•State fee schedule changes undertaken by state workers’ compensation boards or commissions and other third-party payors;
•Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of our costs;
•Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs;
•Our ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers;
•A security breach of our, or our third-party vendors’, information technology systems which may cause a violation of HIPAA and subject us to potential legal and reputational harm;
•Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes;
•Significant legal actions could subject us to substantial uninsured liabilities;
•Litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our business and financial statements;
•Insurance coverage may not be sufficient to cover losses we may incur;
•Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities;
•Our exposure to additional risk due to our reliance on third parties in many aspects of our business;
•Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting;
•Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information;
•Compliance with applicable data interoperability and information blocking rule;
•Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our operations;
•Our ability to adequately protect and enforce our intellectual property and other proprietary rights;
22

•Adverse economic conditions in the U.S. or globally;
•Any negative impact on the global economy and capital markets resulting from other geopolitical tensions;
•The impact of impairment of our goodwill and other intangible assets;
•Our ability to maintain satisfactory credit ratings;
•The effects of the Separation on our business;
•Our ability to achieve the expected benefits of and successfully execute the Separation and related transactions;
•Restrictions on our business, potential tax and indemnification liabilities and substantial charges in connection with the Separation and related transactions;
•The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease similar to the COVID-19 pandemic;
•The loss of key members of our management team;
•Our ability to attract and retain talented, highly skilled employees and a diverse workforce, and on the succession of our senior management;
•Climate change, or legal, regulatory or market measures to address climate change;
•Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters;
•Changes in tax laws or exposures to additional tax liabilities; and
•Changes to United States tariff and import/export regulations and the impact on global economic conditions may have a negative effect on our business, financial condition and results of operations.
You should also carefully read the risk factors described in our Annual Report on Form 10-K in Part I, Item 1A. “Risk Factors” for a description of certain risks that could, among other things, cause our actual results to differ materially from those expressed or implied in our forward-looking statements. You should understand that it is not possible to predict or identify all such factors and you should not consider the risks described above to be a complete statement of all potential risks and uncertainties. We do not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments, except as required by law.
Overview
We were founded in 1979 and have grown to be the largest provider of occupational health services in the United States by number of locations. Our national presence enables us to provide access to high-quality care that supports our mission to improve the health of America’s workforce. As of March 31, 2025, we operated 627 stand-alone occupational health centers in 41 states and 160 onsite health clinics at employer worksites in 36 states. We also have expanded our reach via our telemedicine program serving 43 states and the District of Columbia. In total, we deliver services across 45 states and the District of Columbia. Our patients are generally employed by our main customers — employers across the United States.
Our business is organized into three operating segments based primarily on the type or location of occupational health services provided:
•Occupational health centers: Our occupational health centers operating segment encompasses the occupational health services we deliver at our 627 occupational health center facilities across the United States. In this operating segment, we serve all types of employers, from Fortune 500 to small businesses. The occupational health services provided in this operating segment include workers’ compensation and employer services and we also provide consumer health services.
•Onsite health clinics: Our onsite health clinics operating segment delivers occupational health services and/or employer-sponsored primary care services at an employer’s workplace, including mobile health services and episodic specialty testing services — we deliver our services at 160 permanent on-site locations and multiple other employer locations through our episodic services. In this segment, we serve medium to large-sized employers.
•Other businesses: Our other businesses operating segment is comprised of several complementary services to our core occupational health services offering and includes Concentra Telemed, Concentra Pharmacy, and Concentra Medical Compliance Administration. In this operating segment, we serve all types of employers.
23

All three operating segments are aggregated into a single reportable segment in our condensed consolidated financial statements based on similar services provided, service delivery process involved, target customers, and similar economic characteristics.
The following table represents the percentage of revenue by our operating segments for the periods indicated:
Three Months Ended March 31,
20252024
Occupational health centers
95 %95 %
Onsite health clinics
3 %3 %
Other businesses
2 %2 %
Across our operating segments, we offer a diverse and comprehensive array of occupational health services, including workers’ compensation and employer services, and consumer health services:
•Workers’ compensation services: include the support of workers’ compensation injury, physical rehabilitation, and specialist care.
•Employer services: consist of drug and alcohol screenings, physical examinations and evaluations, clinical testing, and preventive care, as well as direct-to-employer services that include the services described above and advanced primary care at our onsite health clinics.
•Consumer health services: consist of the support of patient-directed urgent care treatment of injuries and illnesses.
The following table sets forth the percentage of our overall visits per day (“VPD”) volume in our occupational health center operating segment by service offering, for the periods presented:
Three Months Ended March 31,
20252024
Workers’ compensation services45 %45 %
Employer services53 %53 %
Consumer health services2 %2 %
The following table sets forth the percentage of visit-related revenue in our occupational health center operating segment by service offering, for the periods presented:
Three Months Ended March 31,
20252024
Workers’ compensation services64 %64 %
Employer services34 %34 %
Consumer health services2 %2 %

24

Significant Events
Nova Acquisition
Effective March 1, 2025, the Company acquired Nova Medical Centers (“Nova”). CHSI entered into an equity purchase agreement to acquire all of the outstanding membership interests for a purchase price of approximately $265 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. We financed the transaction using a combination of $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.
Nova operates 67 occupational health centers in five states, providing workers’ compensation injury care services, physical therapy, drug and alcohol screening, and pre-employment physicals as part of their full suite of occupational health services. The acquisition enabled the Company to expand to more than 775 occupational health centers and onsite health clinics at employer worksites in 42 states.
Debt Financing
On March 3, 2025, the Company completed an amendment to the Credit Agreement to increase our revolving credit facility by $50.0 million from $400.0 million to $450.0 million. The interest rate for the revolving credit facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid. In addition, the amendment to the Credit Agreement also added new debt through an incremental term loan of $102.1 million, which provides an updated Term Loan of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including 25-basis point step down at a net leverage ratio of ≤3.25x.
Equity Purchase Agreement
On April 18, 2025, CHSI entered into an equity purchase agreement with Pivot Occupational Health, LLC to acquire all of the outstanding equity interests of Onsite Innovations, LLC (“Pivot Onsite Innovations”). The transaction values Pivot Onsite Innovations at $55 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. The transaction is expected to close in the second quarter of 2025 and is subject to customary closing conditions set forth in the purchase agreement.
CHSI currently expects to finance the transaction using a combination of cash on hand and available borrowing capacity under its existing Revolving Credit Facility.
Pivot Onsite Innovations operates approximately 200 onsite health clinics at employer locations in over 40 states, providing occupational health, wellness, prevention, and performance services. When combined with Concentra’s current onsite health clinic footprint, the acquisition will enable the Company to expand to more than 350 onsite health clinics at employer worksites.
Regulatory Changes
Our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, contains a detailed discussion of the regulations that affect our business in Part I, Item I. Business—Government Regulations.
25

Operating Metrics
Management utilizes specific key operating metrics to monitor trends and performance in our business and therefore may be important to investors because management may assess our performance based in part on such metrics. Other healthcare providers may present similar measures; however, these measures are susceptible to varying definitions and our key metrics may not be comparable to other similarly titled measures of other companies.
Patient Visits and Visits Per Day Volume
We monitor the number of patient visits per day (“VPD”) volume for each of our major service lines in our occupational health center operating segment — workers’ compensation services, employer services, and consumer health. Management believes that the number of patient visits is the single most important indicator of the volume of services being provided in our centers. VPD volume, which is calculated as total patient visits in a given period divided by total business days for such period, allows for comparability between time periods with different number of business days. Patient visits and VPD volume include only the patients seen in our occupational health centers operating segment and does not include our onsite health clinics or other businesses operating segments.
Revenue Per Visit
Management also measures reimbursement rates utilizing patient revenue per visit which is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers operating segment and does not include our onsite health clinics or other businesses operating segments.
The following table sets forth operating statistics for our occupational health centers operating segment for the periods presented:
 Three Months Ended March 31,
 20252024% Change
Number of patient visits
Workers’ compensation
1,444,880 1,433,084 0.8%
Employer services
1,696,412 1,659,291 2.2%
Consumer health
63,076 63,280 (0.3)%
Total3,204,368 3,155,655 1.5%
VPD Volume
Workers’ compensation
22,935 22,392 2.4%
Employer services
26,927 25,926 3.9%
Consumer health
1,001 989 1.2%
Total50,863 49,307 3.2%
Revenue per visit
Workers’ compensation
$209.09 $195.29 7.1%
Employer services
94.40 90.84 3.9%
Consumer health
136.52 131.57 3.8%
Total$146.94 $139.09 5.6%
Business days
63 64 






26

Facility Counts
The following table sets forth facility counts for our occupational health centers and onsite health clinics operating segments for the periods presented:
 Three Months Ended March 31,
 20252024
Number of occupational health centers—start of period552 544 
Number of occupational health centers acquired72 2 
Number of occupational health centers de novos3 1 
Number of occupational health centers closed/sold— — 
Number of occupational health centers—end of period627 547 
Number of onsite health clinics operated—end of period160 151 
Results of Operations
The following table outlines selected operating data as a percentage of revenue for the periods indicated:
 Three Months Ended March 31,
 20252024
(in thousands)
Amount
Percent(1)
AmountPercent
Revenue$500,752 100.0 %$467,598 100.0 %
Costs and expenses:
Cost of services, exclusive of depreciation and amortization357,101 71.3 336,990 72.1 
General and administrative, exclusive of depreciation and amortization46,713 9.3 36,909 7.9 
Depreciation and amortization16,619 3.3 18,485 4.0 
Total costs and expenses420,433 84.0 392,384 84.0 
Other operating income
— — 284 0.1 
Income from operations80,319 16.0 75,498 16.1 
Other income and expense:
   Loss on early retirement of debt
(875)(0.2)— — 
Interest expense(25,548)(5.1)(111)— 
Interest expense on related party debt— — (9,971)(2.1)
Income before income taxes53,896 10.8 65,416 14.0 
Income tax expense13,254 2.6 15,137 3.2 
Net income40,642 8.1 50,279 10.8 
Less: net income attributable to non-controlling interests
1,731 0.3 1,323 0.3 
Net income attributable to the Company$38,911 7.8 %$48,956 10.5 %
___________________________________________
(1)    Totals in this column may not foot due to rounding.
Three Months Ended March 31, 2025, Compared to Three Months Ended March 31, 2024
Revenue
Revenue increased 7.1% to $500.8 million for the three months ended March 31, 2025, compared to $467.6 million for the three months ended March 31, 2024, driven primarily by the increase in revenue per visit, as described below, and the 72 occupational health centers that were acquired through acquisitions in March 2025.
27

Our total patient visits increased 1.5% to 3,204,368 for the three months ended March 31, 2025, compared to 3,155,655 visits for the three months ended March 31, 2024. Total VPD volume increased 3.2% to 50,863 for the three months ended March 31, 2025, compared to 49,307 for the three months ended March 31, 2024, primarily due to an increase in employer services visits. Workers’ compensation VPD volume increased 2.4% to 22,935 from 22,392, employer services VPD volume increased 3.9% to 26,927 from 25,926, and consumer health VPD volume increased 1.2% to 1,001 from 989, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024.
Revenue per visit increased 5.6% to $146.94 for the three months ended March 31, 2025, compared to $139.09 for the three months ended March 31, 2024. We experienced a higher revenue per visit principally due to increases in the reimbursement rates payable pursuant to certain state fee schedules for workers’ compensation visits, as well as increases in our employer services rates, for the three months ended March 31, 2025. Revenue per visit for workers’ compensation visits increased 7.1% to $209.09 from $195.29, revenue per visit for employer services visits increased 3.9% to $94.40 from $90.84 and revenue per visit for consumer health visits increased by 3.8% to $136.52 from $131.57, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024.
Cost of Services
Our cost of services expense includes all direct and indirect support costs related to providing services to our customers. Cost of services was $357.1 million, or 71.3% of revenue, for the three months ended March 31, 2025, compared to $337.0 million, or 72.1% of revenue, for the three months ended March 31, 2024. The percentage of revenue was lower overall predominantly due to the 7.1% increase in revenue during the period, including the rate gains, as well as operational efficiencies resulting from the replacement of contract clinicians with employed clinicians and general improvements in staffing efficiencies across clinical and operations.
General and Administrative
General and administrative expense includes corporate overhead such as finance, legal, human resources, marketing, corporate offices, and other administrative areas as well as executive compensation. Our general and administrative expenses were $46.7 million, or 9.3% of revenue, for the three months ended March 31, 2025, compared to $36.9 million, or 7.9% of revenue, for the three months ended March 31, 2024. The increase in general and administrative as a percentage of revenue is principally due to the favorable out of period legal expense reversal during the three months ended March 31, 2024, stock compensation expense, Nova acquisition costs, and the addition of new full-time employees to support the separation from Select Medical and operate as a standalone public company.
Depreciation and Amortization
Depreciation and amortization expense was $16.6 million for the three months ended March 31, 2025, or 3.3% of revenue compared to $18.5 million for the three months ended March 31, 2024, or 4.0% of revenue. The decrease was due to an intangible asset fully amortizing in June 2024.
Interest Expense
For the three months ended March 31, 2025, we had interest expense of $25.5 million, compared to $0.1 million for the three months ended March 31, 2024. The increase in interest expense was due to the issuance of an $850.0 million term loan and $650.0 million senior notes in July 2024, and due to the $102.1 million of incremental term loan and $50.0 million in borrowings on the revolving credit facility in March 2025, as described in Note 6—“Long-Term Debt”.
Interest Expense on Related Party Debt
For the three months ended March 31, 2025, we had no interest expense on related party debt with Select, compared to $10.0 million for the three months ended March 31, 2024. The decrease in interest expense is due to the payoff of the revolving promissory note with Select during the three months ended December 31, 2024.
Income Taxes
We recorded income tax expense of $13.3 million for the three months ended March 31, 2025, which represented an effective tax rate of 24.6%. We recorded income tax expense of $15.1 million for the three months ended March 31, 2024, which represented an effective tax rate of 23.1%. Our income tax expense is computed based on annual estimates which we allocate throughout the year based on our income. This intra-period tax allocation may cause our effective tax rate to reflect variances when compared to the prior year as estimates of our annual income and the components of our income tax expense change throughout the year.
28

Non-GAAP Measures
Adjusted EBITDA and Adjusted EBITDA Margin
We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA margin, as defined herein, are important to investors because Adjusted EBITDA and Adjusted EBITDA margin are commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA and Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Adjusted EBITDA and Adjusted EBITDA margin are not measures of financial performance under U.S. GAAP. Items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Adjusted EBITDA and Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the condensed consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA and Adjusted EBITDA margin are not measurements determined in accordance with U.S. GAAP and are thus susceptible to varying definitions, Adjusted EBITDA and Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies.
We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.
The following table reconciles net income to Adjusted EBITDA and net income margin to Adjusted EBITDA margin and should be referenced when we discuss Adjusted EBITDA and Adjusted EBITDA margin.
 Three Months Ended March 31,
 20252024
($ in thousands)
Amount
% of Revenue
Amount
% of Revenue
Reconciliation of Adjusted EBITDA:
Net income$40,642 8.1 %$50,279 10.8 %
Add (Subtract):
Income tax expense13,254 2.6 15,137 3.2 
Interest expense25,548 5.1 111 — 
Interest expense on related party debt— — 9,971 2.1 
Loss on early retirement of debt875 0.2 — — 
Stock compensation expense2,269 0.5 166 — 
Depreciation and amortization16,619 3.3 18,485 4.0 
Separation transaction costs(1)
315 0.1 1,993 0.5 
Nova acquisition costs
3,137 0.6 — — 
Adjusted EBITDA$102,659 20.5 %$96,142 20.6 %
____________________________________________
(1)    Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the condensed consolidated statements of operations.







29

Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share
Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share are used by management to provide useful insight into the underlying performance of our business in each of our operating segments. Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share are not measures of financial performance under U.S. GAAP and are not intended to be substitutes for U.S. GAAP measures such as net income or earnings per common share. These metrics may differ from similarly titled metrics supported by other companies. Concentra believes that the presentation of Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share are important to investors because they are reflective of the financial performance of Concentra’s ongoing operations and provide better comparability of its results of operations between period. Investors should consider these measures in addition to, and not as a replacement for, U.S. GAAP results reported in our financial statements.
We define Adjusted Net Income Attributable to Common Shares as net income attributable to common shares, excluding gain (loss) on early retirement of debt, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and other non-recurring costs not directly tied to operating performance. We define Adjusted Earnings per Common Share as the Adjusted Net Income Attributable to Common Shares divided by the diluted weighted average common shares outstanding.
The following table reconciles net income attributable to common shares and earnings per common share on a fully diluted basis to Adjusted Net Income Attributable to Common Shares and Adjusted Earnings per Common Share on a fully diluted basis.
Three Months Ended March 31,
($ in thousands, except per share amounts)
2025
Per Share(1)
2024
Per Share(1)
Reconciliation of Adjusted Net Income Attributable to Common Shares:
Net income attributable to common shares(1)
$38,456 $0.30 $48,956 $0.47 
Adjustments:(2)
Loss on early retirement of debt865 0.01 — — 
Separation transaction costs(3)
311 — 1,993 0.02 
Nova acquisition costs3,100 0.02 — — 
Total additions, net$4,276 $0.03 $1,993 $0.02 
Less: tax effect of adjustments(4)
(1,052)(0.01)(460)— 
Adjusted Net Income Attributable to Common Shares
$41,680 $0.32 $50,489 $0.49 
Weighted average common shares outstanding - diluted
126,647 104,094 
_____________________________________
(1)    Net income attributable to common shares and earnings per common share are calculated based on the diluted weighted average common shares outstanding in Note 10—“Earnings Per Share”.
(2)    Reflect the common shares allocation of the adjustments.
(3)    Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the condensed consolidated statements of operations.
(4)    Tax impact is calculated using the annual effective tax rate, excluding discrete costs and benefits.
30

Liquidity and Capital Resources
Cash Flows for the Three Months Ended March 31, 2025 and Three Months Ended March 31, 2024
In the following table and analysis, we discuss cash flows from operating activities, investing activities, and financing activities for the periods indicated:
 Three Months Ended March 31,
 20252024
 (in thousands)
Net cash provided by operating activities$11,699 $44,622 
Net cash used in investing activities(294,749)(22,352)
Net cash provided by (used in) financing activities
151,904 (4,092)
Net (decrease) increase in cash
(131,146)18,178 
Cash at beginning of period183,255 31,374 
Cash at end of period$52,109 $49,552 
Operating activities provided $11.7 million and $44.6 million of cash flows during the three months ended March 31, 2025 and 2024, respectively. The decrease in cash flows from operating activities for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024, was primarily due to an increase in interest payments following the recapitalization of debt in July 2024.
Investing activities used $294.7 million and $22.4 million of cash flows for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025, the principal uses of cash were $15.7 million for purchases of property and equipment under our capital program to open de novos and upgrade and maintain existing facilities, and $279.0 million for acquisitions of businesses, which primarily includes the purchase of Nova. For the three months ended March 31, 2024, the principal uses of cash were $17.2 million for purchases of property and equipment and $5.1 million for acquisitions of businesses.
Financing activities provided $151.9 million and used $4.1 million of cash flows for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025, the principal sources of cash were due to the updated term loan, net of issuance costs of $948.8 million and from borrowings on our Revolving Credit Facility of $50.0 million. This was partially offset by payment of the original term loan of $847.9 million. For the three months ended March 31, 2024, the principal uses of cash were distributions to Select of $6.9 million and principal payments on other debt of $2.3 million, offset by $6.6 million in borrowings of other debt.
Capital Resources
We had net working capital of $31.2 million at March 31, 2025, compared to net working capital of $130.0 million at December 31, 2024. The decrease in the net working capital surplus was principally due to a decrease in our cash, which resulted from the Nova acquisition in March 2025. On March 1, 2025, we acquired Nova and financed the transaction using a combination of $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.
On April 18, 2025, CHSI entered into an equity purchase agreement with Pivot Occupational Health, LLC to acquire all of the outstanding equity interests of Onsite Innovations, LLC (“Pivot Onsite Innovations”). The transaction values Pivot Onsite Innovations at $55 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. The transaction is expected to close in the second quarter of 2025 and is subject to customary closing conditions set forth in the purchase agreement. CHSI currently expects to finance the transaction using a combination of cash on hand and available borrowing capacity under its existing Revolving Credit Facility.
A significant component of our net working capital is our accounts receivable. Collection of these accounts receivable is our primary source of cash and is critical to our liquidity and capital resources. Because our accounts receivable is primarily paid for by highly-solvent, creditworthy payors, such as workers’ compensation programs, employer programs, third party administrators, commercial insurance companies, and federal and state governmental authorities, our credit losses have historically been infrequent and insignificant in nature, and we believe the possibility of credit default is remote.
31

Credit Facilities
On July 26, 2024, Concentra Health Services, Inc. (“CHSI”), a wholly-owned subsidiary of Concentra, entered into a senior secured credit agreement (the “Credit Agreement”) that provided for an $850.0 million term loan (the “Term Loan”), and a $400.0 million revolving credit facility, including a $75.0 million sublimit for the issuance of standby letters of credit (the “Revolving Credit Facility” and, together with the Term Loan, the “Credit Facilities”). In March 2025, the Company completed an amendment to the Credit Agreement to increase our Revolving Credit Facility by $50.0 million from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid. In addition, the amendment to the Credit Agreement also added new debt through an incremental term loan of $102.1 million, which provides an updated Term Loan of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including 25-basis point step down at a net leverage ratio of ≤3.25x.
At March 31, 2025, the Company had $386.4 million of availability under its Revolving Credit Facility after giving effect to $50.0 million of borrowings under the Revolving Credit Facility and $13.6 million of outstanding letters of credit.
The Credit Facilities require CHSI to maintain a leverage ratio (as defined in the Credit Agreement), which is tested quarterly and currently must not be greater than 6.50 to 1.00. As of March 31, 2025, the Company was in compliance with all debt covenants.
Hedging
On March 3, 2025 we entered into derivative swap and collar contracts to mitigate our exposure to variable Term SOFR interest rates, which expire on February 29, 2028. The derivative swap contract limits the Term SOFR rate to a fixed rate of 3.829% on $300 million of principal outstanding under our term loan. We also entered into a derivative collar contract, which limits the Term SOFR rate to a cap of 4.500% and floor of 3.001% on $300 million of principal outstanding under our term loan. These derivative contracts limit our Term SOFR variable interest exposure on our $950 million term loan and $50 million of borrowings under the Revolving Credit Facility.
Liquidity
We believe our internally generated cash flows and borrowing capacity under our Revolving Credit Facility will allow us to finance our operations in both the short and long term. As of March 31, 2025, we had cash of $52.1 million and $386.4 million of availability under the Revolving Credit Facility, after giving effect to $50 million of borrowings under the Revolving Credit Facility and $13.6 million of outstanding letters of credit.
As of April 18, 2025 we have a new material cash commitment under our equity purchase agreement with Pivot Occupational Health, LLC to acquire all of the outstanding equity interests of Pivot Onsite Innovations for $55 million, subject to adjustment in accordance with the terms and conditions set forth in the Purchase Agreement. The transaction is expected to close during the second quarter of 2025.
We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.
Use of Capital Resources
We intend to grow through strategic acquisitions of existing occupational health centers as well as building new de novo centers.
Dividend
On May 6, 2025, the Company’s Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable on or about May 29, 2025, to stockholders of record as of the close of business on May 20, 2025.
There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of our Board of Directors after taking into account various factors, including, but not limited to, our financial condition, operating results, available cash and current and anticipated cash needs, the terms of our indebtedness, and other factors our Board of Directors may deem to be relevant. Additionally, certain contractual agreements we are party to, including our credit facilities will limit our ability to pay dividends to our stockholders.
32

Recent Accounting Pronouncements
Refer to Note 2— “Accounting Policies” of the notes to our condensed consolidated financial statements included herein for information regarding recent accounting pronouncements.
Effects of Inflation
The healthcare industry is labor intensive and our largest expenses are labor related costs. Wage and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. There has been minimal inflationary impact on our businesses thus far.
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under our credit facilities, which bear interest rates that are indexed against Term SOFR.
At March 31, 2025, we had outstanding borrowings under our credit facilities consisting of a $950.0 million term loan (excluding unamortized original issue discounts and debt issuance costs of $13.1 million) and $50.0 million of borrowings under our Revolving Credit Facility, which bear interest at variable rates.
In order to mitigate our exposure to rising interest rates, we entered into a derivative swap contract effective on March 3, 2025, which limits the Term SOFR rate to a fixed rate of 3.829% on $300 million of principal outstanding under our term loan. The agreement applies to interest payments through February 29, 2028.
In addition, we entered into a derivative collar contract effective on March 3, 2025, which limits the Term SOFR rate to a cap of 4.500% and floor of 3.001% on $300 million of principal outstanding under our term loan. The agreement applies to interest payments through February 29, 2028.
As of March 31, 2025, the Term SOFR rate was 4.32% and we had $650 million of term loan borrowings and $50.0 million of Revolving Credit Facility, which would be subject to variable interest rates.
At March 31, 2025, each 0.25% increase in market interest rates will impact the annual interest expense on our variable rate debt by $1.5 million per year. Each subsequent 0.25% increase in market interest rates will impact the annual interest expense on our variable rate debt by $1.0 million per year.
33

ITEM 4.  CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, as of March 31, 2025, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the first quarter ended March 31, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.
34

PART II: OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Refer to the “Litigation” section contained within Note 12—“Commitments and Contingencies” of the notes to our condensed consolidated financial statements included herein.
ITEM 1A. RISK FACTORS
Except as set forth below, there have been no material changes in the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024.
Changes to United States tariff and import/export regulations and macroeconomic conditions may have a negative effect on our business, financial condition and results of operations.

The United States has recently enacted and proposed to enact significant new tariffs. Additionally, President Trump has directed various federal agencies to further evaluate key aspects of U.S. trade policy and there has been ongoing discussion and commentary regarding potential significant changes to U.S. trade policies, treaties and tariffs. There continues to exist significant uncertainty about the future relationship between the U.S. and other countries with respect to such trade policies, treaties and tariffs (including retaliatory tariffs in response to tariffs imposed by the United States). These developments, or the perception that any of them could occur, may have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global trade and, in particular, trade between the impacted nations and the U.S. Any of these factors and uncertain and volatile macroeconomic conditions, including low productivity growth, declining business investment, inflationary pressures, fluctuating interests rates, concerns regarding the level of U.S. debt, shifts in monetary and fiscal policy, strained international trade relations, and heightened geopolitical pressures could depress economic activity and have a material adverse effect on our business, financial condition and results of operations.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the three months ended March 31, 2025, none of our directors or executive officers adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
35

ITEM 6. EXHIBITS
NumberDescription
2.1 
2.2*
3.1 
3.2 
10.1†
10.2†*
10.3†*
10.4†*
10.5†*
10.6†*
10.7†*
10.8†*
10.9†*
31.1*
31.2*
32.1*
101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
36

101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
___________________________________________
*    Filed herewith
†    Indicates a management contract or compensatory plan or arrangement
37

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
CONCENTRA GROUP HOLDINGS PARENT, INC.
  
  
Dated:  May 7, 2025
By:/s/ Matthew T. DiCanio
  Matthew T. DiCanio
  President and Principal Financial Officer
  (Duly Authorized Officer)
   
Dated:  May 7, 2025
By:/s/ Su Zan Nelson
  Su Zan Nelson
  Executive Vice President, Chief Accounting Officer
  (Principal Accounting Officer)
 

38

 EX-2.2 2 firstamendmenttoequitypurc.htm EX-2.2 Document
Exhibit 2.2
FIRST AMENDMENT TO
EQUITY PURCHASE AGREEMENT

    This First Amendment to Equity Purchase Agreement is dated effective as of March 1, 2025 (this “Amendment”), is entered into by the Sellers’ Representative (as defined below), the Company and Buyer, and amends the Equity Purchase Agreement, dated January 22, 2025 (the “Purchase Agreement”), by and among CONCENTRA HEALTH SERVICES, INC., a Nevada corporation (“Buyer”); U.S. OCCMED HOLDINGS, LLC D/B/A NOVA MEDICAL CENTERS, a Texas limited liability (the “Company”); Gert Rohde, as Trustee for THE U. ROHDE 2020 TRUST, U/T/A DATED DECEMBER 18, 2020 (“U-Rohde”); Ulf Rohde, as Trustee for THE G. ROHDE 2020 TRUST, U/T/A DATED DECEMBER 18, 2020 (“G-Rohde”); Ulf Rohde, as Trustee for THE J. ROHDE 2020 TRUST, U/T/A DATED DECEMBER 18, 2020 (“J-Rohde”); Gert Rohde, as Trustee for THE M. ROHDE 2020 TRUST, U/T/A DATED DECEMBER 18, 2020 (“M-Rohde”); OCCMED SERVICES, LLC, a Texas limited liability company (“Occmed Services,” and collectively with U-Rohde, G-Rohde, J-Rohde, M-Rohde, “Sellers”), and SHELTON FREY, as Sellers’ Representative (the “Sellers’ Representative”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement.

WHEREAS, Buyer, the Company and the Sellers’ Representative desire to amend the Purchase Agreement in accordance with Section 12.6 of the Purchase Agreement, as set forth below.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree to amend the Purchase Agreement as follows:

1.Amendment to Section 1.1. Each defined term listed below from Section 1.1 of the Purchase Agreement is each hereby amended and restated in its entirety as set forth below:
“Ancillary Agreements” means the Release and Restrictive Covenant Agreements, the Release and Distribution Agreements, the Assignment of Membership Interests, the Escrow Agreement, the Company Professional Association Transfer Documents, the Supplemental Special Indemnity Agreements, the Side Letter, the Leslie Boney Release, the Landlord Consents and the Lease Amendments.
“Sellers’ Representative Holdback Amount” means the sum of $550,000 which shall be governed by the provisions of Section 12.20.
2.Schedule 2.2(b)(i)(A) to the Purchase Agreement. The Purchase Agreement contemplates Schedule 2.2(b)(i)(A), but such schedule was not attached to the Purchase Agreement when the Purchase Agreement was executed. The Purchase Agreement is hereby amended to include Schedule 2.2(b)(i)(A) in the form attached hereto as Exhibit A.


3.Amendment to Section 2.2(b)(iii). Section 2.2(b)(iii) of the Purchase Agreement, is each hereby amended and restated in its entirety as set forth below:
(iii)    an amount of cash equal to $2,800,000 (such amount the “Special Indemnity Escrow Amount” and such amount, including any interest or other amounts earned thereon and less any disbursements therefrom in accordance with this Agreement and the Escrow Agreement, the “Special Indemnity Escrow Funds”) to be deposited into an escrow account (the “Special Indemnity Escrow Account”), which shall be established, held, managed, and paid out in accordance with the Escrow Agreement;
4.Addition of Section 2.2(d). Section 2.2 of the Purchase Agreement is hereby amended to add the following as Section 2.2(d):
(d)    The parties hereto agree that Buyer shall be entitled to rely on the Payment Percentages set forth in Schedule 2.2(b)(i)(A) in making payments under this Agreement and Buyer shall not be responsible for, and shall have no liability for, the calculations or the determinations regarding such calculations in Schedule 2.2(b)(i)(A) or any of the payments with respect thereto, so long as such payments were made in accordance with the Payment Percentages set forth in Schedule 2.2(b)(i)(A).
5.Section 10.2(a)(i) of the Disclosure Schedule. Section 10.2(a)(i) of the Disclosure Schedule is hereby amended and restated in its entirety set forth on Exhibit B hereto.
6.Addition of Section 6.22. The Agreement is hereby amended to add the following Section 6.22:
The Sellers shall take any an all actions necessary to fund USOH 401k LLC and shall fund USOH 401k LLC in accordance with the Side Letter.
7.Addition of Section 8.20. The Agreement is hereby amended to add the following Section 8.20:
8.20 Side Letter. The Side Letter duly executed by each of Gert Rohde, Ulf Rohde and USOH 401k LLC.
8.Addition of Section 8.21. The Agreement is hereby amended to add the following Section 8.21:
8.21 USOH 401k LLC Funding. Evidence that USOH 401k LLC has been funded by March 5, 2025, in accordance with the Side Letter.
9.Amendment to Section 10.2(c)(i). Section 10.2(c)(i) – (iii) of the Purchase Agreement are hereby amended and restated as follows:



(i)    The aggregate amount for which Sellers shall be liable for any Losses (including any expenses incurred by the Buyer Indemnified Parties in defending any Special Indemnified Matter, but excluding Losses arising out of Fraud) subject to indemnification under Section 10.2(a)(i) shall not exceed Two Million Eight Hundred Thousand Dollars and 00/100 Dollars ($2,800,000), plus the amount of all interest accrued in the Special Indemnity Escrow Account; provided that (i) the foregoing limitation shall not apply to the Special Indemnified Matters numbered 1 and 2 on Section 10.2(a)(i) of the Disclosure Schedule (the “Additional Special Indemnified Matters”), and (ii) nothing shall limit Buyer’s rights against Gert Rohde, Ulf Rohde or USOH 401k LLC under that certain letter agreement dated as of [_______, 2025] between Buyer and Gert Rohde, Ulf Rohde and USOH 401k LLC (the “Side Letter”).
(ii)    The aggregate amount for which Occmed Services shall be liable for any Losses (including any expenses incurred by the Buyer Indemnified Parties in defending any Supplemental Special Indemnified Matter, but excluding Losses arising out of Fraud) subject to indemnification under Section 10.2(a)(ii) shall not exceed Three Million Dollars and 00/100 Dollars ($3,000,000.00), plus the amount of all interest accrued in the Supplemental Special Indemnity Escrow Account; provided that for purposes of clarity nothing shall limit Buyer’s rights against the Indemnifying Occmed Services Members under the Supplemental Special Indemnity Agreements.
(iii)    As the exclusive remedy for any Losses under Section 10.2(a) (other than any Losses arising out of Fraud), including any expenses incurred by the Buyer Indemnified Parties in defending any claim, and notwithstanding anything to the contrary set forth herein, the Buyer Indemnified Parties shall be entitled to recover the amount of any Losses solely:
(A)with respect to the Special Indemnified Matters:
1)With respect to the Special Indemnification Matters other than the Additional Special Indemnified Matters, from the Special Indemnity Escrow Funds then remaining in the Special Indemnity Escrow Account; and

2)With respect to the Additional Special Indemnified Matters, (i) first, from the Special Indemnity Escrow Funds then remining in the Special Indemnity Escrow Account, and (ii) thereafter directly from the Sellers, jointly and severally; provided that nothing herein shall limit Buyer’s rights against Gert Rohde, Ulf Rohde or USOH 401k LLC under the Side Letter; or
    (B)     with respect to Supplemental Special Indemnified Matters, from the Supplemental Special Indemnity Escrow Funds then remaining in the Supplemental Special Indemnity Escrow Account; provided that nothing shall limit Buyer’s rights against the Indemnifying Occmed Services Members under the Supplemental Special Indemnity Agreements;



and no Losses (other than Losses arising from Fraud or Losses arising from the Additional Special Indemnified Matters) from any Indemnification Claim shall be recovered or recoverable directly from any Seller or any of their respective Affiliates (whether before or after funds are released from the Special Indemnity Escrow Funds or the Supplemental Special Indemnity Escrow Funds, as applicable); provided that notwithstanding the foregoing nothing shall limit Buyer’s rights against the Indemnifying Occmed Services Members under the Supplemental Special Indemnity Agreements or against Gert Rohde, Ulf Rohde or USOH 401k LLC under the Side Letter.
10.Addition of Section 10.2(n). The Agreement is hereby amended to add the following Section 10.2(n):
If it is determined under the terms of this Agreement (whether by mutual written agreement of the parties or by order of a court of competent jurisdiction or by deemed acceptance pursuant to Section 10.2(j)) that any of the Buyer Indemnified Parties are entitled to an indemnification payment from any Seller, then subject to the other terms of this Agreement, such Seller or Sellers shall make such payment to the applicable Buyer Indemnified Parties within five (5) Business Days of such determination by wire transfer of immediately available funds to an account designated by the Buyer Indemnified Parties.
11.Amendment to Section 10.2(m). Section 10.2(m) of the Agreement is hereby amended and restated as follows:
(m)    Buyer acknowledges and agrees, on behalf of itself, the Buyer Indemnified Parties and each of their respective Affiliates, that, from and after the Closing, their sole and exclusive remedy with respect to any and all claims and Losses (other than claims or Losses arising from Fraud) based upon, arising out of, with respect to, related to, or by reason of the Special Indemnified Matters and the Supplemental Special Indemnified Matters shall be pursuant to the indemnification provisions set forth in this Section 10.2 or, (i) with respect to the Special Indemnified Matters Only, the Side Letter, or (ii) with respect to the Supplemental Special Indemnified Matters only, the Supplemental Special Indemnity Agreements. In furtherance of the foregoing, Buyer hereby waives, on behalf of itself, each other Buyer Indemnified Party and the respective Affiliates to the fullest extent permitted under Law, any and all rights, claims and causes of action based upon, arising out of, related to, with respect to or by reason of any Special Indemnified Matter or Supplemental Special Indemnified Matter that they may have against Sellers and their Affiliates arising under or based upon any Law, except pursuant to the indemnification provisions set forth in this Section 10.2 or, (i) with respect to the Special Indemnified Matters Only, the Side Letter, or (ii) with respect to the Supplemental Special Indemnified Matters only, the Supplemental Special Indemnity Agreements. Nothing in this Section 10.2 shall limit any Buyer Indemnified Parties’ remedies on account of



Fraud, breaches of covenants pursuant to Section 10.1, under the R&W Policy or injunctive relief for breaches of Section 6.8.
12.Amendment to Section 12.2. Section 12.2 of the Purchase Agreement is amended to reflect the following:
If to Sellers, Sellers’ Representative or, prior to Closing, the Company:

Shelton Frey
101 Rainbow Drive #5204
Livingston, TX 77399
Telephone: (618)-534-3049
Email: ***

With a copy (which shall not constitute notice) to:

Becky Busker
3025 S State Hwy 16
Fredericksburg, TX 78624
Email: ***

13.No Other Changes; Interpretation. Except as and to the extent expressly modified by this Amendment, the Purchase Agreement, as so amended by this Amendment, will remain in full force and effect in all respects. Each reference to “hereof,” “herein,” “hereby,” and “this Agreement” in the Purchase Agreement will from and after the effective date hereof refer to the Purchase Agreement as amended by this Amendment. In the event of a conflict between the terms of this Amendment and the terms of the Purchase Agreement, the terms more favorable to Buyer shall control.
14.Entire Agreement. This Amendment, together with the Purchase Agreement and all exhibits and schedules thereto, sets forth the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior contracts, agreements, arrangements, communications, discussions, representations and warranties, whether oral or written, among the parties.
15.Governing Law; Miscellaneous. This Amendment and all of the transactions contemplated herein shall be governed by and construed in accordance with the laws of the State of Texas, without regard to any conflicts of law principles. Article XII of the Purchase Agreement is hereby incorporate herein by reference.
16.Further Amendments. Neither this Amendment nor any of the terms hereof may be terminated, amended, supplemented or modified orally, but only by an instrument in writing signed by the Company, Buyer and the Sellers’ Representative.
17.Counterparts. This Amendment may be executed in any number of counterparts with the same effect as if all signatory parties had signed the same document. All counterparts



shall be construed together and shall constitute one and the same instrument. Any counterpart may be executed via facsimile or other electronic transmission.
[Signatures begin on the next page.]



IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.


COMPANY:

U.S. OCCMED HOLDINGS, LLC D/B/A NOVA MEDICAL CENTERS


By:    /s/ Bruce Meymand______
    Name: Bruce Meymand    
    Title: CEO    

SELLERS’ REPRESENTATIVE:

/s/ Shelton Frey________________
Name: Shelton Frey    


BUYER:

CONCENTRA HEALTH SERVICES, INC.


By: /s/ Matthew DiCanio_______________
Name:    Matthew DiCanio
Title: President





Signature Page to First Amendment to Equity Purchase Agreement


Exhibit A

Payment Percentages

Schedule 2.2(b)(i)(A)
Payment Percentages

SellerPayment Percentage
U. Rohde 2020 Trust26.79%
J. Rohde 2020 Trust26.79%
G. Rohde 2020 Trust17.86%
M. Rohde 2020 Trust17.86%
Occmed Services, LLC10.70%
Total:100.00%







Exhibit B

Schedule 10.2(a)(i)

Special Indemnified Matters
1.The Company 401(k) Plan, including without limitation (i) the failure to timely complete the 401(k) Restructure and/or any or all of the tasks required in Section 1.1(e) of the Disclosure Schedule within the timeframes set forth in the Side Letter, (ii) any breach or violation by Gert Rohde, Ulf Rohde or USOH 401k LLC of the Side Letter, and (iii) any failure by Gert Rohde and/or Ulf Rohde to sufficiently fund USOH 401k, LLC to cover full the costs of any taxes or penalties employees will have from the loan deemed defaults, any gross ups on such payment and any Taxes owed by USOH 401k, LLC related thereto, in addition to other funding requirements set forth Section 1.1(e) of the Disclosure Schedule or the Side Letter.

2.Leslie Boney’s employment with the Company, including without limitation arising out of or relating to (a) her written offer of employment, dated December 21, 2023(the “Offer Letter”), (b) her Executive Employment Agreement dated December 21, 2023 (the “Boney Employment Agreement”), (c) any actual or purported Equity Securities, interests or other purported compensation which (x) are contemplated by the Offer Letter or the Employment Agreement, or (y) claimed to be owed to or held by Leslie Boney with respect to the Company, any Subsidiary thereof, OccMed Services or Buyer its Affiliates, (d) any portion of the Purchase Price or other payments under the Agreement claimed to be owed or payable to Leslie Boney, (e) any actual or alleged breach by the Company of the Offer Letter or Employment Agreement, (e) the failure to obtain the Leslie Boney Release or (f) the claims set forth in that certain demand letter to the Company, dated February 18, 2025, from Renee A. Morgan of Weener Nathan Phillips LLP.
3.Any inaccuracy in the calculations set forth on Schedule 2.2(b)(i)(A).
4.Possible failure to include additional compensation paid to nonexempt employees (e.g., nondiscretionary bonuses, commissions, or other compensation) in the overtime rate calculation for such employees in accordance with applicable federal or state legal requirements.
5.Possible failure to pay service providers classified as independent contractors additional compensation for overtime hours worked (excluding physicians who would be deemed exempt from overtime requirements under applicable legal requirement).
6.Potential misclassification of service providers as independent contractors rather than employees.


7.Potential unclaimed property Liabilities of the Company, its Subsidiaries or the Company Professional Associations.
8.Potential franchise Tax Liabilities, specifically relating to the lack of support for the proposition that the management fee is directly tied to the reimbursement of costs.
9.Potential lack of proper documentation evidencing a Cafeteria Plan prior to the year 2024.
10.Any violations of Laws (including Healthcare Laws) pertaining to restrictions on the corporate practice of medicine due to U.S. Occmed Wisconsin, S.C.’s engagement of Alan Cherkasky, M.D., LLC.
11.Any violation of Programs requirements with respect to Liability or Losses relating to any exclusion from the Federal Employee’s Compensation Act workers’ compensation program. pursuant to the findings in State of Texas vs Nova Healthcare Management, LLP, including any violation of Program requirements with respect to providing proper disclosures on credentialing and recredentialing applications, or otherwise providing written notice to a Program of such exclusion.
12.Any Liabilities or Losses resulting from the inability to enforce any contractual restrictive covenants against Dr. Bryan Novosad, Dr. Jason Carter or Dr. Linda Gregory as a result of such contractual restrictive covenants being drafted in a manner that is not in full compliance with applicable Laws (including Healthcare Laws).






Exhibit C

Letter Agreement

Attached.


    

 EX-10.2 3 con-michaelkosuthemploymen.htm EX-10.2 Document
Exhibit 10.2
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into this 30th day of September, 2015, by and between CONCENTRA INC., a. Delaware corporation, having an office address of 5080 Spectrum Drive, Suite 1200W, Addison, TX 75001 (“Employer”), and MICHAEL A. KOSUTH, an individual, residing at 4 Ayer Court, West Chester, PA 19382 (“Employee”).
BACKGROUND:
A.    Employer is in the business of providing primary care, occupational medicine, urgent care medicine, physical therapy and rehabilitation, veterans primary care medicine at community based outpatient clinics, and employer (or employer’s insurance) paid medical services located throughout the United States (the “Business”).
B.    Employer currently employs Employee as a Senior Vice President of Operations, to provide administrative, management, marketing, and/or supervisory services (the “Services”) in connection with Employer’s operation of the Business throughout the United States.
C.    Employer desires for Employee to continue to be employed by Employer and to render the Services in connection with the Business, subject to the terms and conditions specified below.
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employee and Employer, intending to be legally bound hereby, covenant and agree as follows:
1.    Employment. Effective on the Commencement Date (as defined below), Employer desires for Employee to continue to be employed by Employer and to render the Services in connection with the Business, subject to the terms and conditions set forth herein.
2.    Employee’s Duties and Responsibilities.
2.1    General. During the Employment Term, Employee shall be employed to perform the Services for and on behalf of Employer as further specified in this Section 2. Employee shall have the title of Senior Vice President of Operations. Employee shall report to W. Keith Newton, President and Chief Executive Officer of the Employer, or such other individual as the Chief Executive Officer of Employer may designate in his/her sole discretion.
2.2    Obligations and Duties of Employee. Employee shall devote a minimum of forty (40) hours a week to the performance of Employee’s duties hereunder. Subject to Employee’s right to take paid time off as permitted under Section 3.4 below, Employee’s duties are to be carried out over a 52-week period. Employee agrees to perform Employee’s duties diligently and to the best of Employee’s abilities, and to perform such additional or different
1

duties and services appropriate to Employee’s position that Employee from time to time may be reasonably directed to perform by Employer.
2.3    Authority and Control of Employer. Employee shall at all times comply with, and be subject to, such reasonable policies, procedures, rules and regulations as Employer or its parent company may establish from time to time and provide to Employee in a manner comparable to that used to provide such information to similarly situated employees, including Employer’s Code of Conduct, and all work performed by Employee shall be subject to review and evaluation by Employer.
2.4    Duty; Conflicts; No Prior Restrictions.
(a)    Employee acknowledges and agrees that Employee owes a duty of loyalty, fidelity and allegiance to act at all times in the best interests of Employer and its subsidiaries, affiliates and parent entities (collectively with Employer, the “Company Group”) and to do no act which would injure the Company Group’s business, interests or reputation. Employee shall devote Employee’s full business time, energy and best efforts to the business and affairs of Employer and to the fulfillment of Employee’s obligations hereunder. Employee shall not, during the Employment Term, without the prior written consent of Employer, engage in any other business, investment or activity, directly or indirectly, whether or not such activity is pursued for gain, profit, or other pecuniary advantage, which interferes with the performance of Employee’s duties hereunder or is contrary to the interests of the Company Group. It is agreed that any direct or indirect interest in, connection with, or benefit from any outside activities, particularly commercial activities, which interest might in any way adversely affect the Company Group, involves a possible conflict of interest. In keeping with Employee’s fiduciary duties to Employer, Employee agrees that Employee shall not knowingly become involved in a conflict of interest with the Company Group, or upon discovery thereof, allow such a conflict to continue. Employee shall disclose to Employer any facts that might involve a conflict of interest. Employee shall request the written consent of Employer prior to accepting a position as a trustee, officer or director of any outside organization which might involve a conflict of interest.
(b)    Employee has informed the Company Group that he is not bound by the terms and conditions of any existing non-competition or other restrictive covenant agreements (“Existing Agreement”) that would prevent Employee from accepting this position and performing Employee’s duties with the Company Group. Employee represents and warrants to the Company Group that Employee’s employment by Employer, and Employee’s execution and delivery of this Agreement, will not in any manner violate any Existing Agreement that he entered into with any past employer or other entity. If it is later determined that Employee misrepresented to the Company Group the terms and conditions of an Existing Agreement, then the Company Group may, in its sole and absolute discretion, terminate Employee’s employment for cause. Employee also agrees to indemnify, defend and hold harmless the Company Group, and its affiliates and subsidiaries, from and against all claims, lawsuits, losses, damages, expenses, costs, penalties, etc. arising out or related to any Existing Agreement and/or any claim or assertion that Employee has, either before or during the period Employee is employed by Employer, breached or violated any term or provision of any Existing Agreement.
2

3.    Financial Terms.
3.1    Base Salary. In consideration of Employee’s services hereunder, Employer agrees to pay Employee, during the Employment Term, the annual base salary of $275,000. Such base salary will be paid one week in arrears and in either biweekly or monthly installments based on Employer’s salary policy in effect from time to time. Employee may be considered for annual increases in base salary at Employer’s sole discretion.
3.2    Incentive Compensation.
(a)    Bonus Opportunity. Employee shall be eligible to receive an annual target incentive bonus in an amount up to forty percent (40%) of Employee’s annual base salary, the payment of which and amount (if paid) will be determined solely at the discretion of Employer based on and allocated as follows: the achievement of individual (25%) and Employer performance (75%) objectives. Employee must be actively employed at the time Employee’s incentive compensation is scheduled to be paid to be eligible to receive incentive compensation. The percentages above are subject to change at the discretion of the Employer’s Chief Executive Officer and/or Board of Directors. Employer shall have the right to modify its policies, programs and practices with respect to incentive compensation without the consent of Employee, provided that such modifications shall be effective with respect to Employee only at the beginning of Employer’s fiscal year.
(b)    Restricted Stock Interests and Options. The Compensation Committee of the Board of Directors of Concentra Group Holdings, LLC (“CGH”) has approved the grant of equity incentive awards to Employee, as follows: 750,000 options to purchase CGH’s Class B common stock (the “Stock Options”) at a purchase/strike price of $1.00 per share, subject to equal annual time-based vesting, over a period of 5-years after the full execution of an award agreement. All equity awards shall be subject to Employee’s execution and delivery of award agreements governing their terms.
3.3    Employee Benefits. During the Employment Term, in addition to the compensation paid to Employee pursuant to Sections 3.1 and 3.2 above, Employee shall be entitled to any employment and fringe benefits under Employer’s employment policies and employee benefit plans, as they may exist from time to time, and which are made available by Employer to other similarly situated employees, it being understood that Employee shall be required to make the same contributions and payments in order to receive any of such benefits as may be required of such similarly situated employees. Nothing in this Agreement shall be construed to obligate Employer to institute, maintain, or refrain from changing, amending or discontinuing any incentive compensation or employee benefit program or plan, so long as such actions are similarly applicable to covered employees generally. Employer shall have no obligation to secure or otherwise fund any of the aforesaid benefits and arrangements, and each shall instead constitute an unfounded and unsecured promise to pay money in the future exclusively from the general assets of Employer.
3.4    Paid Time Off. During the Employment Term, Employee shall be entitled to paid time off in accordance with Employer’s paid time off policies in effect from time to time,
3

such paid time off to be, at a minimum, equal to that paid time off to which similarly situated employees of Employer are entitled. Vacation schedules will be coordinated and approved by Employer so as to facilitate the steady ongoing operation of the Business.
3.5    Income and Employment Taxes. Employee shall be an employee of Employer for all purposes. Employer shall withhold amounts from Employee’s compensation in accordance with the requirements of applicable law for federal and state income tax, FICA, FUTA, and other employment or payroll tax purposes. It shall be Employee’s responsibility to report and pay all federal, state, and local taxes arising from Employee’s receipt of compensation hereunder.
3.6    Reimbursement of Expenses. In addition to the compensation provided for under this Section 3, upon submission of proper vouchers and in accordance with the policies and. procedures established by Employer in effect from time to time, Employer shall directly pay or reimburse Employee for all necessary and reasonable travel and lodging expenses incurred by Employee during the Employment Term in connection with Employee’s responsibilities to Employer. In addition, you will be entitled to a one time Relocation Allowance for reasonable expenses incurred in your relocation to the Dallas, Texas metropolitan area, subject to and in accordance with the Relocation Allowance policies and procedures established by Employer in effect from time to time.
4.    Term and Termination.
(a)    This Agreement shall commence on August 8, 2015 (the “Commencement Date”), and remain in effect, unless this Agreement is terminated by either party hereto, or extended by the written agreement of both parties hereto, for a period of one year after the date hereof (the “Employment Term”). Notwithstanding the foregoing, the Employment Term (unless this Agreement has been earlier terminated in accordance with Section 4(b), (c) or (d) below) shall automatically be extended beyond the first anniversary of the Commencement Date for additional periods of one (1) year each unless either party hereto shall notify the other, at least ninety (90) days prior to the end of the then current term, of Employer’s or Employee’s decision not to allow this Agreement to be extended beyond the end of the then current term.
(b)    Employer shall be entitled to terminate this Agreement, for cause, if any of the following events shall occur:
(i)    Employee’s death or upon Employee’s becoming incapacitated due to accident, sickness or other circumstances which render Employee mentally or physically incapable of performing the duties and services required of Employee for a period of ninety (90) consecutive days, as determined by a physician mutually selected by Employer and Employee; or
(ii)    Employee engages in criminal, unethical, or immoral conduct in violation of Employer’s Code of Conduct, or fraudulent conduct, in the reasonably good faith opinion of Employer, or Employee is
4

found guilty of such conduct by any court or governmental agency of competent jurisdiction; or
(iii)    Breach by Employee of any material representation, warranty or other material term or provision in this Agreement, which breach has not been cured to the satisfaction of Employer within twenty (20) calendar days after written notice of such breach; or
(iv)    Intentional failure or refusal to perform specific job duties reasonably required in connection with Employee’s position; provided, however, that such failure or refusal continues (i.e., has not been cured by Employee) within twenty (20) days after Employer notifies Employee in writing of such failure or refusal; or
(v)    The observed use of illegal drugs by Employee at any time or place, or Employee engaging in fraud, sexual harassment, or substance abuse, or any other action in violation of Employer’s Code of Conduct; or
(vi)    Employee’s gross negligence or gross misconduct in. the performance of the duties and services required by Employee.
(c)    Employer shall have the right to terminate Employee’s employment without cause at any time during the Employment Term or any renewal term upon delivery of written notice to Employee. If Employee’s employment is terminated by Employer without cause, Employer will, subject only to Employee’s execution and delivery of a general release in favor of and in a form satisfactory to Employer’s sole discretion, pay Employee severance benefits in the form of salary continuation of ten (10) months of base salary (at the rate in effect on the date of termination). Severance benefits paid to Employee are in lieu of base salary and any other compensation (bonuses, etc.) which Employee had been entitled to, prior to termination under this paragraph, pursuant to this Agreement (regardless of whether there remains some portion of the term of the Agreement). Such severance will be paid to Employee as salary continuation in bi-weekly installments, less applicable withholdings. Employee will not continue to accrue employer benefits, such as paid time off, health and dental insurance, short or long-term disability, life insurance etc. after Employee’s termination date. Employee agrees that if Employee breaches the terms of Section 5 or 6 of the Agreement, Employer shall have the right to discontinue, immediately and permanently, all further severance payments and health benefits hereunder and to obtain, by way of counterclaim or otherwise, repayment of the fall amount or cost thereof.
(d)    Employee may terminate this Agreement at any time for any reason or no reason whatsoever, provided that Employee shall notify Employer, in writing, at least forty-five (45) days prior to the effective date of such termination. If Employee elects to terminate this Agreement within ninety (90) days after the occurrence of a Termination Event (as hereinafter defined), then Employer will be obligated to pay the Severance Benefits to Employee. For
5

purposes of this Section 4(d), the term “Termination Event” shall mean (1) the material reduction by Employer of the scope of Employee’s role and responsibilities, or (2) the reduction by Employer of Employee’s base salary.
(e)    Upon termination of employment pursuant to any provision of Section 4 hereunder, Employee shall be entitled to receive such salary and fringe benefits, if any, accrued under the terms of this Agreement, but unpaid, as of the date of such termination, and all future compensation and all future employee benefits shall cease and terminate as of the date of termination. Employee shall be entitled to pro rata salary through the date of such termination and, if applicable, any severance benefits payable under subsection 4(c) above. Employee shall be not entitled to the pro rata portion of any incentive compensation (bonuses, etc.) accrued but not yet paid as of the date of termination.
5.    Ownership and Protection of Employer Confidential Information and Intellectual Property.
(a)    Contemporaneously herein, Employee will receive and have access to confidential material of Employer. For purposes of this Agreement, Employer Confidential Information includes, but is not limited to, all information not generally known to the public, in spoken, printed, electronic or any other form or medium, relating directly or indirectly to: information concerning strategic business partnerships, information concerning corporate partnerships, business processes, practices, methods, policies, plans, publications, documents, research, operations, services, strategies, techniques, agreements, contracts, terms of agreements, transactions, potential transactions, negotiations, pending negotiations, know-how, trade secrets, computer programs, computer software, applications, operating systems, software design, web design, work-in-process, databases, manuals, records, articles, systems, material, sources of material, supplier information, vendor information, financial information, results, accounting information, accounting records, legal information, marketing information, advertising information, pricing information, credit information, design information, payroll information, staffing information, personnel information, employee lists, supplier lists, vendor lists, developments, reports, internal controls, security procedures, graphics, drawings, sketches, market studies, sales information, revenue, costs, formulae, notes, communications, algorithms, product plans, designs, styles, models, ideas, audiovisual programs, inventions, unpublished patent applications, original works of authorship, discoveries, experimental processes, experimental results, specifications, customer information, customer lists, client information, patient lists, manufacturing information, factory lists, distributor lists, and buyer lists or any existing or prospective customer, supplier, investor or other associated third party, or of any other person or entity that has entrusted information to Employer in confidence.
(b)    All intellectual property information, ideas, concepts, improvements, discoveries and inventions, whether patentable or not, which are conceived, made, developed or acquired by Employee or which are disclosed or made known to Employee, individually or in conjunction with others, during the Employment Term (whether during business hours or otherwise and whether on Employer’s premises or elsewhere) which relate to the Company Group’s past, present or anticipated business, products or services shall be disclosed to Employer
6

and are and shall be the sole and exclusive property of Employer. All memoranda, notes, records, files, correspondence, drawings, manuals, models, specifications, computer programs, maps and all other writings or materials of any type embodying any of such information, ideas, concepts, improvements, discoveries and inventions are and shall be the sole and exclusive property of Employer. Employee hereby specifically sells, assigns, and transfers to Employer all of Employee’s right, title and interest in and to all such information, ideas, concepts, improvements, discoveries or inventions, and any United States or foreign applications for patents, inventor’s certificates, or other industrial rights that may be filed thereon, including divisions, continuations, continuations-in-part, reissues and/or extensions thereof.
(c)    Employee understands that the above list is not exhaustive, and that Employer Confidential Information also includes other information that is marked or otherwise identified as confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is known or used.
(d)    Employee shall not, during or after the term of Employee’s employment hereunder, disclose either the Company Group’s proprietary information or trade secrets to any other person or entity for any reason or purpose whatsoever, without the written consent of the Company Group. All written materials, notes, records and other documents made by, or coming into the possession of, Employee during the term hereof which contain or disclose any of the foregoing shall be and remain the property of the Company Group. Upon the termination of this Agreement for any reason whatsoever, Employee shall promptly, at Employer’s written request, deliver the same, and all copies thereof, to the Company Group.
6.    Non-Solicitation; Non-Compete. Because of Employer’s legitimate business interest as described herein and the good and valuable consideration offered to Employee, during the Employment Term and for a period of two (2) years after the termination of Employee’s employment (the “Restricted Period”), for any reason, Employee shall not:
(a)    Non-Solicitation of Employees. Directly or indirectly, through any entity, family member or agent, without the express written consent of Employer (which consent may be withheld in Employer’s sole discretion), solicit or contact, cause others to solicit or contact, with a view to engaging or employing, nor shall Employee actually engage or employ, any person who is, or at any time was during the two-year period immediately preceding the termination date, an employee or consultant of the Company Group; or
(b)    Non-Solicitation of Customers. Directly or indirectly, solicit or entice away from the Company Group any customer, client, physician, patient, referral source and/or payor of the Company Group at any time during the two-year period immediately preceding the date of Employee’s termination with Employer.
(c)    Non-Compete. Directly or indirectly, personally, or as an employee, officer, director, partner, member, owner, shareholder, investor or principal of, or consultant or independent contractor with, another person, participate in any role or position with a Competing Business (defined below) in the Restricted Territory that involves Prohibited Activity (defined
7

below). This restriction includes engaging in any preparatory activities respecting the commencement of any Competing Business, including the discussion, either publicly or privately of Employer’s development, invention, or creation of, product or service concepts, product or service designs, underwriting techniques, policy and application forms, marketing intelligence, inventions, technology, or other related information. During the Restricted Period, Employee must obtain the advance written approval of Employer prior to engaging in employment or other compensatory services (including services as an agent or independent contractor) for any Competing Business.
(d)    Employee’s passive ownership of less than five percent (5%) of the securities of a publicly traded company shall not be treated as an action in violation of the restrictions set forth herein above.
(e)    For purposes of this Agreement, “Competing Business” shall mean any business or commercial activity about which Employee has had access to Confidential Employer Information, and in which Employer or Company Group is or has been engaged at any time within the last two years of Employee’s employment with Employer, including, without limitation, (a) primary care occupational medicine; (b) urgent care medicine; (c) physical therapy and rehabilitation; (d) veterans primary care medicine at community based outpatient clinics; (e) employer (or employer’s insurance) paid medical services for injuries or matters, including, without limitation, physical exams, laboratory testing, x-rays, audiometry, spirometry, electrocardiography, drug screens, injuries and illnesses, on-site medical evaluations; (f) independent medical examinations; and (g) consulting with employers regarding healthcare programs and policies; or in any other business that provides a product or service that would conflict with, compete with or replace products or services managed or sold by Employer.
(f)    For purposes of this Agreement, “Prohibited Activity” means any service or activity on behalf of a Competing Business that involves the planning, management, supervision or providing of services that are similar in nature or purpose to those services Employee provided to Employer or its affiliates within the last two years of Employee’s employment with Employer, or any other activities that would involve the use or disclosure of Confidential Employer information.
(g)    For purposes of this Agreement, “Restricted Territory” shall mean the geographical markets in which the Employer or its affiliates have been engaged in business or commercial activities and about which Employee has had access to Confidential Employer Information, in the last two years of Employee’s employment with Employer.
(h)    The parties hereto agree that if, in any proceeding, the court or other authority shall refuse to enforce the covenants herein set forth because such covenants cover too extensive a geographic area or too long a period of time, any such covenant shall be deemed appropriately amended and modified in keeping with the intention of the parties to the maximum extent permitted by law.
(i)    Employee acknowledges that Employee’s obligations under Section 5 and 6 shall be fully binding and enforceable regardless of the reason for the termination of Employee’s employment, and whether such termination was voluntary or involuntary. The two
8

(2) year restrictive period above shall be deemed tolled during any period in which Employee is in violation of Employee’s obligations under Section 5 and 6. Employee agrees that, in any action to enforce Employee’s obligations, the Company Group shall be entitled to a full two (2) year period of protection, which two (2) year period shall be determined without including any period of Employee’s breach.
(j)    Employee hereby acknowledges and agrees that Employee’s obligations under this Agreement, including the restrictive covenants, are assignable by Employer subject to its existing terms and conditions.
7.    Protection of Company Group; Equitable Relief.
(a)    Employee expressly acknowledges and agrees that the covenants and agreements set forth in Sections 5 and 6 are necessary in order to protect, maintain and preserve the value and goodwill of the businesses of the Company Group, as well as the proprietary and other legitimate business interests of the members of the Company Group. Employee acknowledges and agrees that the covenants and agreements of Employee set forth in Sections 5 and 6 are a material reason for the payment of the salary, incentive compensation and benefits provided for in this Agreement.
(b)    The parties hereto hereby acknowledge and agree that the restrictions and obligations set forth herein, including but not limited to the restrictions and obligations set forth in Sections 5 and 6 herein, are reasonable and necessary, and that any violation thereof would result in substantial and irreparable injury to Employer, and that Employer may not have an adequate remedy at law with respect to any such violation. Accordingly, Employee agrees that, in the event of any actual or threatened violation of any restriction or obligation set forth herein, Employer shall have the right and privilege to obtain, in addition to any other remedies that may be available, equitable relief; including temporary and permanent injunctive relief, to cease or prevent any actual or threatened violation of any provision hereof.
(c)    Any claim that Employee may have against Employer, including a claim for breach of this Agreement by Employer, shall not constitute a defense and shall not relieve Employee from complying with all of Employee’s obligations under Sections 5 and 6.
8.    Miscellaneous.
8.1    Governing Law. This Agreement shall be governed and interpreted in accordance with, and the rights of the parties shall be determined by, the internal laws of the State of Texas without reference to its conflicts of laws principles.
8.2    Severability. If any provision of this Agreement shall be declared invalid or illegal for any reason whatsoever, then notwithstanding such invalidity or illegality, the remaining terms and provisions of this Agreement shall remain in full force and effect in the same manner as if the invalid or illegal provision bad not been contained herein.
8.3    Amendment. No alteration or modification of this Agreement shall be valid unless made in writing and executed by each of the parties hereto.
9

8.4    Counterparts. This Agreement may be executed in more than one counterpart, and each executed counterpart shall be considered as the original.
8.5    Successors; Binding Agreement. This Agreement shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective personal representatives, successors and permitted assigns.
8.6    Notices. Any notice or other communication by one party hereto to the other shall be in writing and shall be given, and be deemed to have been given, if either hand delivered or mailed, postage prepaid, certified mail (return receipt requested), addressed as follows:
If to Employer:Concentra Group Holdings Parent, Inc.
5080 Spectrum Drive, Suite 1200W
Addison, TX 75001
Attn: President & CEO
With a copy to:Select Medical Corporation
4714 Gettysburg Road
Mechanicsburg, PA 17055
Attention: General Counsel
If to Employee:Michael A. Kosuth
4 Ayer Court
West Chester, PA 19382
Either party hereto may change the address for notice by notifying the other party, in writing, of the new address.
8.7    Waiver. A waiver of the breach of any term or condition of this Agreement shall not be deemed to constitute a waiver of any subsequent breach of the same or any other term or condition.
8.8    Assignment. Employee shall have no right to assign this Agreement. Employer may assign its rights and obligations hereunder to any (a) member of the Company Group or (b) successor in ownership of the Business, but any such assignment hereunder shall be subject to its existing terms and conditions.
8.9    Entire Agreement. This Agreement contains the entire agreement of the parties relating to the subject matter hereof and supersedes and merges all previous agreements and discussions between Employer and Employee, and constitutes the entire agreement of the parties with respect to Employee’s employment by Employer; provided, however, that the non-disclosure, non-solicitation, and non-competition restrictive covenant terms and conditions of your existing Employment Agreement dated November 19, 2010, by and between you and
10

Employer, shall survive the execution and delivery of this Agreement and remain in full force and effect for the benefit of Employer and its affiliates in accordance with its respective terms,
8.10    Survival. The covenants contained in Sections 2.4, 4(c), 5, 6, 7, and 8 shall survive any termination or expiration of this Agreement.
8.11    Expenses. Each of the parties hereto shall ‘bear his, her or its own costs and expenses, including attorneys’ fees and disbursements, incurred in connection with this Agreement and the transactions contemplated hereby; provided, however, in the event that it is necessary for (a) the Company Group to retain the services of an attorney or to initiate legal proceedings to enforce Employee’s obligations hereunder, then in the event that the Company Group is the prevailing party, the Company Group shall be entitled to recover from Employee, and Employee shall pay to Employer, all fees, costs and expenses of enforcing any right under or in respect to this Agreement, including, without limitation, reasonable fees and expenses of attorneys and accountants, and court costs, or (b) Employee to retain the services of an attorney or to initiate legal proceedings to enforce any obligation of Employer hereunder, then in the event that Employee is the prevailing party, Employee shall be entitled to recover from Employer all fees, costs and expenses of enforcing such obligation hereunder, including, without limitation, reasonable fees and expenses of attorneys and accountants, and court costs.
[THE NEXT PAGE FOLLOWING IS THE SIGNATURE PAGE]

[THIS REMAINING SPACE IS INTENTIONALLY LEFT BLANK]

11

IN WITNESS WHEREOF, the parties hereto have set their hands and seals as of the day and year first above written.
EMPLOYER:
CONCENTRA INC.
By: /s/ W. Keith Newton    
Name: W. Keith Newton
Title: President and CEO
EMPLOYEE:
By: /s/ Michael A. Kosuth    
Michael A. Kosuth
12
 EX-10.3 4 con-johnandersonemployment.htm EX-10.3 Document
Exhibit 10.3
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into on this 19th day of November, 2010, by and between (i) CONCENTRA INC., a Delaware corporation (“Employer”) and (ii) John R. Anderson, D.O. (“Executive”). All references to Employer in this Agreement shall include any successor in interest to Employer.
RECITALS:
A.    Employer has employed Executive in an executive position and has determined that Executive holds an important position with Employer. In anticipation of the merger of HumMS, Inc., a wholly-owned subsidiary of Humana Inc. with and into Employer (the “Merger”), whereby Employer will become a wholly-owned subsidiary of Humana Inc., Executive is being asked to enter into this Agreement.
B.    Management will be essential to maintain the stability of Employer during the anticipation of the Merger and to promote the successful closing of the Merger. Employer and Executive understand and agree that as part of and to induce Humana Inc. and HumMS, Inc. to enter into an Agreement and Plan of Merger with Employer providing for the Merger (the “Merger Agreement”), it is necessary to execute this Agreement and thereby to provide for the eventual termination of any and all prior agreements and contracts between the parties and for Executive to release and waive any and all claims, known or unknown, that may arise from such agreements and contracts or the termination of such agreements and contracts.
C.    Employer understands that anticipation of the Merger presents significant concerns for Executive with respect to his/her financial and job security. Employer desires to assure itself of Executive’s services during the period in which it is confronting such a situation, and to provide Executive certain financial assurances to enable Executive to perform the responsibilities of his/her position without undue distraction and to exercise judgment without bias due to personal circumstances.
D.    Employer further desires to assure itself that in the event the Merger is consummated, its business is not harmed by Executive’s subsequent competition with Employer’s, Humana Inc.’s, or their affiliates’ business. To achieve these objectives, Employer and Executive desire to enter into this Agreement.
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, it is agreed by and between Employer and Executive as follows:
1.    EFFECTIVE DATE, EFFECTIVE TIME AND EMPLOYMENT AT WILL. The date upon which Humana Inc., HumMS, Inc. and Employer execute and deliver the Merger Agreement shall constitute the effective date of this Agreement (“Effective Date”). The Effective Time, as defined in Section 2.2 of the Merger Agreement, shall be 11:59 p.m. on the date of filing of the Certificate of Merger with the Secretary of State of the State of Delaware in accordance with the DGCL. All other capitalized terms, unless otherwise defined in this Agreement, shall have the same meaning as ascribed to such terms in the Merger Agreement.


EMPLOYER OFFERS AND EXECUTIVE ACCEPTS AND AGREES TO BE EMPLOYED ON AN EMPLOYMENT AT-WILL BASIS FOLLOWING THE EFFECTIVE TIME. NOTHING IN THIS AGREEMENT CONSTITUTES AN EMPLOYMENT CONTRACT BETWEEN EXECUTIVE AND EMPLOYER THAT GUARANTEES TO EXECUTIVE EMPLOYMENT BEYOND THE EFFECTIVE TIME. Employment at-will means that Employer and Executive may unilaterally terminate the employment relationship and this Agreement at will, with or without notice or Cause or Good Reason. None of the promised benefits or other terms promised in this Agreement alter this at-will employment relationship or create a presumption of employment for any specified period of time. Unless terminated sooner by Employer or Executive, this Agreement shall expire on the later of the third anniversary of the Effective Time and December 31, 2013; provided, notwithstanding such expiration, all compensation earned and payable to Executive pursuant to the terms of this Agreement shall survive the expiration of this Agreement.
2.    TERMINATION OF AGREEMENT. Notwithstanding the provisions of this Agreement, this Agreement shall automatically terminate and shall be void ab initio in the event that the Merger Agreement terminates or the Merger contemplated by the Merger Agreement is not consummated on or before December 31, 2010, or such later date as may be established as the date of termination of the Merger Agreement by agreement of Employer, Humana Inc. and HumMS, Inc.
3.    EFFECT ON PRIOR AGREEMENTS. During the period commencing as of the Effective Date and expiring immediately prior to the Effective Time (the “Pre-Closing Period”), the terms of that certain Physician Services Agreement dated October 1, 1993, by and between Employer and Executive, as amended (the “Current Employment Agreement”), shall remain in full force and effect. From and after the Effective Time, and without any further consideration or action by Employer or Executive, this Agreement shall supersede, render void and terminate the Current Employment Agreement and any other prior agreements Executive may have had with Employer or its predecessor entities. The foregoing notwithstanding, Executive’s non-disclosure, non-solicitation and non-competition provisions undertaken in his/her Current Employment Agreement or other agreement, or under duties of fiduciary or loyalty, shall remain in full force and effect for the benefit of Employer and its affiliates throughout the term of this Agreement and after termination of employment as provided by their terms. Further, this Agreement shall not affect: (a) Executive’s rights to receive his/her regular compensation and benefits accrued and unpaid through the Effective Time, including any rights to paid vacation or sick time; or (b) any rights Executive may have under the terms of the Merger Agreement, including any indemnity rights.
4.    DUTIES. Executive agrees to devote his/her full attention to the business and affairs of Employer and its affiliates and to use best efforts to perform faithfully, diligently and efficiently the duties and responsibilities he/she is given as an Executive of Employer and such other duties and responsibilities reasonably commensurate with Executive’s skills, ability, and training and that may otherwise be assigned to Executive from time to time by Employer. Executive assumes the highest duties of loyalty and fiduciary responsibilities to Employer and
2

shall not engage in any actions which violate these duties or constitute a conflict of interest of any sort.
5.    BASE SALARY AND BENEFITS FROM AND AFTER EFFECTIVE TIME. From and after the Effective Time:
5.1    Base Salary. Employer shall pay Executive on a salary basis at a rate equivalent to Two Hundred and Eighty Thousand Dollars and No Cents ($280,000.00) per calendar year (“Base Salary”), less tax withholdings as designated in the tax forms submitted by Executive or otherwise required by law. Base Salary shall be paid on a semi-monthly or biweekly basis, Executive is an exempt status employee pursuant to federal and state wage and hour laws; accordingly, Executive will not be paid overtime. Executive’s Base Salary shall be evaluated and subject to increase from time to time, consistent with Employer’s policy based on an annual performance review. Employer and Executive understand and agree that the description of payment on a calendar year or annual basis does not affect the employment at-will status provided in Section 1, and therefore, it does not create a presumption that employment is for any definite period of time. Upon termination of Executive’s employment, Executive understands and agrees that he/she is entitled to Base Salary provided in this paragraph earned up to the date of termination, with the exception of the terms provided in Section 6.
5.2    Employee Benefit Plans. Executive shall participate, to the extent he/she may be eligible, solely in the “employee benefit plans” (as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended) maintained from time to time by Employer for employees of Employer and its subsidiaries. Executive will be required to pay his/her portion of premiums or related payments as designated in such employee benefit plans and/or as designated by Employer. Executive shall be required to comply with the conditions attendant to coverage by such plans and shall comply with and be entitled to benefits only in accordance with the terms and conditions of such plans as they may be amended from time to time. Nothing herein contained shall be construed as requiring Employer to establish or continue any particular employee benefit plan in discharge of its obligations under this Agreement. At Employer’s sole discretion, Employer may replace such employee benefit plans with employee benefit plans similar to Employer’s affiliates. Upon termination of Executive’s employment, Executive’s active coverage or participation in such employee benefit plans shall end, unless otherwise provided by the terms of such plans or by law.
5.3    Management Incentive Plan. Subject to all terms, conditions, provisions and obligations of Employer’s Management Incentive Plan, as amended from time to time for all similarly situated executives of Employer and its subsidiaries (“MIP”), Executive shall participate in the MIP, which shall be paid in cash on an annual basis. Executive’s targeted incentive amount will be 30% of his/her Base Salary. MIP is based upon meeting specific objectives, determined annually. To receive payment under the MIP, Executive must be a current employee of Employer or its affiliates at the end of the calendar year for which the MIP is awarded.
5.4    Equity Compensation. Subject to all terms, conditions and provisions and obligations of, and only upon execution of, the Humana Inc. Restricted Stock Unit
3

Agreement Under the 2003 Stock Incentive Plan, attached hereto as Exhibit “A” (the “Restricted Stock Unit Agreement”), issued pursuant to the Humana Inc. Amended and Restated 2003 Stock Incentive Plan (for purposes of this subsection “Plan”), Executive shall receive a grant of restricted stock units of Humana Inc. (“Restricted Stock Units”), the vesting for some of which is performance-based, and some of which is time based, the target amount totaling $400,000.00, each determined on the date of grant (the “Equity Compensation”). Executive may receive up to 175% of target Restricted Stock Units based on business performance as described in the Restricted Stock Unit Agreement. The Restricted Stock Unit Agreement will be executed, as soon as feasible, after the Effective Time. Except as otherwise set forth in the Restricted Stock Unit Agreement, the Restricted Stock Units will become vested at the end of a three-year performance period both for the time vested units, and, if pre-determined levels of performance are achieved, for the performance-based vesting units. Performance metrics are defined in Appendix A to the Restricted Stock Unit Agreement. The specific number of Restricted Stock Units to be issued shall be determined on the Closing Date, as defined in the Merger Agreement, based on the average of the high and low prices of Humana Inc. common stock on the New York Stock Exchange on that day and the individual target award level. The terms of the Restricted Stock Unit Agreement shall govern and control any conflict between the terms of this Agreement and the terms of the Restricted Stock Unit Agreement.
5.5    Continuing Medical Education. Executive shall be reimbursed for reasonable business expenses and costs associated with his/her annual Continuing Medical Education requirements in accordance with Employer’s expense reimbursement policies.
5.6    Vacation, Holidays and Leave Days. Executive shall earn vacation days per annum on a pro rata basis, and other holiday and leave days, consistent with Employer’s policies for employees of Employer and its subsidiaries.
5.7    No Other Compensation. Executive understands and agrees that, except as expressly provided in this Agreement, he/she is not entitled to and Employer is under no obligation to provide him/her any other compensation, payment, bonus, equity, property, or money pursuant to his/her employment.
6.    COMPENSATION UPON TERMINATION. From and after the Effective Time:
6.1    Termination Without Cause, Upon Death or Disability, or for Good Reason. Employer and Executive understand and agree that if this Agreement and Executive’s employment are terminated by Employer without Cause, or on account of the death or Disability of Executive, or by Executive for Good Reason, then Executive or his/her heirs shall receive the following:
(a)    any earned and unpaid Base Salary of Executive through the date of such termination and all bonuses earned and relating to any prior calendar year and not yet paid;
4

(b)    if such termination occurs within twelve (12) months after the Effective Time, then Employer will continue to pay Executive’s Base Salary, in semi-monthly or biweekly installments consistent with prior practice (net of applicable withholdings), for a period of nine (9) months. If such termination occurs twelve (12) months or more after the Effective Time, Employer will continue to pay Executive’s Base Salary, in semi-monthly or biweekly installments consistent with prior practice (net of applicable withholdings), for a period equal to two weeks per year of service with Employer (including all years of service with Employer prior to the Effective Time) for a minimum of four weeks and maximum of fifty-two weeks; and
(c)    all other compensation and benefits payable upon such termination under other plans and programs of Employer or as required by law, in accordance with the terms of such plans and programs or applicable law.
Payments to Executive under Section 6.1(b) shall be conditioned upon the prior execution and delivery to Employer of a customary release and waiver of claims from Executive (or Executive’s duly appointed legal representative in the case of death or Disability). (A form of customary release, which is subject to change, but substantially reflects the form Executive would be required to execute and deliver, is attached hereto as Exhibit “B”). Except as provided in this Agreement, no further compensation, benefits or obligations shall be due to Executive upon such termination under the terms of this Agreement.
6.2    Termination for Cause or other than for Death, Disability or Good Reason. Employer and Executive understand and agree that if this Agreement and Executive’s employment are terminated by Employer for Cause, or by Executive other than on account of his/her death or Disability, or by Executive without Good Reason, then the following shall apply:
(a)    Executive or his/her heirs shall receive his/her earned and unpaid Base Salary through the date of such termination and all bonuses earned and relating to any prior year and not yet paid;
(b)    Executive may receive all other compensation and benefits payable upon such termination under other plans and programs of Employer or as required by law, but only if and to the extent expressly permitted by the terms of such plans and programs or required by applicable law.
(c)    Except as provided in this Agreement, no further compensation, benefits or obligations shall be due to Executive upon such termination under the terms of this Agreement.
6.3    Certain Definitions.
(a)    For purposes of this Agreement, “Disability” shall mean that Executive (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment affecting Executive which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or is, by reason of any medically determinable physical or mental impairment affecting Executive which
5

can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than 3 months under an accident and health plan of Employer covering its employees.
(b)    For purposes of this Agreement, “Cause” shall mean that Executive: (i) has committed fraud or misappropriated, stolen or embezzled funds or property from Employer or an affiliate of Employer or secured or attempted to secure personally any profit in connection with any transaction entered into on behalf of Employer or any affiliate of Employer; (ii) has been convicted of a felony or failed to contest prosecution for a felony; or (iii) has willfully engaged in misconduct or dishonesty which is determined by the Board of Directors of Humana Inc. to be directly and materially harmful to the business or reputation of Employer or any of its affiliates.
(c)    For purposes of this Agreement, “Good Reason” shall mean (i) a failure by the Employer to comply in all material respects with any material provision of this Agreement, (ii) without the consent of Executive, a material reduction in Executive’s Base Salary other than a reduction generally applicable to similarly situated executives of Employer, or (iii) without the consent of Executive, relocation of Executive’s principal workplace outside a 40 mile radius of 30800 Telegraph Road, Suite 3900, Bingham Farms, Michigan 48025. For a resignation to be treated as “Good Reason” under this Agreement, Executive must provide to the Employer reasonable and specific written notice of such failure within 30 days after it occurs, the Employer shall be given a reasonable opportunity to cure, which shall not be less than 60 days, and if no cure has been effected or initiated within such period of time Executive must resign his/her employment within 120 days after the initial existence of one or more of the foregoing conditions.
7.    NON-COMPETITION OBLIGATION.
7.1    In consideration of Executive’s access to and receipt of significant Confidential Information (defined below) concerning Employer and its affiliates and his/her corresponding duty not to disclose such information, as well as his/her continuing employment opportunity with Employer after the Effective Time, the MIP, and the Equity Compensation to be provided by Employer hereunder, Executive hereby covenants and agrees that for a period commencing on the Effective Time and ending twelve (12) months after the effective date of Executive’s termination of employment with Employer (the “Restricted Period”), Executive directly or indirectly, personally, or as an employee, officer, director, partner, member, owner, shareholder, investor or principal of, or consultant or independent contractor with, another person, shall not participate in any role or position with a Competing Business (defined below) in the Restricted Territory that involves Prohibited Activity (defined below) (either as an executive, contractor, investor, partner, or in any other role with a Competing Business). This restriction includes engaging in any preparatory activities respecting the commencement of any Competing Business, including the discussion, either publicly or privately of Employer’s development, invention, or creation of, product or service concepts, product or service designs, underwriting techniques, policy and application forms, marketing intelligence, inventions, technology, or other related information. During the Restricted Period, Executive must obtain the advance written
6

approval of Employer prior to engaging in employment or other compensatory services (including services as an agent or independent contractor) for any Competing Business. Notwithstanding the foregoing, Executive shall not be prohibited from working as a physician not engaged in the practice of occupational medicine.
7.2    Executive’s passive ownership of less than five percent (5%) of the securities of a publicly traded company shall not be treated as an action in violation of the restrictions set forth herein above.
7.3    For purposes of this Agreement, “Competing Business” shall mean any business or commercial activity about which Executive has had access to Confidential Information, and in which Employer or any of its affiliates is or has been engaged at any time within the last two years of his/her employment with Employer, including, without limitation, (a) primary care occupational medicine; (b) urgent care medicine; (c) employer (or employer’s insurance) paid medical services for injuries or matters, including, without limitation, physical exams, laboratory testing, x-rays, audiometry, spirometry, electrocardiography, drug screens, injuries and illnesses, on-site medical evaluations; (d) independent medical examinations; (e) consulting with employers regarding healthcare programs and policies; or in any other business that provides a product or service that would conflict with, compete with or replace products or services sold by Employer that Executive was involved in, including, but not limited to, Employer’s Concentra Medical Centers, Auto Injury Solutions, and Health Solutions businesses.
7.4    For purposes of this Agreement, “Prohibited Activity” means any service or activity on behalf of a Competing Business that involves the planning, management, supervision or providing of services that are similar in nature or purpose to those services Executive provided to the Employer or its affiliates within the last two years of Executive’s employment with Employer, or any other activities that would involve the use or disclosure of Confidential Information.
7.5    For purposes of this Agreement, “Restricted Territory” shall mean the geographical markets in which the Employer or its affiliates have been engaged in business or commercial activities and about which Executive has had access to Confidential Information, in the last two years of his/her employment with Employer.
8.    NON-SOLICITATION OBLIGATION.
8.1    In consideration of Executive’s access to and receipt of significant Confidential Information concerning Employer and its affiliates and his/her corresponding duty not to disclose such information, as well as Executive’s continuing employment opportunity with Employer after the Effective Time, the MIP, and Equity Compensation to be provided by Employer hereunder, Executive hereby covenants and agrees that during the Restricted Period (defined above), Executive will not directly or indirectly:
(a)    Induce or solicit, or attempt to induce or solicit any employee, independent contractor, or agent, to discontinue working for or doing business with Employer or
7

its affiliates, whether for the purpose of working for any competitor of Employer or any affiliate thereof or otherwise.
(b)    Have any business-related contact with, call on or solicit, or attempt to call on or solicit, any Covered Entity on behalf of a Competing Business, or supervise or manage any such contact or solicitation activity.
(c)    Knowingly interfere with or ham any business relationship Employer may have with any contractor, referral source, provider, or supplier; this includes but is not limited to, an agreement not to induce any supply or service resource (including investment and other financing resources) to withdraw, curtail, or cancel the furnishing of supplies or services (including investment and other financing resources) to Employer.
8.2    For purposes of this Agreement, “Covered Entity” means the customers and referral sources of Employer or its affiliates (such as administrators, insurers, and employers) that have an established business relationship with the Employer or its affiliates at the relevant time of enforcement and that Executive had business-related contact with or was provided Confidential Information about in the last two years of his/her employment with Employer. “Covered Entity” does not include any persons or entities who, due to no fault of Executive and without any wrongdoing or other involvement by Executive and for reasons entirely unrelated to Executive, have fully and finally decided that they are not going to do further business with Employer or its affiliates and have in fact ceased doing any business with Employer or any of its affiliates at the relevant time of enforcement.
9.    CONFIDENTIALITY. In return for the promises made in this Agreement, Employer shall provide to Executive certain Confidential Information concerning Employer and its affiliates. Executive shall hold in a fiduciary capacity for the benefit of Employer and its affiliates all proprietary, trade secret, or confidential information, knowledge, or data relating to Employer or any of its affiliated companies, and their respective businesses, (i) obtained by Executive during employment by Employer or any of its affiliated companies and (ii) not otherwise public knowledge (other than by reason of an unauthorized act by Executive). Confidential Information includes, but is not limited to, the following types of information, in any location (including work and personal locations of any type), and in any format (hard or soft copy, documents and emails), pertaining to Employer or its affiliates: historical and current and potential customers or business referral sources; historical current or potential products; customer/member/provider or associate medical and dental information, claims information, other personal information, contract information and contract negotiation information and terms; contact information for customers and customer preferences and needs; information concerning employees, partners, vendors, and contractors including identities, contact information, compensation or other terms of engagement, and performance; business opportunities and strategies; training regarding processes, data, techniques and operations; information regarding products, networks, methods, referral sources, operations, plans, prices, gross and net profit margins, finances, budgets, forecasts, business and marketing techniques and strategies, pricing information, compilations of otherwise available information, developments, inventions, formulas, methods, processes, practices, specifications, designs, software, information
8

technology systems, configuration information, drawings, images, recordings, and other information and documents concerning Employer or its affiliates, their business operations and relationships that are not generally available to the public, and any other information designated as Confidential (collectively referred to in this Agreement as “Company Information”). If Executive is unsure whether or not a particular fact, matter, conversation, information or document is Company Information, Executive agrees to preserve the confidentiality of the item in question and receive clarification from the appropriate Employer manager or other internal authority. During employment, such Confidential Information shall only be used for the benefit of Employer or its affiliates. After termination of Executive’s employment with Employer, Executive shall not, without the prior written consent of Employer, unless compelled pursuant to an order of a court or other body having jurisdiction over such matter, use, access, communicate or divulge any such information, knowledge, or data to anyone other than Employer and those designated by it. Upon termination of employment, and without request by Employer, Executive shall immediately return to Employer all Confidential Information in his/her possession.
10.    REASONABLENESS OF SCOPE AND DURATION. Executive represents that his/her experience, capabilities and circumstances are such that the provisions contained in Sections 7, 8 and 9 will not prevent him/her from earning a livelihood. Executive hereby acknowledges that the limitations as to time, character or nature and geographic scope placed on his/her subsequent employment by Sections 7, 8 and 9 of this Agreement are reasonable and fair. If the territorial scope or time limitation of Sections 7, 8 and 9 are deemed unreasonable by a court of competent jurisdiction, they shall be reduced to the extent necessary to be deemed reasonable and, as so reduced, shall be enforced. It is understood that the covenants made by Executive in Sections 7, 8, 9, 10 and 11 shall survive the expiration or termination of this Agreement, if it expires or terminates after the Effective Time.
11.    REMEDIES AND ENFORCEABILITY.
11.1    Executive understands and agrees that Employer may not be adequately compensated by damages for a breach by Executive of any of the covenants and agreements contained herein, and that Employer shall, in addition to all other remedies, be entitled to injunctive relief and specific performance. Executive hereby affirmatively waives the requirement that Employer post any bond. Nothing herein contained will be construed as prohibiting Employer from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of money damages, and if Employer prevails, it shall also be entitled to the payment of any and all reasonable fees, disbursements, and other charges of the attorneys and collection agents, court costs, and all other costs of enforcement.
11.2    In the event that Executive institutes any proceeding to enforce his/her rights under, or to recover damages for breach of this Agreement, Executive, if he/she is the prevailing party, shall be entitled to recover from Employer any and all reasonable fees, disbursements, and other charges of the attorneys and collection agents, court costs, and all other costs of enforcement incurred by him. Likewise, if Employer prevails in any dispute with Executive under the terms of this Agreement, Employer shall be entitled to recover from Executive all if its reasonable costs and fees incurred, including attorney fees.
9

12.    GOVERNING LAW. This Agreement shall be governed by, and shall be construed and enforced in accordance with, the laws of the State of Texas, without giving effect to any conflict of law rule or principle of such state or any other jurisdiction. All proceedings to enforce any terms of this Agreement shall be brought in a court of competent jurisdiction in Dallas County, Texas.
13.    TIME PERIODS. All time periods referenced in Sections 7, 8 and 9 of this Agreement shall be computed by excluding from such computation any time during which Executive is in violation of any provision of this Agreement and any time during which there is pending in any court of competent jurisdiction any action (including any appeal from any final judgment) brought by any person, whether or not a party to this Agreement, in which action Employer seeks to enforce the agreements and covenants in Sections 7, 8, and 9 of this Agreement or in which any individual or entity contests the validity of such agreements and covenants or their enforceability or seeks to avoid their performance or enforcement.
14.    ENTIRE AGREEMENT. This Agreement and its Exhibits A and B constitute the entire agreement between the parties hereto with respect to the matters referred to herein. There are no promises, representations, inducements, or statements between the parties other than those that are expressly contained herein. The foregoing notwithstanding, this Agreement does not supercede or replace any of Executive’s existing obligations under the Current Employment Agreement or other agreements regarding non-disclosure, non-competition or non-solicitation or duties of fiduciary or loyalty under common law.
15.    AMENDMENT. This Agreement may only be amended by an agreement in writing signed by the party against whom enforcement is sought.
16.    BINDING EFFECT. This Agreement shall be binding upon, and shall inure to the benefit of, the parties, their personal representatives, heirs, devisees, successors and assigns. The duties and covenants of Executive under this Agreement, being personal, may not be delegated. Employer may assign its rights and obligations under this Agreement.
17.    HEADINGS, SECTION REFERENCES; CONSTRUCTION. Section headings or captions contained in this Agreement are inserted only as a matter of convenience and reference and in no way define, limit, extend or describe the scope of this Agreement, or the intent of any provision hereof. All references herein to Sections shall refer to Sections of this Agreement unless the context clearly otherwise requires. Unless the context clearly states otherwise, the use of the singular or plural in this Agreement shall include the other and the use of any gender shall include all others. The parties have participated jointly in the negotiation and drafting of this Agreement. If any ambiguity or question of intent or interpretation arises, no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.
18.    POLICIES, REGULATIONS AND GUIDELINES FOR EMPLOYEES. Employer and its affiliates may, from time to time, issue policies, rules, regulations, guidelines, procedures or other informational material, whether in the form of handbooks, memoranda or otherwise, relating to Employer’s employees. Executive acknowledges and agrees that such
10

material are general guidelines for Executive’s information and shall not be construed to alter, modify or amend this Agreement for any purpose whatsoever.
19.    SEVERABILITY OF PROVISIONS. If a court holds any provision of this Agreement or its application to any person or circumstance invalid, illegal or unenforceable, the remainder of this Agreement, or the application of such provision to persons or circumstances other than those to which it was held to be invalid, illegal or unenforceable, shall not be affected, and shall be valid, legal and enforceable to the fullest extent permitted by law, but only if and to the extent such enforcement would not materially and adversely frustrate the parties’ essential objectives as expressed in this Agreement. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties intend that the court or arbitrator add to this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be valid and enforceable, so as to effect the original intent of the parties to the greatest extent possible.
20.    SECTION 409A.
20.1    If Executive is a “key employee,” as defined in Section 416(i) of the Internal Revenue Code (the “Code”) (without regard to paragraph 5 thereof), except to the extent permitted under Section 409A of the Code, no benefit or payment that is subject to Section 409A of the Code (after taking into account all applicable exceptions to Section 409A of the Code, including but not limited to the exceptions for short-term deferrals and for “separation pay only upon an involuntary separation from service”) shall be made under this Agreement on account of Executive’s “separation from service,” as defined in Section 409A of the Code, with the Employer until the later of the date prescribed for payment in this Agreement and the first day of the seventh calendar month that begins after the date of Executive’s separation from service (or, if earlier, the date of death of Executive).
20.2    For purposes of Section 409A of the Code (including, but not limited to, application of the exceptions for short-term deferrals and for “separation pay only upon an involuntary separation from service”), each payment provided for under this Agreement is hereby designated as a separate payment, rather than a part of a larger single payment or one of a series of payments.
20.3    Any amount that Executive is entitled to be reimbursed under this Agreement will be reimbursed to Executive as promptly as practicable and in any event not later than the last day of the calendar year after the calendar year in which the expenses, if any, to be reimbursed are incurred, and the amount of the expenses eligible for reimbursement during any calendar year will not affect the amount of expenses eligible for reimbursement in any other calendar year. In addition, any such reimbursement payments described in this Section shall not be subject to liquidation or exchange for any other payment or benefit. In addition, any reimbursement payments described in this Section shall not be subject to liquidation or exchange for any other payment or benefit.
20.4    In the event that Executive is required to execute a release to receive any payments from the Employer that constitute nonqualified deferred compensation under Section
11

409A of the Code, payment of such amounts shall not commence until the 60th day following Executive’s separation from service with the Employer. Any installment payments suspended during such 60 day period shall be paid as a single lump sum payment on the first payroll date following the end of such suspension period.
21.    RELEASE. Subject to the condition that the Effective Time occurs, and taking effect automatically from and after the Effective Time without further act or deed of Executive or Employer, Executive hereby waives and releases any and all claims and causes of action against Employer and its affiliates, known or unknown, in any way related directly or indirectly to Executive’s status as an employee, officer or director of Employer, on or prior to the date hereof, together with any and all claims related to the anticipated termination of the Current Employment Agreement or other agreements, contracts, plans or promises with Employer upon consummation of the Merger; provided, however, that nothing herein shall constitute a waiver or release by Executive of any compensation or benefits accrued and unpaid under the terms of the Current Employment Agreement or such other agreements, contracts, plans or promises, or any claims or rights of Executive under the terms of this Agreement or the terms of the Merger Agreement. Employer and Executive understand and acknowledge that treatment of the stock options granted to Executive in prior agreements, if any, will be governed by the terms of the Merger Agreement. In consideration of Executive’s continuing employment opportunity with Employer after the Effective Time and the MIP, and the Equity Compensation to be provided by Employer hereunder, Executive further agrees at the Effective Time to sign a second release of claims, which substitutes the Effective Time for the date of this Agreement, but which is otherwise substantially similar in form and substances to the above release in this Section 21.
[Signature Page Follows]
12

IN WITNESS WHEREOF, as their free and voluntary act, the parties have executed this letter Agreement as of the date indicated.

Occupational Health Centers of Michigan, P.C.,

BY: /s/ W. Tom Fogerty        /s/ John R. Anderson        
John R. Anderson
1-12-11        1-12-11        
Date                            Date

13

AMENDMENT TO THE
EMPLOYMENT AGREEMENT
Between
John R. Anderson, D.O.
and
Occupational Health Centers of Michigan, P.C.
THE EFFECTIVE DATE OF THIS AMENDMENT IS: May 1, 2012
By this Amendment to the Employment Agreement dated November 24, 2010 (“Employment Agreement”) between John R. Anderson, D.O. (“Executive”) and Occupational Health Centers of Michigan, P.C., (the “P.C.”), Executive, P.C. and Concentra Inc. (“Concentra”) agree as set forth below:
WHEREAS, Executive, the P.C., and Concentra desire that Concentra replace the P.C. as the Employer under the Agreement;
NOW, THEREFORE, as of the effective date of this Amendment, the parties agree the Employment Agreement is amended by replacing the P.C. with Concentra as the Employer for all purposes. Wherever the Employment Agreement refers to the P.C. or the Employer, such reference shall apply solely to Concentra. Concentra agrees to assume all duties and obligations as the Employer under the Employment Agreement. The P.C. shall no longer be a party to the Employment Agreement.
The parties further agree that this Amendment does not terminate the Employment Agreement and does not entitle Executive to any compensation or benefits under Section 6 of the Employment Agreement.
IN WITNESS WHEREOF, have by respective offices executed and delivered this Amendment to the Employment Agreement.
[Signature Page Follows]

14

/s/ John R. Anderson, D.O.        Date 5/1/2012    
John R. Anderson, D.O.

/s/ W. Tom Fogerty        Date 5/3/2012    
Occupational Health Centers of Michigan, P.C.
By: W. Tom Fogerty    
Its: President    
/s/ Jim Greenwood        Date 5/3/2012    
Concentra Inc.
By: Jim Greenwood    
Its: CEO    

15

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT
THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT is made as of this 1st day of January, 2016, by and between Concentra Inc., a Delaware corporation and its subsidiaries and other affiliates (collectively the “Employer”), having an address of 5080 Spectrum Drive, Suite 1200W, Addison, TX, and John R. Anderson, D.O., an individual, (the “Executive”) residing at 6591 Bridgewater Dr., West Bloomfield, MI 48322.
BACKGROUND
A.    The parties previously executed and delivered that certain Employment Agreement, dated November 24, 2010 and amended on May 1, 2012 (hereinafter collectively referred to as the “Agreement”), pursuant to which the parties agreed to honor the covenants and other agreements set forth therein. All capitalized terms not specifically defined herein shall have the meanings ascribed to them in the Agreement.
B.    The parties now desire to amend the Agreement as hereinafter provided to acknowledge extension of the term and other agreed upon terms and conditions.
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employer and Executive, intending to be legally bound hereby, covenant and agree as follows:
2.    Amendment and Restatement of Section 1. Section 1 of the Agreement entitled “Effective Date, Effective Time and Employment at Will” is hereby amended and restated in its entirety as follows:
“Effective Date, Effective Time and Employment at Will. This Agreement shall commence on January 1, 2014 (the “Effective Date”) and remain in effect, unless this Agreement is terminated by either party hereto, or extended by the written agreement of both parties hereto, for a period of one (1) year after the date hereof (the “Employment Term”). Notwithstanding the foregoing, the Employment Term (unless this Agreement has been earlier terminated in accordance with Section below) shall automatically be extended beyond the first anniversary of the Effective Date for additional periods of one (1) year each unless either party hereto shall notify the other, at least ninety (90) days prior to the end of the then current term, of Employer’s or Employee’s decision not to allow this Agreement to be extended beyond the end of the then current term.”
3.    Amendment and Restatement of Section 5.1. Section 5.1 of the Agreement entitled “Base Salary” is hereby amended and restated in its entirety as follows:
“Base Salary. Employer shall pay Executive on a salary basis at a rate equivalent to Three Hundred Sixty-Five Thousand Nineteen Dollars and Twenty Cents ($365,019.20) per calendar year (“Base Salary”), less tax withholdings as designated in the tax forms submitted by Executive or otherwise required by law. Base Salary shall be paid on semi-monthly basis, Executive is an exempt status employee pursuant to federal and state wage and hour laws; accordingly, Executive will not be paid overtime. Executive’s Base Salary shall be evaluated and
16

subject to increase from time to time, consistent with Employer’s policy based on an annual performance review. Employer and Executive understand and agree that the description of payment on a calendar year or annual basis does not affect the employment at-will status provided in Section 1, and therefore, it does not create a presumption that employment is for any definite period of time. Upon termination of Executive’s employment, Executive understands and agrees that he/she is entitled to Base Salary provided in this paragraph earned up to the date of termination, with the exception of the terms provided in Section 6.”
4.    Amendment and Restatement of Section 5.4. Section 5.4 of the Agreement entitled “Equity Compensation” is hereby amended and restated in its entirety as follows:
“Restricted Stock Interests and Options. The Compensation Committee of the Board of Directors of Concentra Group Holdings, LLC (“CGH”) has approved the grant of equity incentive awards of Executive, as follows: 600,000 options to purchase CGH’s Class B common stock (the “Stock Options”) at a purchase/strike price of $1.00 per share, subject to equal annual time-based vesting, over a period of 5-years after the full execution of an award agreement. All equity awards shall be subject to Executive’s execution and delivery of award agreements governing their terms.”
5.    Amendment and Restatement of Section 6.1(c). Section 6.1(c) of the Agreement is hereby amended and restated in its entirety as follows:
“(c)    all other compensation and benefits payable upon such termination under other plans and program of Employer or as required by law, in accordance with the terms of such plans and programs or applicable law.
Payments to Executive under Section 6.1(b) shall be conditioned upon the prior execution and delivery to Employer of a general release in favor of and in a form satisfactory to Employer’s sole discretion. Except as provided in this Agreement, no further compensation, benefits or obligations shall be due to Executive upon such termination under the terms of this Agreement.”
6.    Reaffirmation of Section 7. Section 7 of the Agreement entitled “Non-Competition Obligation” shall hereby be reaffirmed. Executive hereby acknowledges and agrees that the provisions of Section 7, in their entirety, are binding upon Executive, and are enforceable against Executive, in accordance with their respective terms.
7.    Reaffirmation of Section 8. Section 8 of the Agreement entitled “Non-Solicitation Obligation” shall hereby be reaffirmed. Executive hereby acknowledges and agrees that the provisions of Section 8, in their entirety, are binding upon Executive, and are enforceable against Executive, in accordance with their respective terms.
8.    Reaffirmation of Section 9. Section 9 of the Agreement entitled “Confidentiality” shall hereby be reaffirmed. Executive hereby acknowledges and agrees that the provisions of Section 9, in their entirety, are binding upon Executive, and are enforceable against Executive, in accordance with their respective terms.
17

9.    No Other Modifications. Except as expressly amended hereby, the Agreement shall remain unmodified and in full force and effect.
[THE NEXT PAGE FOLLOWING IS THE SIGNATURE PAGE]
18

IN WITNESS WHEREOF, the parties hereto have set their hands and seals to this instrument as of the day and year first above written.
EMPLOYER
CONCENTRA, INC.
By: /s/ W. Keith Newton    
W. Keith Newton


EXECUTIVE:
/s/ John R. Anderson, D.O.    
John R. Anderson, D.O.
19
 EX-10.4 5 kosuth-amendmenttoemployme.htm EX-10.4 Document
Exhibit 10.4
CONCENTRA, INC.

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

    This FIRST AMENDMENT (“Amendment”) hereby amends that certain EMPLOYMENT AGREEMENT, entered into as of September 30, 2015 (the “Prior Agreement”), by and between Concentra, Inc. (“Employer”) and Michael Kosuth (“Employee”).

WHEREAS, Employer’s parent, Concentra Group Holdings Parent, Inc. (“Parent”), was formerly a wholly owned subsidiary of Select Medical Corporation (“Select”);

WHEREAS, Parent completed an initial public offering of its common stock on July 26, 2024 and on November 25, 2024, Select distributed its remaining shares of common stock of Parent to its stockholders, thereby completing the spin-off of Parent and Employer from Select; and

WHEREAS, Employer and Employee desire to amend certain terms of the Prior Agreement and to incorporate additional terms as provided herein.

    NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promise set forth in this Amendment, and for other consideration, the receipt and adequacy of which are hereby acknowledged, Employer and Employee (intending to be legally bound) hereby agree as follows:

1.Any reference to “Company Group” in the Prior Agreement shall be deemed a reference to Parent and its affiliates and subsidiaries, collectively.

2.Section 1 of the Prior Agreement is hereby replaced in its entirety with the following:

“1.     Adoption of Agreement by Parent. This Agreement and all rights and obligations hereunder is hereby adopted and assumed by Parent, in addition to Employer, but without any duplication of payments and/or benefits to Employee, and accordingly, Parent hereby, in addition to Employer, but without any duplication of payments and/or benefits to Employee, shall honor any and all of such rights and obligations and shall be an express party to this Agreement. In connection with the foregoing, references in the Agreement to “Employer” in the capacity as an employer shall be deemed to be references to Parent as the context may require. Notwithstanding the foregoing, Employer will continue to be a party to this Agreement and will be jointly and severally liable for all obligations hereunder with Parent.”

3.The reference to Employee’s title in Section 2.1 of the Prior Agreement to “Senior Vice President of Operations” is hereby replaced with “Executive Vice President and Chief Operating Officer – East Group of Parent.”



4.Section 3.2(b) of the Prior Agreement is hereby replaced in its entirety with the following:
“(b) [Reserved.]”
5.The following is hereby added at the end of Section 4(d) of the Prior Agreement:
“Employee must provide Employer with a written notice detailing the specific circumstances alleged to constitute a Termination Event within thirty (30) days after the first occurrence of such circumstances, provide Employer with thirty (30) days to cure such circumstances in all material respects and, if not so cured, actually terminate employment within thirty (30) days following the expiration of Employer’s thirty (30)-day cure period. Otherwise, any claim of such circumstances as a “Termination Event” shall be deemed irrevocably waived by Employee.”
6.Section 8.6 of the Prior Agreement is hereby replaced in its entirety with the following:
“8.6    Notices. Any notice or other communication by one party hereto to the other shall be in writing and shall be given, and be deemed to have been given, if either hand delivered or mailed, postage prepaid, certified mail (return receipt requested), addressed as follows:
If to Employer:Concentra Group Holdings Parent, Inc.
5080 Spectrum Drive, Suite 1200W
Addison, TX 75001
Attn: President & CEO

If to Employee, at the address (or the email address) shown in the books and records of Employer.”
7.New Section 9 is hereby added to the Prior Agreement as follows:

“9. Section 409A. This Agreement is intended to comply with, or otherwise be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and guidance promulgated thereunder (collectively “Code Section 409A”) and shall be interpreted in a manner consistent therewith. In no event whatsoever shall Employer be liable for any additional tax, interest or penalty that may be imposed on Employee by Code Section 409A or damages for failing to comply with Code Section 409A. Notwithstanding anything to the contrary herein, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute “nonqualified deferred compensation” for purposes of Code Section 409A upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” In addition, the entitlement


to any series of payments provided for in this Agreement shall be treated as a series of separate payments rather than a single payment for purposes of Section 409A of the Code. Notwithstanding anything to the contrary in this Agreement, if Employee is deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered “nonqualified deferred compensation” for purposes of Code Section 409A payable on account of a “separation from service,” such payment or benefit shall not be made or provided until the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such “separation from service” of Employee, and (B) the date Employee’s death, to the extent required under Code Section 409A. Upon the expiration of the foregoing delay period, all payments and benefits delayed pursuant to this Section 9 (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Employee in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. To the extent that reimbursements or other in-kind benefits under this letter agreement constitute “nonqualified deferred compensation” for purposes of Code Section 409A, (a) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Employee, (b) any right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (c) no such reimbursement, expenses eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.”

8.New Section 10 is hereby added to the Prior Agreement as follows:

“10.     Clawback. Employee acknowledges and agrees that Employee is and will be subject to the compensation recovery policy for incentive-based compensation that was adopted by the Board of Directors of Parent, as may be amended from time to time, and any other compensation recovery policies that Parent or Employer may adopt from time to time. For the avoidance of doubt, no recovery under any such compensation recovery policy will be an event giving rise to Employee of a right to resign following a Termination Event.”

9.New Section 11 is hereby added to the Prior Agreement as follows:

“11.     Trade Secrets; Whistleblowing. Notwithstanding anything to the contrary in this Agreement or otherwise, Employee understands and acknowledges that Employer has informed Employee that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for (a) the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law or (b) the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal. Additionally, notwithstanding anything to the contrary in this Agreement or otherwise, Employee understands and acknowledges that Employer has informed Employee that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade


secret information in the court proceeding if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to a court order. Nothing in this Agreement or any other agreement between Employee and Employer shall be interpreted to limit or interfere with Employee’s right to report good faith suspected violations of law to applicable government agencies, including the Equal Employment Opportunity Commission, National Labor Relation Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other applicable federal, state or local governmental agency, in accordance with the provisions of any “whistleblower” or similar provisions of local, state or federal law. Employee may report such suspected violations of law, even if such action would require Employee to share Employer’s proprietary information or trade secrets with the government agency, provided that any such information is protected to the maximum extent permissible and any such information constituting trade secrets is filed only under seal in connection with any court proceeding. Lastly, nothing in this Agreement or any other agreement between Employee and Employer will be interpreted to prohibit Employee from collecting any financial incentives in connection with making such reports or require Employee to notify or obtain approval by Employer prior to making such reports to a government agency.”
10.Except as hereby amended or modified herein, the terms and conditions of the Prior Agreement shall remain unchanged and in full force and effect.




IN WITNESS WHEREOF, the parties hereto have executed this Amendment, this 27th day of February, 2025.

Employer:

CONCENTRA, INC.


By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Secretary___________________________


CONCENTRA GROUP HOLDINGS PARENT, INC.

By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Executive Vice President and Secretary__



AGREED AND ACCEPTED:

Employee:


/s/ Mike Kosuth___________________________
Name: Michael Kosuth






 EX-10.5 6 anderson-amendmenttoemploy.htm EX-10.5 Document
Exhibit 10.5
CONCENTRA, INC.

THIRD AMENDMENT TO EMPLOYMENT AGREEMENT

    This THIRD AMENDMENT (“Amendment”) hereby amends that certain EMPLOYMENT AGREEMENT, entered into as of November 19, 2010, as amended on May 1, 2012 and January 1, 2016 (the “Prior Agreement”), by and between Concentra, Inc. (“Employer”) and John Anderson (“Executive”).

WHEREAS, Employer’s parent, Concentra Group Holdings Parent, Inc. (“Parent”), was formerly a wholly owned subsidiary of Select Medical Corporation (“Select”);

WHEREAS, Parent completed an initial public offering of its common stock on July 26, 2024 and on November 25, 2024, Select distributed its remaining shares of common stock of Parent to its stockholders, thereby completing the spin-off of Parent and Employer from Select; and

WHEREAS, Employer and Executive desire to amend certain terms of the Prior Agreement and to incorporate additional terms as provided herein.

    NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promise set forth in this Amendment, and for other consideration, the receipt and adequacy of which are hereby acknowledged, Employer and Executive (intending to be legally bound) hereby agree as follows:

1.The following is hereby added at the end of Section 1 of the Prior Agreement:
“Executive shall have the title of Executive Vice President and Chief Medical Officer of Parent.”
2.Section 5.4 of the Prior Agreement is hereby replaced in its entirety with the following:
“5.4 [Reserved.]”
3.The following is hereby added at the end of Section 6.1(c) of the Prior Agreement:

“Such release shall be executed and delivered (and no longer subject to revocation, if applicable) within sixty (60) days following termination. Payment of such amounts shall not commence until the sixtieth (60th) day following such termination, with any installment payments suspended during such sixty (60) day period being paid as a single lump sum payment on the first payroll date following the end of such suspension period.”

4.Section 20.1 of the Prior Agreement is hereby replaced in its entirety with the following:



“20.1.    If Executive is a “specified employee,” as defined in Section 409A(a)(2)(B) of the Internal Revenue Code (the “Code”), no benefit or payment that constitutes “nonqualified deferred compensation” for purposes of Section 409A of the Code shall be made under this Agreement on account of Executive’s “separation from service,” as defined in Section 409A of the Code, with Employer until the later of the date prescribed for payment in this Agreement and the first day of the seventh calendar month that begins after the date of Executive’s separation from service (or, if earlier, the date of death of Executive).”

5.Section 20.4 of the Prior Agreement is hereby deleted in its entirety.

6.New Section 22 is hereby added to the Prior Agreement as follows:

“22.     Clawback. Executive acknowledges and agrees that Executive is and will be subject to the compensation recovery policy for incentive-based compensation that was adopted by the Board of Directors of Parent, as may be amended from time to time, and any other compensation recovery policies that Parent or Employer may adopt from time to time. For the avoidance of doubt, no recovery under any such compensation recovery policy will be an event giving rise to a right of Executive to resign for Good Reason.”

7.New Section 23 is hereby added to the Prior Agreement as follows:

“23.     Trade Secrets; Whistleblowing. Notwithstanding anything to the contrary in this Agreement or otherwise, Executive understands and acknowledges that Employer has informed Executive that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for (a) the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law or (b) the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal. Additionally, notwithstanding anything to the contrary in this Agreement or otherwise, Executive understands and acknowledges that Employer has informed Executive that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to a court order. Nothing in this Agreement or any other agreement between Executive and Employer shall be interpreted to limit or interfere with Executive’s right to report good faith suspected violations of law to applicable government agencies, including the Equal Employment Opportunity Commission, National Labor Relation Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other applicable federal, state or local governmental agency, in accordance with the provisions of any “whistleblower” or similar provisions of local, state or federal law. Executive may report such suspected violations of law, even if such action would require Executive to share Employer’s proprietary information or trade secrets with the government agency, provided that any such information is protected to the maximum extent permissible and any such information constituting trade secrets is filed only under seal in connection with any court proceeding. Lastly, nothing in this Agreement or any
2

other agreement between Executive and Employer will be interpreted to prohibit Executive from collecting any financial incentives in connection with making such reports or require Executive to notify or obtain approval by Employer prior to making such reports to a government agency.”
8.New Section 24 is hereby added to the Prior Agreement as follows:

“24.     Adoption of Agreement by Parent. This Agreement and all rights and obligations hereunder is hereby adopted and assumed by Parent, in addition to Employer, but without any duplication of payments and/or benefits to Executive, and accordingly, Parent hereby, in addition to Employer, but without any duplication of payments and/or benefits to Executive, shall honor any and all of such rights and obligations and shall be an express party to this Agreement. In connection with the foregoing, references in the Agreement to “Employer” in the capacity as an employer shall be deemed to be references to Parent as the context may require. Notwithstanding the foregoing, Employer will continue to be a party to this Agreement and will be jointly and severally liable for all obligations hereunder with Parent.”

9.Except as hereby amended or modified herein, the terms and conditions of the Prior Agreement shall remain unchanged and in full force and effect.


3

IN WITNESS WHEREOF, the parties hereto have executed this Amendment, this 27th day of February, 2025.

Employer:

CONCENTRA, INC.


By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Secretary___________________________


CONCENTRA GROUP HOLDINGS PARENT, INC.

By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Executive Vice President and Secretary__



AGREED AND ACCEPTED:

Executive:


/s/ John Anderson______________________
Name: John Anderson





4
 EX-10.6 7 delorimier-amendmenttoempl.htm EX-10.6 Document
Exhibit 10.6
CONCENTRA, INC.

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

    This FIRST AMENDMENT (“Amendment”) hereby amends that certain EMPLOYMENT AGREEMENT, entered into as of August 10, 2015 (the “Prior Agreement”), by and between Concentra, Inc. (“Employer”) and John deLorimier (“Employee”).

WHEREAS, Employer’s parent, Concentra Group Holdings Parent, Inc. (“Parent”), was formerly a wholly owned subsidiary of Select Medical Corporation (“Select”);

WHEREAS, Parent completed an initial public offering of its common stock on July 26, 2024 and on November 25, 2024, Select distributed its remaining shares of common stock of Parent to its stockholders, thereby completing the spin-off of Parent and Employer from Select; and

WHEREAS, Employer and Employee desire to amend certain terms of the Prior Agreement and to incorporate additional terms as provided herein.

    NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promise set forth in this Amendment, and for other consideration, the receipt and adequacy of which are hereby acknowledged, Employer and Employee (intending to be legally bound) hereby agree as follows:

1.Any reference to “Company Group” in the Prior Agreement shall be deemed a reference to Parent and its affiliates and subsidiaries, collectively.

2.Section 1 of the Prior Agreement is hereby replaced in its entirety with the following:

“1.     Adoption of Agreement by Parent. This Agreement and all rights and obligations hereunder is hereby adopted and assumed by Parent, in addition to Employer, but without any duplication of payments and/or benefits to Employee, and accordingly, Parent hereby, in addition to Employer, but without any duplication of payments and/or benefits to Employee, shall honor any and all of such rights and obligations and shall be an express party to this Agreement. In connection with the foregoing, references in the Agreement to “Employer” in the capacity as an employer shall be deemed to be references to Parent as the context may require. Notwithstanding the foregoing, Employer will continue to be a party to this Agreement and will be jointly and severally liable for all obligations hereunder with Parent.”

3.The reference to Employee’s title in Section 2.1 of the Prior Agreement to “Executive Vice President, Chief Marketing and Sales Officer” is hereby replaced with “Executive Vice President and Chief Digital and Data Officer of Parent.”



4.Section 3.2(b) of the Prior Agreement is hereby replaced in its entirety with the following:
“(b) [Reserved.]”
5.Section 8.6 of the Prior Agreement is hereby replaced in its entirety with the following:
“8.6    Notices. Any notice or other communication by one party hereto to the other shall be in writing and shall be given, and be deemed to have been given, if either hand delivered or mailed, postage prepaid, certified mail (return receipt requested), addressed as follows:
If to Employer:Concentra Group Holdings Parent, Inc.
5080 Spectrum Drive, Suite 1200W
Addison, TX 75001
Attn: President & CEO

If to Employee, at the address (or the email address) shown in the books and records of Employer.”
6.New Section 9 is hereby added to the Prior Agreement as follows:

“9. Section 409A. This Agreement is intended to comply with, or otherwise be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and guidance promulgated thereunder (collectively “Code Section 409A”) and shall be interpreted in a manner consistent therewith. In no event whatsoever shall Employer be liable for any additional tax, interest or penalty that may be imposed on Employee by Code Section 409A or damages for failing to comply with Code Section 409A. Notwithstanding anything to the contrary herein, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute “nonqualified deferred compensation” for purposes of Code Section 409A upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” In addition, the entitlement to any series of payments provided for in this Agreement shall be treated as a series of separate payments rather than a single payment for purposes of Section 409A of the Code. Notwithstanding anything to the contrary in this Agreement, if Employee is deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered “nonqualified deferred compensation” for purposes of Code Section 409A payable on account of a “separation from service,” such payment or benefit shall not be made or provided until the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such “separation from service” of Employee, and (B) the date Employee’s death, to the extent required under Code Section 409A. Upon the expiration of the foregoing delay period, all


payments and benefits delayed pursuant to this Section 9 (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Employee in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. To the extent that reimbursements or other in-kind benefits under this letter agreement constitute “nonqualified deferred compensation” for purposes of Code Section 409A, (a) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Employee, (b) any right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (c) no such reimbursement, expenses eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.”

7.New Section 10 is hereby added to the Prior Agreement as follows:

“10.     Clawback. Employee acknowledges and agrees that Employee is and will be subject to the compensation recovery policy for incentive-based compensation that was adopted by the Board of Directors of Parent, as may be amended from time to time, and any other compensation recovery policies that Parent or Employer may adopt from time to time. For the avoidance of doubt, no recovery under any such compensation recovery policy will be an event giving rise to Employee of a right to resign for “constructive termination” or similar term.”

8.New Section 11 is hereby added to the Prior Agreement as follows:

“11.     Trade Secrets; Whistleblowing. Notwithstanding anything to the contrary in this Agreement or otherwise, Employee understands and acknowledges that Employer has informed Employee that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for (a) the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law or (b) the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal. Additionally, notwithstanding anything to the contrary in this Agreement or otherwise, Employee understands and acknowledges that Employer has informed Employee that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to a court order. Nothing in this Agreement or any other agreement between Employee and Employer shall be interpreted to limit or interfere with Employee’s right to report good faith suspected violations of law to applicable government agencies, including the Equal Employment Opportunity Commission, National Labor Relation Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other applicable federal, state or local governmental agency, in accordance with the provisions of any “whistleblower” or similar provisions of local, state or federal law. Employee may report such suspected violations of law, even if such action would require Employee to share Employer’s proprietary information


or trade secrets with the government agency, provided that any such information is protected to the maximum extent permissible and any such information constituting trade secrets is filed only under seal in connection with any court proceeding. Lastly, nothing in this Agreement or any other agreement between Employee and Employer will be interpreted to prohibit Employee from collecting any financial incentives in connection with making such reports or require Employee to notify or obtain approval by Employer prior to making such reports to a government agency.”
9.Except as hereby amended or modified herein, the terms and conditions of the Prior Agreement shall remain unchanged and in full force and effect.




IN WITNESS WHEREOF, the parties hereto have executed this Amendment, this 27th day of February, 2025.

Employer:

CONCENTRA, INC.


By: /s/ Timothy Ryan_____________________
Print Name: Timothy Ryan__________________
Print Title: Secretary___________________________


CONCENTRA GROUP HOLDINGS PARENT, INC.

By: /s/ Timothy Ryan_____________________
Print Name: Timothy Ryan__________________
Print Title: Executive Vice President and Secretary_



AGREED AND ACCEPTED:

Employee:


/s/ John deLorimier______________________
Name: John deLorimier








 EX-10.7 8 newton-amendmenttoemployme.htm EX-10.7 Document
Exhibit 10.7
CONCENTRA, INC.
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

    This FIRST AMENDMENT (“Amendment”) hereby amends that certain EMPLOYMENT AGREEMENT, entered into as of June 25, 2015 (the “Prior Agreement”), by and between Concentra, Inc. (the “Company”) and Keith Newton (the “Executive”).

WHEREAS, Company’s parent, Concentra Group Holdings Parent, Inc. (“Parent”), was formerly a wholly owned subsidiary of Select Medical Corporation (“Select”);

WHEREAS, Parent completed an initial public offering of its common stock on July 26, 2024 and, on November 25, 2024, Select distributed its remaining shares of common stock of Parent to its stockholders, thereby completing the spin-off of Parent and the Company from Select; and

WHEREAS, the Company and the Executive desire to amend certain terms of the Prior Agreement and to incorporate additional terms as provided herein.

    NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promise set forth in this Amendment, and for other consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Executive (intending to be legally bound) hereby agree as follows:

1.Section 1 of the Prior Agreement is hereby replaced in its entirety with the following:
“1.    Adoption of Agreement by Parent. This Agreement and all rights and obligations hereunder is hereby adopted and assumed by Parent, in addition to the Company, but without any duplication of payments and/or benefits to Executive, and accordingly, Parent hereby, in addition to the Company, but without any duplication of payments and/or benefits to Executive, shall honor any and all of such rights and obligations and shall be an express party to this Agreement. In connection with the foregoing, references in the Agreement to the “Company” in the capacity as an employer shall be deemed to be references to Parent as the context may require. Notwithstanding the foregoing, the Company will continue to be a party to this Agreement and will be jointly and severally liable for all obligations hereunder with Parent.”
2.Section 3(a) of the Prior Agreement is hereby replaced in its entirety with the following:
“(a)    During the term hereof, the Executive shall serve as the Chief Executive Officer of Parent and as a member of the Board of Directors of Parent (the “Board”); provided, however, that if the Executive’s employment with Parent terminates for any reason, then concurrently with such termination, the Executive will resign from the Board unless otherwise agreed in writing by the Board and the Executive. In addition, and without further compensation, the Executive shall serve as a director and/or officer of one or more of Parent’s subsidiaries if so elected or appointed from time to time.”


3.Section 5(e)(v) of the Prior Agreement is hereby replaced in its entirety with the following:
“(v) a Change in Control.”
4.Section 5(e)(vi) of the Prior Agreement is hereby deleted in its entirety.
5.Section 5(g)(ii) of the Prior Agreement is hereby replaced in its entirety with the following:
“(ii)    For purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute “nonqualified deferred compensation” for purposes of Section 409A, all references to “termination of employment” and correlative phrases shall be construed to require a “separation from service” (as defined in Section 1.409A-1(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term “specified employee” means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i).”
6.Section 13(b) of the Prior Agreement is hereby replaced in its entirety with the following:
    “(b) “Change in Control” shall have the meaning ascribed to such term under the Concentra Group Holdings Parent, Inc. 2024 Equity Incentive Plan, as may be amended or amended and restated from time to time.”
7.Section 13(d) of the Prior Agreement is hereby replaced in its entirety with the following:
“(d) [Reserved.]”
8.Section 13(f) of the Prior Agreement is hereby replaced in its entirety with the following:
“(f) “Person” means a natural person, a corporation, a limited liability company, an association, a partnership, an estate, a trust and any other entity or organization, other than Parent or any of its affiliates.”
9.Section 13(g) of the Prior Agreement is hereby replaced in its entirety with the following:
“(g) [Reserved.]”
10.New Section 26 is hereby added to the Prior Agreement as follows:

“26.    Clawback. The Executive acknowledges and agrees that the Executive is and will be subject to the compensation recovery policy for incentive-based compensation that was adopted by the Board of Directors of Parent, as may be amended from time to time, and any other compensation recovery policies that Parent or the Company may adopt from time to time. For the avoidance of doubt, no recovery under any such compensation recovery policy will be an event giving rise to a right of the Executive to resign for Good Reason.”

2

11.New Section 27 is hereby added to the Prior Agreement as follows:

“27.    Trade Secrets; Whistleblowing. Notwithstanding anything to the contrary in this Agreement or otherwise, the Executive understands and acknowledges that the Company has informed the Executive that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for (i) the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law or (ii) the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal. Additionally, notwithstanding anything to the contrary in this Agreement or otherwise, the Executive understands and acknowledges that the Company has informed the Executive that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to a court order. Nothing in this Agreement or any other agreement between the Executive and the Company shall be interpreted to limit or interfere with the Executive’s right to report good faith suspected violations of law to applicable government agencies, including the Equal Employment Opportunity Commission, National Labor Relation Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other applicable federal, state or local governmental agency, in accordance with the provisions of any “whistleblower” or similar provisions of local, state or federal law. The Executive may report such suspected violations of law, even if such action would require the Executive to share the Company’s proprietary information or trade secrets with the government agency, provided that any such information is protected to the maximum extent permissible and any such information constituting trade secrets is filed only under seal in connection with any court proceeding. Lastly, nothing in this Agreement or any other agreement between the Executive and the Company will be interpreted to prohibit the Executive from collecting any financial incentives in connection with making such reports or require the Executive to notify or obtain approval by the Company prior to making such reports to a government agency.”

12.Except as hereby amended or modified herein, the terms and conditions of the Prior Agreement shall remain unchanged and in full force and effect.


3

IN WITNESS WHEREOF, the parties hereto have executed this Amendment, this 27th day of February, 2025.

Company:

CONCENTRA, INC.


By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Secretary___________________________


CONCENTRA GROUP HOLDINGS PARENT, INC.

By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Executive Vice President and Secretary__


AGREED AND ACCEPTED:

Executive:


/s/ Keith Newton______________________
Name: Keith Newton







4
 EX-10.8 9 dicanio-amendmenttoemploym.htm EX-10.8 Document
Exhibit 10.8
CONCENTRA, INC.

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT

    This SECOND AMENDMENT (“Amendment”) hereby amends that certain EMPLOYMENT AGREEMENT, entered into as of August 19, 2015, as amended on October 25, 2024 (the “Prior Agreement”), by and between Concentra, Inc. (“Employer”) and Matthew DiCanio (“Employee”).

WHEREAS, Employer’s parent, Concentra Group Holdings Parent, Inc. (“Parent”), was formerly a wholly owned subsidiary of Select Medical Corporation (“Select”);

WHEREAS, Parent completed an initial public offering of its common stock on July 26, 2024 and on November 25, 2024, Select distributed its remaining shares of common stock of Parent to its stockholders, thereby completing the spin-off of Parent and Employer from Select; and

WHEREAS, Employer and Employee desire to amend certain terms of the Prior Agreement and to incorporate additional terms as provided herein.

    NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promise set forth in this Amendment, and for other consideration, the receipt and adequacy of which are hereby acknowledged, Employer and Employee (intending to be legally bound) hereby agree as follows:

1.Any reference to “Company Group” in the Prior Agreement shall be deemed a reference to Parent and its affiliates and subsidiaries, collectively.

2.Section 1 of the Prior Agreement is hereby replaced in its entirety with the following:

“1.     Adoption of Agreement by Parent. This Agreement and all rights and obligations hereunder is hereby adopted and assumed by Parent, in addition to Employer, but without any duplication of payments and/or benefits to Employee, and accordingly, Parent hereby, in addition to Employer, but without any duplication of payments and/or benefits to Employee, shall honor any and all of such rights and obligations and shall be an express party to this Agreement. In connection with the foregoing, references in the Agreement to “Employer” in the capacity as an employer shall be deemed to be references to Parent as the context may require. Notwithstanding the foregoing, Employer will continue to be a party to this Agreement and will be jointly and severally liable for all obligations hereunder with Parent.”

3.The reference to Employee’s title in Section 2.1 of the Prior Agreement to “President & Chief Financial Officer of Employer and its parent company, Concentra Group Holdings Parent, Inc. (“Parent”) is hereby replaced with “President and Chief Financial Officer of Parent.”



4.Section 3.2(b) of the Prior Agreement is hereby replaced in its entirety with the following:
“(b) [Reserved.]”
5.The last sentence of Section 4(d) of the Prior Agreement is hereby replaced with the following:
“Employee must provide Employer with a written notice detailing the specific circumstances alleged to constitute a Termination Event within thirty (30) days after the first occurrence of such circumstances, provide Employer with thirty (30) days to cure such circumstances in all material respects and, if not so cured, actually terminate employment within thirty (30) days following the expiration of Employer’s thirty (30)-day cure period. Otherwise, any claim of such circumstances as a “Termination Event” shall be deemed irrevocably waived by Employee. For purposes of this Section 4(d), the term “Change in Control” shall have the meaning ascribed to such term under the Concentra Group Holdings Parent, Inc. 2024 Equity Incentive Plan, as may be amended or amended and restated from time to time.”
6.Section 8.6 of the Prior Agreement is hereby replaced in its entirety with the following:
“8.6    Notices. Any notice or other communication by one party hereto to the other shall be in writing and shall be given, and be deemed to have been given, if either hand delivered or mailed, postage prepaid, certified mail (return receipt requested), addressed as follows:
If to Employer:Concentra Group Holdings Parent, Inc.
5080 Spectrum Drive, Suite 1200W
Addison, TX 75001
Attn: President & CEO
If to Employee, at the address (or the email address) shown in the books and records of Employer.”
7.New Section 9 is hereby added to the Prior Agreement as follows:

“9. Section 409A. This Agreement is intended to comply with, or otherwise be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and guidance promulgated thereunder (collectively “Code Section 409A”) and shall be interpreted in a manner consistent therewith. In no event whatsoever shall Employer be liable for any additional tax, interest or penalty that may be imposed on Employee by Code Section 409A or damages for failing to comply with Code Section 409A. Notwithstanding anything to the contrary herein, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute “nonqualified deferred compensation” for purposes of Code Section 409A upon or following a termination of employment unless such


termination is also a “separation from service” within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” In addition, the entitlement to any series of payments provided for in this Agreement shall be treated as a series of separate payments rather than a single payment for purposes of Section 409A of the Code. Notwithstanding anything to the contrary in this Agreement, if Employee is deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered “nonqualified deferred compensation” for purposes of Code Section 409A payable on account of a “separation from service,” such payment or benefit shall not be made or provided until the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such “separation from service” of Employee, and (B) the date Employee’s death, to the extent required under Code Section 409A. Upon the expiration of the foregoing delay period, all payments and benefits delayed pursuant to this Section 9 (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Employee in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. To the extent that reimbursements or other in-kind benefits under this letter agreement constitute “nonqualified deferred compensation” for purposes of Code Section 409A, (a) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Employee, (b) any right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (c) no such reimbursement, expenses eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.”

8.New Section 10 is hereby added to the Prior Agreement as follows:

“10.     Clawback. Employee acknowledges and agrees that Employee is and will be subject to the compensation recovery policy for incentive-based compensation that was adopted by the Board of Directors of Parent, as may be amended from time to time, and any other compensation recovery policies that Parent or Employer may adopt from time to time. For the avoidance of doubt, no recovery under any such compensation recovery policy will be an event giving rise to Employee of a right to resign following a Termination Event.”

9.New Section 11 is hereby added to the Prior Agreement as follows:

“11.     Trade Secrets; Whistleblowing. Notwithstanding anything to the contrary in this Agreement or otherwise, Employee understands and acknowledges that Employer has informed Employee that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for (a) the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law or (b) the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal. Additionally, notwithstanding anything to the contrary in this Agreement or


otherwise, Employee understands and acknowledges that Employer has informed Employee that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to a court order. Nothing in this Agreement or any other agreement between Employee and Employer shall be interpreted to limit or interfere with Employee’s right to report good faith suspected violations of law to applicable government agencies, including the Equal Employment Opportunity Commission, National Labor Relation Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other applicable federal, state or local governmental agency, in accordance with the provisions of any “whistleblower” or similar provisions of local, state or federal law. Employee may report such suspected violations of law, even if such action would require Employee to share Employer’s proprietary information or trade secrets with the government agency, provided that any such information is protected to the maximum extent permissible and any such information constituting trade secrets is filed only under seal in connection with any court proceeding. Lastly, nothing in this Agreement or any other agreement between Employee and Employer will be interpreted to prohibit Employee from collecting any financial incentives in connection with making such reports or require Employee to notify or obtain approval by Employer prior to making such reports to a government agency.”
10.Except as hereby amended or modified herein, the terms and conditions of the Prior Agreement shall remain unchanged and in full force and effect.




IN WITNESS WHEREOF, the parties hereto have executed this Amendment, this 27th day of February, 2025.

Employer:

CONCENTRA, INC.


By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Secretary___________________________


CONCENTRA GROUP HOLDINGS PARENT, INC.

By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Executive Vice President and Secretary__



AGREED AND ACCEPTED:

Employee:


/s/ Matthew DiCanio______________________
Name: Matthew DiCanio






EX-10.9 10 nelson-amendmenttoemployme.htm EX-10.9 Document
Exhibit 10.9
CONCENTRA, INC.

FIRST AMENDMENT TO EMPLOYMENT LETTER AGREEMENT

    This FIRST AMENDMENT (“Amendment”) hereby amends that certain EMPLOYMENT LETTER AGREEMENT, entered into as of January 14, 2016 (the “Prior Agreement”), by and between Concentra, Inc. (the “Company”) and SuZan Nelson (“you”).

WHEREAS, the Company’s parent, Concentra Group Holdings Parent, Inc. (“Parent”), was formerly a wholly owned subsidiary of Select Medical Corporation (“Select”);

WHEREAS, Parent completed an initial public offering of its common stock on July 26, 2024 and, on November 25, 2024, Select distributed its remaining shares of common stock of Parent to its stockholders, thereby completing the spin-off of Parent and the Company from Select; and

WHEREAS, you and the Company desire to amend certain terms of the Prior Agreement and to incorporate additional terms as provided herein.

    NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promise set forth in this Amendment, and for other consideration, the receipt and adequacy of which are hereby acknowledged, you and the Company (intending to be legally bound) hereby agree as follows:

1.The reference to your title in the first paragraph of the Prior Agreement to “Senior Vice President, Chief Financial Officer of Concentra, Inc.” is hereby replaced with “Executive Vice President and Chief Accounting Officer of Concentra Group Holdings Parent, Inc.”

2.New paragraph 12 is hereby added to the Prior Agreement as follows:

“12.    Section 409A. This letter agreement is intended to comply with, or otherwise be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and guidance promulgated thereunder (collectively “Code Section 409A”) and shall be interpreted in a manner consistent therewith. In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on you by Code Section 409A or damages for failing to comply with Code Section 409A. Notwithstanding anything to the contrary herein, a termination of employment shall not be deemed to have occurred for purposes of any provision of this letter agreement providing for the payment of any amounts or benefits that constitute “nonqualified deferred compensation” for purposes of Code Section 409A upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Code Section 409A and, for purposes of any such provision of this letter agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” In addition, the entitlement to any series of payments provided for in this letter agreement shall be treated as a series of separate payments rather than a single payment for


purposes of Section 409A of the Code. Notwithstanding anything to the contrary in this letter agreement, if you are deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered “nonqualified deferred compensation” for purposes of Code Section 409A payable on account of a “separation from service,” such payment or benefit shall not be made or provided until the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such “separation from service”, and (B) the date of your death, to the extent required under Code Section 409A. Upon the expiration of the foregoing delay period, all payments and benefits delayed pursuant to this paragraph 12 (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this letter agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. To the extent that reimbursements or other in-kind benefits under this letter agreement constitute “nonqualified deferred compensation” for purposes of Code Section 409A, (a) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by you, (b) any right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (c) no such reimbursement, expenses eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.”

3.New paragraph 13 is hereby added to the Prior Agreement as follows:

“13.    Clawback. You acknowledge and agree that you are and will be subject to the compensation recovery policy for incentive-based compensation that was adopted by the Board of Directors of Parent, as may be amended from time to time, and any other compensation recovery policies that Parent or the Company may adopt from time to time. For the avoidance of doubt, no recovery under any such compensation recovery policy will be an event giving rise to you of a right to resign for “constructive termination” or similar term.”

4.New paragraph 14 is hereby added to the Prior Agreement as follows:

“14.    Trade Secrets; Whistleblowing. Notwithstanding anything to the contrary in this letter agreement or otherwise, you understand and acknowledge that the Company has informed you that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for (a) the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law or (b) the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal. Additionally, notwithstanding anything to the contrary in this letter agreement or otherwise, you understand and acknowledge that the Company has informed you that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding if the individual files any document containing the


trade secret under seal and does not disclose the trade secret, except pursuant to a court order. Nothing in this letter agreement or any other agreement between you and the Company shall be interpreted to limit or interfere with your right to report good faith suspected violations of law to applicable government agencies, including the Equal Employment Opportunity Commission, National Labor Relation Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other applicable federal, state or local governmental agency, in accordance with the provisions of any “whistleblower” or similar provisions of local, state or federal law. You may report such suspected violations of law, even if such action would require you to share the Company’s proprietary information or trade secrets with the government agency, provided that any such information is protected to the maximum extent permissible and any such information constituting trade secrets is filed only under seal in connection with any court proceeding. Lastly, nothing in this letter agreement or any other agreement between you and the Company will be interpreted to prohibit you from collecting any financial incentives in connection with making such reports or require you to notify or obtain approval by the Company prior to making such reports to a government agency.”
5.New paragraph 15 is hereby added to the Prior Agreement as follows:

“15.    Adoption of Agreement by Parent. This Agreement and all rights and obligations hereunder is hereby adopted and assumed by Parent, in addition to the Company, but without any duplication of payments and/or benefits to you, and accordingly, Parent hereby, in addition to the Company, but without any duplication of payments and/or benefits to you, shall honor any and all of such rights and obligations and shall be an express party to this Agreement. In connection with the foregoing, references in the Agreement to “Company” in the capacity as an employer shall be deemed to be references to Parent as the context may require. Notwithstanding the foregoing, the Company will continue to be a party to this Agreement and will be jointly and severally liable for all obligations hereunder with Parent.”

6.Except as hereby amended or modified herein, the terms and conditions of the Prior Agreement shall remain unchanged and in full force and effect.




IN WITNESS WHEREOF, the parties hereto have executed this Amendment, this 27th day of February, 2025.

Company:

CONCENTRA, INC.


By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Secretary___________________________


CONCENTRA GROUP HOLDINGS PARENT, INC.

By: /s/ Timothy Ryan______________________
Print Name: Timothy Ryan___________________
Print Title: Executive Vice President and Secretary _



AGREED AND ACCEPTED:

Employee:


/s/ Su Zan Nelson________________________
Name: SuZan Nelson








 EX-31.1 11 cghp-331202510qxex311.htm EX-31.1 Document

EXHIBIT 31.1
 
CONCENTRA GROUP HOLDINGS PARENT, INC.
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION
 
I, William K. Newton, certify that:
 
1.    I have reviewed this quarterly report on Form 10-Q of Concentra Group Holdings Parent, Inc.;
 
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 7, 2025/s/ William K. Newton
 William K. Newton
 Chief Executive Officer

 EX-31.2 12 cghp-331202510qxex312.htm EX-31.2 Document

EXHIBIT 31.2
 
CONCENTRA GROUP HOLDINGS PARENT, INC.
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION
 
I, Matthew T. DiCanio, certify that:
 
1.    I have reviewed this quarterly report on Form 10-Q of Concentra Group Holdings Parent, Inc.;
 
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 7, 2025/s/ Matthew T. DiCanio
 Matthew T. DiCanio
 President and Chief Financial Officer

 EX-32.1 13 cghp-331202510qxex321.htm EX-32.1 Document

EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Concentra Group Holdings Parent, Inc. (the “Company”) for the period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, William K. Newton and Matthew T. DiCanio, Chief Executive Officer and President and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:
 
(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.
 
May 7, 2025

/s/ William K. Newton
William K. Newton
Chief Executive Officer
 
 
/s/ Matthew T. DiCanio
Matthew T. DiCanio
President and Chief Financial Officer

 EX-101.SCH 14 cghp-20250331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952158 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952159 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952160 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Redeemable Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Accrued and Other Liabilities link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Relationship with Select link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Derivatives link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 9952177 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Redeemable Non-Controlling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Accrued and Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Derivatives Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Redeemable Non-Controlling Interests - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Redeemable Non-Controlling Interests - Schedule of Redeemable Non-Controlling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Long-Term Debt - Components of Long-Term Debt And Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Long-Term Debt - Principal Maturities Of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Accrued and Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Earnings per Share - Net Income Attributable to the Company, Units Outstanding, and Participating Units Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Earnings per Share - Computation of EPS Under the Two-Class Method (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Relationship with Select (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Segment Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Segment Information - Selected Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Acquisitions - Nova Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Acquisitions - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Derivatives Instruments - Schedule of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Derivatives Instruments - Derivative Impact on Statements of Income and Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Accumulated Other Comprehensive Income - AOCI Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Accumulated Other Comprehensive Income - AOCI Tax Benefit/Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Accumulated Other Comprehensive Income - Reclassifications from ACOI (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 cghp-20250331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 16 cghp-20250331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 17 cghp-20250331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Total assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Including Goodwill Distributions to Select Payments of Distributions to Affiliates Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Prepaid income taxes Prepaid Taxes Relationship with Select Related Party Transactions Disclosure [Text Block] Purchases of property and equipment Segment, Expenditure, Addition to Long-Lived Assets Schedule of lease cost Lease, Cost [Table Text Block] Cover [Abstract] Cover [Abstract] Net (decrease) increase in cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Obligations payable Other Liabilities, Current Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Long-term debt, net of current portion Long-Term Debt and Lease Obligation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of computation of basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash dividend declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Cash (refund received) paid for taxes Income Taxes Paid, Net Distributions to and purchases of non-controlling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Pay vs Performance Disclosure [Line Items] Redeemable non-controlling interests Balance, beginning Balance, ending Redeemable Noncontrolling Interest, Equity, Carrying Amount Line of Credit Facility [Table] Line of Credit Facility [Table] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Tax benefit on components of other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Gains/(losses) related to derivatives designated as hedging instruments: Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Lease, Cost [Abstract] Lease, Cost [Abstract] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Other occupational health center revenue Occupational Health Center, Other [Member] Occupational Health Center, Other Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Schedule of long-term debt and notes payable Schedule of Long-Term Debt Instruments [Table Text Block] Variable Interest Entities Variable Interest Entity Disclosure [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Income taxes payable Taxes Payable, Current Schedule of derivative instruments Schedule of Derivative Instruments [Table Text Block] Schedule of accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Term Loan Term Loan Secured Debt [Member] Equity Components [Axis] Equity Components [Axis] Concentra Term Loan Concentra Term Loan [Member] Concentra Term Loan Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Net income attributable to the Company Business Acquisition, Pro Forma Net Income (Loss) Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Total annual aggregate limit of insurance coverage Malpractice Insurance, Annual Coverage Limit Use of Estimates Use of Estimates, Policy [Policy Text Block] Accrued payroll Accrued Salaries, Accrued Bonuses, And Accrued Payroll Taxes, Current Accrued Salaries, Accrued Bonuses, And Accrued Payroll Taxes, Current Total costs and expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Adjustment to Compensation, Amount Adjustment to Compensation Amount Capital in excess of par Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Diluted EPS Earnings Per Share, Diluted [Abstract] Number of states in which entity operates Number of States in which Entity Operates Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging Instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Shared service fee from related party Contractually Specified Servicing Fees, Amount Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Schedule of derivative instruments, effect on other comprehensive income (loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Credit Facility [Domain] Credit Facility [Domain] Cash at beginning of period Cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Current assets: Assets, Current [Abstract] Goodwill Goodwill Term Loan Term Loan [Member] Term Loan Professional liability claims Professional Malpractice Liability Insurance [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Fair Value Disclosures [Abstract] Comprehensive income attributable to the Company Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Credit spread adjustment Debt Instrument, Basis Spread on Variable Rate Onsite health clinics Onsite Health Clinics [Member] Onsite Health Clinics Award Type Award Type [Axis] Basic EPS Earnings Per Share, Basic [Abstract] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Number of occupational health centers operated by entity Number of Occupational Health Centers Operated by Entity Number of Occupational Health Centers Operated by Entity Loss on extinguishment of debt Deferred Debt Issuance Cost, Writeoff Total liabilities Liabilities Liabilities Non-controlling interests Equity, Attributable to Noncontrolling Interest Personnel expenses Labor and Related Expense Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Distributions to redeemable non-controlling interests Noncontrolling Interest, Distributions to Redeemable Noncontrolling Interests Noncontrolling Interest, Distributions to Redeemable Noncontrolling Interests Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Current operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Finance lease cost: Lessee, Finance Lease, Description [Abstract] Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity 2025 Long-Term Debt And Finance Lease Obligation, Repayments Of Principal, Remainder Of Fiscal Year Long-Term Debt And Finance Lease Obligation, Repayments Of Principal, Remainder Of Fiscal Year Principal payments on other debt Repayments of Debt and Lease Obligation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Subsequent Event [Line Items] Subsequent Event [Line Items] Members' unit, beginning balance Members' unit, ending balance Members' Capital Before Tax Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total collar contracts Derivative Assets (Liabilities), at Fair Value, Net Business combinations, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Basis of Presentation and Consolidation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Net deferred gains/(losses) on cash flow hedges reclassified to net income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Undistributed Earnings, Basic [Abstract] Undistributed Earnings, Basic [Abstract] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholders’ equity Equity, Attributable to Parent Related Party Related Party [Member] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense Interest Expense, Nonoperating Before Tax Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of pro forma unaudited results of operations Business Acquisition, Pro Forma Information [Table Text Block] Fair Value, Recurring Fair Value, Recurring [Member] Borrowings of other debt Proceeds from Other Debt Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Carrying Value Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Schedule of fair value measurements Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Weighted average participating shares outstanding (in shares) Incremental Common Shares Attributable to Participating Nonvested Shares with Non-forfeitable Dividend Rights Nova acquisition costs Business Combination, Acquisition Related Costs 2029 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Gross Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of selected financial data for reportable segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Nonrelated Party Nonrelated Party [Member] Net income from acquiree Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Nova Acquisition Nova Acquisition [Member] Nova Acquisition Identifiable tangible assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Tangible Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Tangible Assets Total Stockholders’ Equity Parent [Member] Subsequent Event [Table] Subsequent Event [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] 2027 Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Two Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Two Distribution to Parent Distribution to Parent Adjustments To Member's Contributed Capital, Distributions To Parent Adjustments To Member's Contributed Capital, Distributions To Parent Net income attributable to redeemable non-controlling interests Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Acquisitions Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Total lease cost Lease, Cost Accrued and other liabilities Accrued and other liabilities Accounts Payable and Other Accrued Liabilities, Current Thereafter Long-term Debt, Maturities, Repayments Of Principal After Year Four Long-term Debt, Maturities, Repayments Of Principal After Year Four PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Gains/(losses) on hedges before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Number of less than wholly owned subsidiaries Number Of Less Than Wholly Owned Subsidiaries Number Of Less Than Wholly Owned Subsidiaries Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Proceeds from term loans, net of issuance costs Proceeds from Issuance of Secured Debt Variable lease cost Variable Lease, Cost Conversion of LLC to Corporation and impact of reverse stock split Conversion of LLC to Corporation and impact of reverse stock split Stock Issued During Period, Value, Conversion of Units Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Capital in excess of par Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Occupational Health Centers Occupational Health Centers [Member] Occupational Health Centers Recent Accounting Guidance Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Diluted EPS (in dollars per share) Earnings Per Share, Diluted Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Accrued vacation Accrued Vacation, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Member Units Member Units [Member] Ownership [Axis] Ownership [Axis] Number of operating segments Number of Operating Segments Less: Distributed and undistributed income attributable to participating shares - basic EPS Participating shares - basic Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock compensation expense Share-Based Payment Arrangement, Noncash Expense Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Payments on term loans Repayments of Secured Debt Workers’ compensation Occupational Health Center, Workers Compensation [Member] Occupational Health Center, Workers Compensation Income tax expense Income tax expense Income Tax Expense (Benefit) Other income and expense: Nonoperating Income (Expense) [Abstract] Interest rate of debt (as a percent) Debt Instrument, Interest Rate, Stated Percentage Notional amount Derivative, Notional Amount 6.875% senior notes 6.875% Senior Notes Due July 15, 2032 [Member] 6.875% Senior Notes Due July 15, 2032 Supplemental information Supplemental Cash Flow Information [Abstract] Distributed and undistributed income attributable to common shares Net income allocated to common shares - diluted Net Income (Loss) Available to Common Stockholders, Diluted Revenue Revenue from Contract with Customer, Excluding Assessed Tax Product Information [Line Items] Product Information [Line Items] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Statement of Comprehensive Income [Abstract] Nova Medical Centers Nova Medical Centers [Member] Nova Medical Centers Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Income from operations Operating Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Floor Derivative, Floor Interest Rate Total liabilities and equity Liabilities and Equity Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Other identifiable intangible assets, net Other Intangible Assets, Net Derivative Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Current portion of long-term debt and notes payable Long-Term Debt and Lease Obligation, Current Schedule of principal maturities of long-term debt and notes payable Schedule of Maturities of Long-Term Debt [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Reportable Segment Reportable Segment [Member] Reportable Segment Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Net Cash Flow Hedge Adjustments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Loss contingency, number of patients Loss Contingency, Number Of Patients Loss Contingency, Number Of Patients Segment Adjusted EBITDA Segment Adjusted EBITDA Adjusted EBITDA Measure of profit (loss) for reportable segments Product and Service [Axis] Product and Service [Axis] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Redemption value adjustment on non-controlling interests Redemption value adjustment on redeemable non-controlling interests Noncontrolling Interest, Change in Redemption Value Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of reconciliation of Adjusted EBITDA to income before income taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Consideration transferred Business Combination, Consideration Transferred Number of putative class actions claims transferred Loss Contingency, Number of Putative Class Actions Claims Transferred Loss Contingency, Number of Putative Class Actions Claims Transferred Carrying Value Long-Term Debt And Finance Lease Obligation Long-Term Debt And Finance Lease Obligation Cap Derivative, Cap Interest Rate LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Derivative, term of contract Derivative, Term of Contract Concentra Credit Facilities Concentra Credit Facilities [Member] Concentra Credit Facilities Derivatives and Hedging Derivatives, Policy [Policy Text Block] Loss contingency, new claims filed, number Loss Contingency, New Claims Filed, Number Employer services Occupational Health Center, Employer Services [Member] Occupational Health Center, Employer Services 2026 Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Next Twelve Months Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Next Twelve Months Fixed Rate Derivative, Fixed Interest Rate Restatement Determination Date Restatement Determination Date Fair Value Estimate of Fair Value Measurement [Member] Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Cash paid to acquire business, available borrowing capacity Payments To Acquire Businesses, Gross, Available Borrowing Capacity Payments To Acquire Businesses, Gross, Available Borrowing Capacity Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Total revenue Business Acquisition, Pro Forma Revenue Derivative Instrument [Axis] Derivative Instrument [Axis] Principal Outstanding Total Long-Term Debt, Gross Exercise Price Award Exercise Price Dividends payable Dividends Payable, Current Earnings per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Leases Lessee, Finance Leases [Text Block] Costs and expenses: Costs and Expenses [Abstract] Schedule of Variable Interest Entities [Table] Variable Interest Entity [Table] Loss on derivatives Net of Tax Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 2028 Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Three Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Three Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Business combination, expected price of acquisition Business Combination, Price of Acquisition, Expected Borrowings on revolving facilities and related party revolving promissory note Proceeds from Lines of Credit PEO PEO [Member] Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other assets Increase (Decrease) in Other Noncurrent Assets Onsite Innovations Onsite Innovations [Member] Onsite Innovations 2025 Long-Term Debt, Maturity, Remainder of Fiscal Year Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Collar contracts Collar [Member] Collar Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Non-current deferred tax liability Deferred Income Tax Liabilities, Net Conversion of LLC to Corporation and Impact of Reverse Stock Split (in shares) Select special stock distribution (in shares) Stock Issued During Period, Shares, Conversion of Units Principal Outstanding Total Long-Term Debt, Gross And Finance Lease Obligation Long-Term Debt, Gross And Finance Lease Obligation Changes in operating assets and liabilities, net of effects of business combinations: Increase (Decrease) in Operating Capital [Abstract] Increase in revolving credit facility Line of Credit Facility, Increase (Decrease), Net PEO Total Compensation Amount PEO Total Compensation Amount Facility expenses Occupancy, Net Accrued interest Interest Payable, Current Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Swap contracts Swap [Member] Revolving Credit Facility Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Other expenses Segment Reporting, Other Segment Item, Amount Consumer health Occupational Health Center, Consumer Health [Member] Occupational Health Center, Consumer Health Accrued and Other Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Components of accrued and other liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Segment Information Segment Reporting Disclosure [Text Block] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Net deferred gains/(losses) on cash flow hedges reclassified to net income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Stock compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Separation transaction costs Professional Fees Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Increase (Decrease) in Partners' Capital [Roll Forward] Increase (Decrease) in Partners' Capital [Roll Forward] Title Trading Arrangement, Individual Title Standby letters of credit Standby Letters of Credit [Member] Consolidated Entities [Axis] Consolidated Entities [Axis] Statement [Table] Statement [Table] Concentra Group Holdings Parent Concentra Group Holdings Parent [Member] Interest expense on related party debt Interest Expense, Debt Measurement Frequency [Domain] Measurement Frequency [Domain] Accounting Policies Significant Accounting Policies [Text Block] Less: comprehensive income attributable to non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Interest on lease liabilities Finance Lease, Interest Expense, Net Of Buyouts Finance Lease, Interest Expense, Net Of Buyouts Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Schedule of cash flow hedging instruments, statements of financial performance and financial position, location Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Members' unit, beginning balance (in shares) Members' unit, ending balance (in shares) Common Unit, Outstanding Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination, Separately Recognized Transactions [Table] Business Combination, Separately Recognized Transactions [Table] (Gain) loss on sale of assets Gain (Loss) on Disposition of Assets Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior notes Senior Notes [Member] Available borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity 2029 Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Four Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Four 2028 Long-Term Debt, Maturity, Year Three Net revenues of acquiree Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Debt instrument, covenant, leverage ratio Debt Instrument, Covenant, Leverage Ratio Debt Instrument, Covenant, Leverage Ratio Earnings per common share (Note 10): Earnings Per Share [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Schedule of reclassification out of accumulated other comprehensive income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Payments on related party revolving promissory note Repayments of Long-Term Lines of Credit General and administrative, exclusive of depreciation and amortization General and Administrative Expense Deferred income taxes Deferred Income Taxes and Tax Credits Onsite Innovations Acquisition Onsite Innovations Acquisition [Member] Onsite Innovations Acquisition Non-current liability Other Noncurrent Liabilities [Member] 2027 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Concentra Revolving Credit Facility Concentra Revolving Credit Facility [Member] Concentra Revolving Credit Facility Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Long-term debt fair value Long-Term Debt, Fair Value Carrying Value Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Net income attributable to non-controlling interests Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest Fair Value as of Grant Date Award Grant Date Fair Value Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Subsequent Events [Abstract] Subsequent Events [Abstract] Net deferred (losses)/gains on cash flow hedges Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Level 2 Fair Value, Inputs, Level 2 [Member] Unamortized Issuance Costs Debt Issuance Costs, Net Long-Term Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Stockholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Total occupational health center revenue Occupational Health Center [Member] Occupational Health Center Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Principal outstanding Debt Instrument, Face Amount Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Basis of Presentation and Consolidation Consolidation, Policy [Policy Text Block] Distributions to and purchases of non-controlling interests Payments of Ordinary Dividends, Noncontrolling Interest Restatement Determination Date: Restatement Determination Date [Axis] Other debt Other debt, including finance leases Notes Payable, Other Payables [Member] Title of 12(b) Security Title of 12(b) Security Common stock, $0.01 par value, 700,000,000 shares authorized, 128,171,952 and 128,125,952 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Cash Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Current liability Other Current Liabilities [Member] Loss on early retirement of debt Gain (Loss) on Extinguishment of Debt Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Redeemable Non-Controlling Interests Noncontrolling Interest Disclosure [Text Block] Depreciation and amortization Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Fair Value Measurement [Domain] Fair Value Measurement [Domain] Basic (in dollars per share) Basic EPS (in dollars per share) Earnings Per Share, Basic Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Nature of Operation, Product Information, Concentration of Risk [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Ownership [Domain] Ownership [Domain] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Distributed and undistributed income attributable to common shares Net income allocated to common shares - basic Net Income (Loss) Available to Common Stockholders, Basic Number of onsite health clinics Number of Onsite Health Clinics Operated by Entity Number of Onsite Health Clinics Operated by Entity Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Total assets Assets Outstanding letters of credit Long-Term Line of Credit Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Debt Instrument, Basis Point Step Down Debt Instrument, Basis Point Step Down Debt Instrument, Basis Point Step Down Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Thereafter Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal After Year Four Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal After Year Four Other non-current liabilities Other Liabilities, Noncurrent Cost of services, exclusive of depreciation and amortization Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 12) Commitments and Contingencies Termination Date Trading Arrangement Termination Date Related Party Transaction [Table] Related Party Transaction [Table] Net deferred (losses)/gains on cash flow hedges Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract] 2026 Long-Term Debt, Maturity, Year One Entity Address, City or Town Entity Address, City or Town Schedule of recognized identified assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Number of class action lawsuit pending Loss Contingency, Number of Class Action Lawsuit Pending Loss Contingency, Number of Class Action Lawsuit Pending Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Select Medical Corporation Select Medical Corporation [Member] Select Medical Corporation [Member] Stock compensation expense Share-Based Payment Arrangement, Expense Net income attributable to the Company Net income attributable to the Company Gains on hedges Net Income (Loss) Attributable to Parent Other operating income Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Consolidated Entities [Domain] Consolidated Entities [Domain] Revenue Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Non-controlling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Cash dividends declared for common shareholders ($0.0625 per share) Dividends, Common Stock Accrued other Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Unamortized Premium (Discount) Debt Instrument, Unamortized Discount (Premium), Net Document Period End Date Document Period End Date Other Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Cash paid to acquire business, term loan add-on Payments To Acquire Businesses, Gross, Term Loan Add-On Payments To Acquire Businesses, Gross, Term Loan Add-On Insider Trading Arrangements [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other current assets Other Current Assets [Member] Other current assets Increase (Decrease) in Other Current Assets PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Less: net income attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Reclassification adjustment for gains included in net income Net of Tax Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Schedule of redeemable non-controlling interests Redeemable Noncontrolling Interest [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Related Party [Axis] Related and Nonrelated Parties [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Business Combination, Separately Recognized Transactions [Line Items] Business Combination, Separately Recognized Transactions [Line Items] Proceeds from sale of assets Proceeds from Sale of Productive Assets Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Redeemable Non-Controlling Interests Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Less: Distributed and undistributed income attributable to participating shares - diluted EPS Participating shares - diluted Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Entity Filer Category Entity Filer Category Other Other Businesses [Member] Other Businesses Commitments and Contingencies Loss Contingencies [Line Items] Letter of Credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 18 cghp-20250331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 20 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - shares
 3 Months Ended
Mar. 31, 2025
Apr. 30, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2025  
Document Transition Report false  
Entity File Number 001-42188  
Entity Registrant Name CONCENTRA GROUP HOLDINGS PARENT, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 30-1006613  
Entity Address, Address Line One 5080 Spectrum Drive  
Entity Address, Address Line Two Suite 1200W  
Entity Address, City or Town Addison  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 75001  
City Area Code 972  
Local Phone Number 364-8000  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol CON  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   128,171,952
Entity Central Index Key 0002014596  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
XML 21 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash $ 52,109 $ 183,255
Accounts receivable 258,128 217,719
Prepaid income taxes 1,392 1,544
Other current assets 39,960 34,689
Total current assets 351,589 437,207
Operating lease right-of-use assets 463,032 435,595
Property and equipment, net 207,271 197,930
Goodwill 1,444,563 1,234,707
Other identifiable intangible assets, net 249,788 204,725
Other assets 12,995 11,000
Total assets 2,729,238 2,521,164
Current liabilities:    
Current operating lease liabilities 96,301 75,442
Current portion of long-term debt and notes payable 15,758 10,093
Accounts payable 35,188 19,752
Dividends payable 8,010 0
Accrued and other liabilities 165,134 201,899
Total current liabilities 320,391 307,186
Non-current operating lease liabilities 405,914 396,914
Long-term debt, net of current portion 1,618,473 1,468,917
Non-current deferred tax liability 24,362 25,380
Other non-current liabilities 29,037 24,043
Total liabilities 2,398,177 2,222,440
Commitments and contingencies (Note 12)
Redeemable non-controlling interests 18,609 18,013
Stockholders’ equity:    
Common stock, $0.01 par value, 700,000,000 shares authorized, 128,171,952 and 128,125,952 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 1,282 1,281
Capital in excess of par 263,105 260,837
Retained earnings 44,454 13,553
Accumulated other comprehensive loss (1,722) 0
Total stockholders’ equity 307,119 275,671
Non-controlling interests 5,333 5,040
Total equity 312,452 280,711
Total liabilities and equity $ 2,729,238 $ 2,521,164
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 700,000,000 700,000,000
Common stock, shares issued (in shares) 128,171,952 128,125,952
Common stock, shares outstanding (in shares) 128,171,952 128,125,952
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue $ 500,752 $ 467,598
Costs and expenses:    
Cost of services, exclusive of depreciation and amortization 357,101 336,990
General and administrative, exclusive of depreciation and amortization [1] 46,713 36,909
Depreciation and amortization 16,619 18,485
Total costs and expenses 420,433 392,384
Other operating income 0 284
Income from operations 80,319 75,498
Other income and expense:    
Loss on early retirement of debt (875) 0
Interest expense (25,548) (111)
Income before income taxes 53,896 65,416
Income tax expense 13,254 15,137
Net income 40,642 50,279
Less: net income attributable to non-controlling interests 1,731 1,323
Net income attributable to the Company $ 38,911 $ 48,956
Earnings per common share (Note 10):    
Basic (in dollars per share) $ 0.30 $ 0.47
Diluted (in dollars per share) $ 0.30 $ 0.47
Related Party    
Other income and expense:    
Interest expense on related party debt $ 0 $ (9,971)
[1] Includes transaction services agreement fees of $3.7 million for the three months ended March 31, 2025, and shared service fees from a related party of $3.8 million for the three months ended March 31, 2024. See Note 11—“Relationship with Select”, for additional information.
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Related Party    
Shared service fee from related party $ 3.7 $ 3.8
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Net income $ 40,642 $ 50,279
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]    
Loss on derivatives (1,808) 0
Reclassification adjustment for gains included in net income 86 0
Other comprehensive income (1,722) 0
Comprehensive income 38,920 50,279
Less: comprehensive income attributable to non-controlling interests 1,731 1,323
Comprehensive income attributable to the Company $ 37,189 $ 48,956
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
Statement of Comprehensive Income [Abstract]  
Tax benefit on components of other comprehensive income $ 574
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($)
$ in Thousands
Total
Member Units
Total Stockholders’ Equity
Common Stock
Capital in excess of par
Retained Earnings
Accumulated Other Comprehensive Loss
Non-controlling Interests
Members' unit, beginning balance (in shares) at Dec. 31, 2023   447,081,000            
Members' unit, beginning balance at Dec. 31, 2023   $ 470,303            
Increase (Decrease) in Partners' Capital [Roll Forward]                
Distribution to Parent $ (6,891) $ (6,891) $ (6,891)          
Conversion of LLC to Corporation and Impact of Reverse Stock Split (in shares)   (447,081,000)   104,094,000        
Conversion of LLC to Corporation and impact of reverse stock split 0 $ (463,412) 0 $ 1,041 $ 462,371      
Beginning balance at Dec. 31, 2023 1,160,962   1,155,596     $ 685,293   $ 5,366
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income attributable to the Company 48,956   48,956     48,956    
Net income attributable to non-controlling interests 270   0         270
Distribution to Parent (6,891) $ (6,891) (6,891)          
Distributions to and purchases of non-controlling interests (369)   0         (369)
Redemption value adjustment on non-controlling interests (1,901)   (1,901)     (1,901)    
Select special stock distribution (in shares)   (447,081,000)   104,094,000        
Conversion of LLC to Corporation and impact of reverse stock split 0 $ (463,412) 0 $ 1,041 462,371      
Ending balance (in shares) at Mar. 31, 2024       104,094,000        
Ending balance at Mar. 31, 2024 $ 1,201,027   1,195,760 $ 1,041 462,371 732,348   5,267
Beginning balance (in shares) at Dec. 31, 2024 128,125,952     128,126,000        
Beginning balance at Dec. 31, 2024 $ 280,711   275,671 $ 1,281 260,837 13,553 $ 0 5,040
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income attributable to the Company 38,911   38,911     38,911    
Net income attributable to non-controlling interests 293   0         293
Cash dividends declared for common shareholders ($0.0625 per share) (8,010)   (8,010)     (8,010)    
Issuance of restricted stock (in shares)       46,000        
Issuance of restricted stock 0   0 $ 1 (1)      
Stock compensation expense 2,269   2,269   2,269      
Redemption value adjustment on non-controlling interests 0              
Other comprehensive loss $ (1,722)   (1,722)       (1,722)  
Ending balance (in shares) at Mar. 31, 2025 128,171,952     128,172,000        
Ending balance at Mar. 31, 2025 $ 312,452   $ 307,119 $ 1,282 $ 263,105 $ 44,454 $ (1,722) $ 5,333
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical)
 3 Months Ended
Mar. 31, 2025
$ / shares
Statement of Stockholders' Equity [Abstract]  
Cash dividend declared (in dollars per share) $ 0.0625
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating activities    
Net income $ 40,642 $ 50,279
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 16,619 18,485
Loss on extinguishment of debt 51 0
(Gain) loss on sale of assets (1) 43
Stock compensation expense 2,269 166
Amortization of debt discount and issuance costs 976 0
Deferred income taxes (1,028) (2,521)
Other 11 12
Changes in operating assets and liabilities, net of effects of business combinations:    
Accounts receivable (21,145) (13,505)
Other current assets (2,753) (7,315)
Other assets 902 722
Accounts payable and accrued liabilities (24,844) (1,744)
Net cash provided by operating activities 11,699 44,622
Investing activities    
Business combinations, net of cash acquired (279,018) (5,144)
Purchases of property and equipment (15,732) (17,231)
Proceeds from sale of assets 1 23
Net cash used in investing activities (294,749) (22,352)
Financing activities    
Proceeds from term loans, net of issuance costs 948,848 0
Payments on term loans (847,875) 0
Borrowings of other debt 6,468 6,618
Principal payments on other debt (4,695) (2,276)
Distributions to and purchases of non-controlling interests (842) (1,543)
Distributions to Select 0 (6,891)
Net cash provided by (used in) financing activities 151,904 (4,092)
Net (decrease) increase in cash (131,146) 18,178
Cash at beginning of period 183,255 31,374
Cash at end of period 52,109 49,552
Supplemental information    
Cash paid for interest 38,137 9,958
Cash (refund received) paid for taxes (48) 34
Nonrelated Party    
Financing activities    
Borrowings on revolving facilities and related party revolving promissory note 50,000 0
Related Party    
Financing activities    
Borrowings on revolving facilities and related party revolving promissory note 0 10,000
Payments on related party revolving promissory note $ 0 $ (10,000)
XML 30 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)
Mar. 31, 2025
Dec. 31, 2024
6.875% senior notes | Senior notes    
Interest rate of debt (as a percent) 6.875% 6.875%
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Organization
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Concentra Group Holdings Parent, Inc., a Delaware corporation, conducts substantially all of its business through Concentra Health Services, Inc. (“CHSI”) and its subsidiaries. As the context may require, the “Company,” “we,” “our” or similar words in this report refer collectively to Concentra and its subsidiaries.
The Company is the largest provider of occupational health services in the United States based on number of locations. As of March 31, 2025, we operated 627 stand-alone occupational health centers in 41 states and 160 onsite health clinics at employer worksites in 36 states. The Company provides a diverse and comprehensive array of occupational health services, including workers’ compensation and employers services, and consumer health services.
XML 32 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Accounting Policies
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Accounting Policies Accounting Policies
Basis of Presentation and Consolidation
The Company operated as part of Select Medical Corporation (“Select”) until Select made a special stock distribution of 104,093,503 shares of the Company’s common stock to Select’s stockholders (the “Distribution”) on November 25, 2024. The Company’s consolidated financial statements prior to the Distribution have been prepared from Select’s historical accounting records and derived from the condensed consolidated financial statements of Select to present the Company as if it had been operating on a standalone basis. The unaudited condensed consolidated financial statements of the Company as of March 31, 2025, and for the three months ended March 31, 2025 and 2024, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods.
The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the full fiscal year ended December 31, 2025. These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (File No. 001-42188).
The condensed consolidated financial statements include the assets, liabilities, revenue, and expenses based on our legal entity structure as well as direct and indirect costs that are attributable to our operations. Indirect costs are the costs of support functions that are partially provided on a centralized basis by Select and its affiliates, which include finance, human resources, benefits administration, procurement support, information technology, legal, corporate governance and other professional services. Indirect costs were allocated to the Company, prior to the IPO, for the purposes of preparing the consolidated financial statements based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method, primarily based on headcount or other allocation methodologies that are considered to be a reasonable reflection of the utilization of services provided or the benefit received by the Company during the periods presented, depending on the nature of the services received. Subsequent to the IPO, the support services provided by Select have been billed to the Company pursuant to a transitional services agreement, as further described in Note 11—“Relationship with Select”.
The income tax amounts in these condensed consolidated financial statements prior to the Distribution have been calculated based on a separate return methodology and are presented as if our income gave rise to separate federal and state consolidated income tax return filing obligations in the respective jurisdictions in which we operate. Adjustments to income tax expense resulting from the application of the separate return methodology, as compared to tax obligations determined by the Company’s inclusion in Select’s consolidated income tax provision, were assumed to be immediately settled with Select through contributed capital/capital in excess of par as reflected on the condensed consolidated balance sheets, and reflected as a (distribution)/contribution to Select on the condensed consolidated statements of changes in stockholders’/members’ equity and the condensed consolidated statements of cash flows within financing activities.
The condensed consolidated financial statements include the accounts of the Company and the subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions within the Company are eliminated in consolidation. Transactions between the Company and Select have been included in these condensed consolidated financial statements. The transactions with Select are settled in cash, other than the assumed income tax settlement noted above, and are reflected within the condensed consolidated statement of cash flows as an operating or financing activity determined by the nature of the transaction.
Derivatives and Hedging
The Company is exposed to certain risks relating to its ongoing financial arrangements. The primary risk managed using derivative instruments is to reduce variability in interest cash flows on its variable-rate debt. Interest rate swaps and collars are entered into to manage interest rate risk associated with the Company’s variable-rate debt. As a matter of policy, we do not use highly leveraged derivative instruments, nor do we use financial instruments for speculative purposes.
ASC 815 requires entities to recognize all derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship.
Our designated derivative contracts include interest rate swap and collar agreements, which effectively modify the Company’s exposure to interest rate risk by converting the Company’s floating-rate debt to a fixed-rate basis (for interest rate swap arrangements) and capping and flooring the interest rates (for collar arrangements) for the next three years, thus reducing the impact of interest-rate changes on future interest expense. These agreements involve the receipt of floating-rate amounts in exchange of fixed-rate interest payments and the application of cap and floor rates over the term of the agreements without an exchange of the underlying principal amount.
Our derivatives are designated as cash flow hedges and qualify for hedge accounting treatment. Gains or losses on cash flow hedges are deferred as a component of accumulated other comprehensive income or losses and reclassified into earnings at the time the hedged item affects earnings, presented in the same income statement line item as the underlying hedged item (i.e., in “interest expense” when the hedged transactions are interest cash flows associated with floating-rate debt).
To qualify for hedge accounting, a specified level of hedge effectiveness between the hedging instrument and the hedged item must be achieved at inception and maintained throughout the hedged period. We formally document our risk management objectives, our strategies for undertaking the hedge transactions, the nature of and relationships between the hedging instruments and hedged items, and the method for assessing hedge effectiveness. Additionally, for qualified hedges of forecasted transactions, we specifically identify the significant characteristics and expected terms of the forecasted transactions.
If it becomes probable that a forecasted transaction will not occur, previously deferred gains and losses related to those forecasted transactions would be recognized in earnings in the current period.
Recent Accounting Guidance Not Yet Adopted
Income Taxes
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.
The ASU is effective for the Company’s annual financial statements for the year ended December 31, 2025. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have on the disclosures in our consolidated financial statements.
Expense Disaggregation
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which is intended to improve the disclosures of expenses by providing more
detailed information about the types of expenses in commonly presented expense captions. The ASU requires entities to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption; as well as a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendment also requires disclosure of the total amount of selling expense and, in annual reporting periods, an entity’s definition of selling expenses.
The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2024-03 will have on the disclosures in our consolidated financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Redeemable Non-Controlling Interests
 3 Months Ended
Mar. 31, 2025
Noncontrolling Interest [Abstract]  
Redeemable Non-Controlling Interests Redeemable Non-Controlling Interests
The Company’s redeemable non-controlling interests are comprised of membership interests held by equity holders other than the Company in five less than wholly-owned subsidiaries. These shares are subject to redemption rights. The changes in redeemable non-controlling interests are as follows:
20252024
(in thousands)
Balance as of January 1$18,013 $16,477 
Net income attributable to redeemable non-controlling interests1,438 1,053 
Distributions to redeemable non-controlling interests
(842)(1,174)
Redemption value adjustment on redeemable non-controlling interests— 1,901 
Balance as of March 31$18,609 $18,257 
XML 34 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Variable Interest Entities
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Variable Interest Entities Variable Interest Entities
Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices that directly employ physicians and from exercising control over medical decisions by physicians. In these states, the Company enters into long-term management agreements with affiliated professional medical groups (referred to as “Managed PCs”) that are owned by licensed physicians which, in turn, employ or contract with physicians who provide professional medical services in its occupational health centers. The Company also enters into a stock transfer restriction agreement with the respective equity holders, which provide for the Company to direct the transfer of ownership of the Managed PCs to other licensed physicians at any time. The long-term management agreements provide for various administrative and management services to be provided by the Company to the Managed PCs, including, but not limited to, billing and collections, accounting, non-physician personnel, supplies, security and maintenance, and insurance. The Company has the right to receive income as an ongoing management fee, and effectively absorbs all of the residual interests of the Managed PCs. Based on the provisions of the management and stock transfer agreements, the Managed PCs are variable interest entities for which the Company is the primary beneficiary and consolidates the Managed PCs under the variable interest entity model. There are no restrictions on the use of the assets of the Managed PCs or on the settlement of its liabilities. Additionally, the Company fully indemnifies the licensed physician owners from all claims, demands, costs, damages, losses, liabilities, and other amounts arising from the ownership and operation of the medical practices, excluding gross negligence.
As of March 31, 2025, and December 31, 2024, the total assets of the Company’s variable interest entities were $235.3 million and $213.9 million, respectively, and are principally comprised of accounts receivable. As of March 31, 2025, and December 31, 2024, the total liabilities of the Company’s variable interest entities were $51.8 million and $57.5 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of $180.9 million and $157.0 million as of March 31, 2025, and December 31, 2024, respectively. These intercompany balances are eliminated in consolidation.
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Leases
 3 Months Ended
Mar. 31, 2025
Leases [Abstract]  
Leases Leases
The Company’s total lease cost is as follows:
Three Months Ended March 31,
20252024
(in thousands)
Operating lease cost$27,317 $24,790 
Finance lease cost:
Amortization of right-of-use assets58 211 
Interest on lease liabilities(2)55 
Variable lease cost5,615 5,256 
Total lease cost$32,988 $30,312 
Leases Leases
The Company’s total lease cost is as follows:
Three Months Ended March 31,
20252024
(in thousands)
Operating lease cost$27,317 $24,790 
Finance lease cost:
Amortization of right-of-use assets58 211 
Interest on lease liabilities(2)55 
Variable lease cost5,615 5,256 
Total lease cost$32,988 $30,312 
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Long-Term Debt
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
Long-Term Debt Long-Term Debt
As of March 31, 2025, the Company’s long-term debt is as follows:
 Principal OutstandingUnamortized Premium (Discount)Unamortized Issuance CostsCarrying Value
(in thousands)
6.875% senior notes
$650,000 $— $(11,533)$638,467 
Credit facilities:
Revolving Credit Facility
50,000 — — 50,000 
Term Loan
950,000 (956)(12,126)936,918 
Other debt(1)
8,846 — — 8,846 
Total debt$1,658,846 $(956)$(23,659)$1,634,231 
____________________________________________
(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.
As of March 31, 2025, principal maturities of the Company’s long-term debt and notes payable are as follows:
 20252026202720282029ThereafterTotal
(in thousands)
6.875% senior notes
$— $— $— $— $— $650,000 $650,000 
Credit facilities:
Revolving Credit Facility
— — — — 50,000 — 50,000 
Term Loan
7,125 9,500 9,500 9,500 9,500 904,875 950,000 
Other debt, including finance leases5,369 1,311 467 483 151 1,065 8,846 
Total debt$12,494 $10,811 $9,967 $9,983 $59,651 $1,555,940 $1,658,846 
As of December 31, 2024, the Company’s long-term debt and notes payable are as follows:
 Principal OutstandingUnamortized Premium (Discount)Unamortized Issuance CostsCarrying Value
(in thousands)
6.875% senior notes
$650,000 $— $(11,925)$638,075 
Credit facilities:
Term Loan
847,875 (995)(11,468)835,412 
Other debt(1)
5,523 — — 5,523 
Total debt$1,503,398 $(995)$(23,393)$1,479,010 
____________________________________________
(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.
Credit Facilities
On July 26, 2024, Concentra Health Services, Inc. (“CHSI”), a wholly-owned subsidiary of Concentra, entered into a senior secured credit agreement (the “Credit Agreement”) that provides for an $850.0 million term loan (the “Term Loan”), and a $400.0 million revolving credit facility, including a $75.0 million sublimit for the issuance of standby letters of credit (the “Revolving Credit Facility” and, together with the Term Loan, the “Credit Facilities”). In March 2025, the Company completed an amendment to the Credit Agreement to increase our Revolving Credit Facility by $50.0 million from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid. In addition, the amendment to the Credit Agreement also added new debt through an incremental term loan of $102.1 million, which provides an updated Term Loan of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including 25-basis point step down at a net leverage ratio of ≤3.25x.
At March 31, 2025, the Company had $386.4 million of availability under its Revolving Credit Facility after giving effect to $50.0 million of borrowings under the Revolving Credit Facility and $13.6 million of outstanding letters of credit.
The Credit Facilities require CHSI to maintain a leverage ratio (as defined in the Credit Agreement), which is tested quarterly and currently must not be greater than 6.50 to 1.00. As of March 31, 2025, the Company was in compliance with all debt covenants.
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued and Other Liabilities
 3 Months Ended
Mar. 31, 2025
Payables and Accruals [Abstract]  
Accrued and Other Liabilities Accrued and Other Liabilities
The following table sets forth the components of accrued and other liabilities on the condensed consolidated balance sheets:
March 31, 2025December 31, 2024
(in thousands)
Accrued payroll$42,999 $75,657 
Accrued vacation43,909 43,647 
Accrued interest9,695 21,849 
Accrued other52,003 58,396 
Income taxes payable16,528 2,350 
Accrued and other liabilities$165,134 $201,899 
XML 38 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value of Financial Instruments
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:
•Level 1 – inputs are based upon quoted prices for identical instruments in active markets.
•Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.
•Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.
The Company’s derivative instruments are based on quotes from the market makers that derive fair values from market data, and therefore, are classified as Level 2.

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the Credit Facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the Concentra senior notes is based on quoted market prices. The carrying value of the Company’s other debt, as disclosed in Note 6—“Long-Term Debt”, approximates fair value.

We did not have any Level 3 financial assets or liabilities in any period presented.

The fair values and the levels within the fair value hierarchy of financial instruments recorded on the condensed consolidated balance sheets were (in thousands):
March 31, 2025December 31, 2024
Financial InstrumentLevel
Balance Sheet Classification
Carrying ValueFair ValueCarrying ValueFair Value
Derivatives designated as hedging instruments(in thousands)
Swap contracts
Level 2
Other current assets
$347 $347 $— $— 
Swap contractsLevel 2Non-current liability(1,759)(1,759)— — 
Total swap contracts
(1,412)(1,412)— — 
Collar contractsLevel 2Current liability(121)(121)— — 
Collar contractsLevel 2
Non-current liability
(763)(763)— — 
Total collar contracts
(884)(884)
Total fair value
$(2,296)$(2,296)$— $— 
6.875% senior notes
Level 2$638,467 $657,150 $638,075 $660,972 
Credit facilities:
Revolving Credit Facility
Level 2$50,000 $49,465 $— $— 
Term LoanLevel 2$936,918 $947,625 $835,412 $853,174 
The Company’s other financial instruments, which primarily consist of cash, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table disaggregates the Company’s revenue for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
(in thousands)
Occupational health centers:
Workers’ compensation$302,107 $279,866 
Employer services160,140 150,735 
Consumer health8,611 8,326 
Other occupational health center revenue2,064 2,145 
Total occupational health center revenue472,922 441,072 
Onsite health clinics16,550 15,857 
Other11,280 10,669 
Total revenue$500,752 $467,598 
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Earnings per Share
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
As of March 31, 2025, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the three months ended March 31, 2025, the Company applied the two-class method because its unvested restricted shares were participating securities.
As of March 31, 2024, the Company’s capital structure consists of common stock and there were no participating shares or securities outstanding.
The following table sets forth the net income attributable to the Company, its shares, and its participating shares:
Basic and Diluted EPS
Three Months Ended March 31,
20252024
(in thousands)
Net income$40,642 $50,279 
Less: net income attributable to non-controlling interests
1,731 1,323 
Net income attributable to the Company38,911 48,956 
Less: distributed and undistributed income attributable to participating securities
455 — 
Distributed and undistributed income attributable to common shares
$38,456 $48,956 
The following table set forth the computation of EPS. For the three months ended March 31, 2025, the Company applied the two-class method.
Three Months Ended March 31, 2025
Three Months Ended March 31, 2024
Net Income Attributable to the Company
Shares(1)
Basic and Diluted EPSNet Income Attributable to the Company
Shares(1)
Basic and Diluted EPS
(in thousands, except for per share amounts)
Common shares$38,456 126,647 $0.30 $48,956 104,094 $0.47 
Participating securities
455 1,500 $0.30 — — $— 
Total Company
$38,911 $48,956 
____________________________________________
(1)    Represents the weighted average shares outstanding during the period.
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Relationship with Select
 3 Months Ended
Mar. 31, 2025
Related Party Transactions [Abstract]  
Relationship with Select Relationship with Select
On November 25, 2024, Concentra became a fully independent company upon the completion of the Distribution and Select ceased to be a related party on that date. The Company continues to have material agreements with Select, including a separation agreement, a transition services agreement, a tax matters agreement and an employee matters agreement.
Shared Services Agreement and Transition Services Agreement
The Company pays Select a fee for the shared support functions provided on a centralized basis by Select and its affiliates. Prior to the IPO, the shared services fee was governed by a shared services agreement between the Company and Select which was reassessed and adjusted annually. The transition services agreement, which became effective concurrent with the IPO, now provides the framework for the services provided by Select and the applicable fee for such services. For the three months ended March 31, 2025, the transaction services agreement fees were $3.7 million, and for the three months ended March 31, 2024, the shared service fees from a related party were $3.8 million.
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Litigation
The Company is a party to various legal actions, proceedings, and claims, and regulatory and other governmental audits and investigations in the ordinary course of its business, including, but not limited to, legal actions and claims alleging professional malpractice, general liability for property damage, personal and bodily injury, violations of federal and state employment laws, often in the form of wage and hour class action lawsuits, and liability for data breaches. Many of these actions involve large claims and significant defense costs and sometimes, as in the case of wage and hour class actions, are not covered by insurance. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties.
To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating. The Company currently maintains insurance coverages under a combination of policies with a total annual per claim aggregate limit of $29.0 million for professional malpractice liability insurance and general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. In addition, the Company purchases additional primary care limits in certain patient compensation fund states, including Indiana, Kansas, Louisiana, Nebraska, Pennsylvania and Wisconsin. The Company also maintains additional types of liability insurance covering claims that, due to their nature or amount, are not covered by or not fully covered by the applicable professional malpractice and general liability insurance policies, including workers compensation, property and casualty, directors and officers, cyber liability, and employment practices liability insurance coverages. Our insurance policies generally are silent with respect to punitive damages so coverage is available to the extent insurable under the law of any applicable jurisdiction, and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities.
California Department of Insurance Investigation. On February 5, 2024, the Company received a subpoena from the California Department of Insurance relating to an investigation under the California Insurance Frauds Prevention Act, Cal. Ins. Code § 1871.7 et seq., which allows a whistleblower to file a false claims lawsuit based on the submission of false or fraudulent claims to insurance companies. The subpoena seeks documentation relating mainly to the Company’s billing and coding for physical therapy claims submitted to commercial insurers and workers’ compensation carriers located or doing business in California. The Company has produced data and other documents requested by the California Department of Insurance and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.
Perry Johnson & Associates, Inc. Data Breach. On November 10, 2023, Perry Johnson & Associates, Inc., a third-party vendor of health information technology solutions that provides medical transcription services (“PJ&A”), notified CHSI that certain information related to particular Concentra patients was potentially affected by a cybersecurity event. In February 2024,
Concentra sent notices to almost four million patients who may have been impacted by the data breach. During the first quarter of 2024, Concentra became aware of six putative class action lawsuits filed against PJ&A and Concentra related to the data breach. Five of the putative class action lawsuits have been transferred to the U.S. District Court for the Eastern District of New York and consolidated with the one class action lawsuit pending there. Plaintiffs filed a Consolidated Class Action Complaint on August 19, 2024 against PJ&A, Concentra, Select Medical Holdings Corporation and other unrelated defendants under the caption In re Perry Johnson & Associates Medical Transcription Data Security Breach Litigation (“Consolidated Complaint”). The Consolidated Complaint alleges that the plaintiffs have suffered injuries and damages under theories of negligence, breach of contract, and failure to comply with statutory duties, including duties under HIPAA, FTC guidelines and industry standards, and various state consumer protection and deceptive trade practice laws. In March 2025, pursuant to a Case Management Order (“Court Order”), five of the named plaintiffs in the Consolidated Complaint filed an amended Direct-Filed Class Action Complaint in the U.S. District Court for the Eastern District of New York. Pursuant to this Court Order, the Direct-Filed Class Action Complaint will be remanded to the United States District Court for the Northern District of Texas after the conclusion of pretrial proceedings. The Company is working with its cybersecurity risk insurance policy carrier and does not believe that the data breach or the lawsuits will have a material impact on its operations or financial performance. However, at this time, the Company is unable to predict the timing and outcome of these matters.
Physical Therapy Billing. In 2021, Select Medical Corporation (“Select”), the former parent of the Company, received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services (“HHS”), is investigating Select in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, et seq. The letter specified that the investigation relates to Select’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from Select. Although the DOJ’s initial requests involved Select’s outpatient therapy clinics, in 2022 and 2023, the DOJ sought and the Company produced additional data and documents relating to the physical therapy services furnished by the Company. In May 2024, by order of the U.S. District Court for the Middle District of Florida, a qui tam lawsuit that is related to the DOJ’s investigation was unsealed after the U.S. filed a notice declining to intervene in the case. The lawsuit, filed in May 2021 and amended in October 2021, was brought by Kathleen Kane, a physical therapist formerly employed in Select’s outpatient division, against Select Medical Corporation, Select Physical Therapy Holdings, Inc. and Select Employment Services, Inc., but does not name the Company as a defendant. The amended complaint alleges that the defendants billed Federally funded health programs for one-on-one therapy services when group therapy was performed or overbilled for one-on-one therapy services, billed for unreimbursable unskilled physical therapy services, and submitted claims containing signatures of therapists who did not provide the billed services. The Company is fully cooperating on this investigation, but at this time, is unable to predict the timing and outcome of this matter.
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information
13.    Segment Information
Our business is organized into three operating segments based primarily on the type or location of occupational health services provided: (i) occupational health centers, (ii) onsite health clinics, and (iii) other businesses. All three operating segments are aggregated into a single reportable segment in our consolidated financial statements based on similar services provided, service delivery process involved, target customers, and similar economic characteristics. Across our operating segments, we offer a diverse and comprehensive array of services, which includes workers’ compensation, employer services and consumer health. Our patients are generally employed by our main customers - employers across the United States.
Occupational health services are focused on the diagnosis and treatment of work-related injuries and illnesses (workers’ compensation services) and employer services such as examinations, physicals, tests and screenings, vaccinations, and a range of consulting services designed to protect employees from workplace hazards.
The chief operating decision maker (“CODM”) is our Chief Executive Officer. The CODM uses Segment Adjusted EBITDA in the annual budgeting and forecasting process, in the review of budget-to-actual and prior year variances to make decisions about the allocation of operating and capital resources, and to establish management’s compensation.
The following table is representative of the significant categories, including significant expenses, regularly provided to the CODM when managing the Company’s single reporting segment.
Three Months Ended March 31,
20252024
(in thousands)
Revenue$500,752 $467,598 
Expenses:(1)
Personnel expenses
281,658 268,372 
Facility expenses
48,382 43,805 
Other expenses
68,053 59,279 
Total segment expenses398,093 371,456 
Segment Adjusted EBITDA$102,659 $96,142 
Total assets$2,729,238 $2,366,162 
Purchases of property and equipment$15,732 $17,231 
Depreciation and amortization$16,619 $18,485 
____________________________________________
(1)    Includes transaction services agreement fees of $3.7 million and shared services fees from a related party $3.8 million for the three months ended March 31, 2025 and 2024, respectively. See Note 11—“Relationship with Select”, for additional information.
Segment Adjusted EBITDA is calculated as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.
The following table reconciles Segment Adjusted EBITDA to income before income taxes for the periods indicated.
 Three Months Ended March 31,
 20252024
(in thousands)
Segment Adjusted EBITDA
$102,659 $96,142 
Interest expense(25,548)(111)
Interest expense on related party debt
— (9,971)
Loss on early retirement of debt
(875)— 
Stock compensation expense
(2,269)(166)
Depreciation and amortization
(16,619)(18,485)
Separation transaction costs(1)
(315)(1,993)
Nova acquisition costs
(3,137)— 
Income before income taxes
$53,896 $65,416 
____________________________________________
(1)    Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations.
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Acquisitions
 3 Months Ended
Mar. 31, 2025
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Acquisitions
14.    Acquisitions
Nova Acquisition
Effective March 1, 2025, the Company acquired Nova Medical Centers (“Nova”). CHSI entered into an equity purchase agreement to acquire all of the outstanding membership interests for a purchase price of approximately $265 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. We financed the transaction using a combination of $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand.
Nova operates 67 occupational health centers in five states, providing workers’ compensation injury care services, physical therapy, drug and alcohol screening, and pre-employment physicals as part of their full suite of occupational health services. The acquisition enabled the Company to expand to more than 775 occupational health centers and onsite health clinics at employer worksites in 42 states.
The Nova acquisition met the definition of a business pursuant to Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, and the acquisition was accounted for as a business combination under the acquisition method of accounting. The Company allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary estimated fair values. The fair values are based on inputs that are unobservable in the market and therefore represent Level 3 inputs.
The Company is in the process of completing its assessment of the acquisition-date fair values of the assets acquired and liabilities assumed and determining the estimated useful lives of long-lived assets and finite-lived intangible assets; therefore, the values set forth are subject to adjustment during the measurement period. The amount of these potential adjustments could be significant. The Company expects to complete its purchase price allocation activities by December 31, 2025.
Pursuant to ASC Topic 810, Consolidation, certain Nova affiliated entities were determined to be a variable interest entity, and the Company was determined to be their primary beneficiary. As a result, the Company obtained a controlling financial interest and Nova has been consolidated into the Company's financial results.
The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):
Identifiable tangible assets
$45,667 
Identifiable intangible assets
38,471 
Goodwill
205,633 
Total assets
289,771 
Total liabilities
24,600 
Consideration given
$265,171 

The preliminary estimate for goodwill of $205.6 million has been recognized for the business combination, representing the excess of the consideration given over the fair value of identifiable net assets acquired. The value of goodwill is derived from Nova’s future earnings potential and its assembled workforce. The amount of goodwill is expected to be deductible for tax purposes.

For the period March 1, 2025 through March 31, 2025, Nova had total revenue and net income of $11.2 million and $1.2 million, respectively, which was included in the condensed consolidated financial statements.

Pro Forma Results

The following unaudited consolidated pro forma financial results combine the historical results of Nova and the Company to present the results as if the Nova acquisition had occurred on January 1, 2024. The pro forma information is presented for illustration purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition occurred on that date, nor is it indicative of future results.
Three Months Ended March 31,
20252024
(unaudited)
(in thousands)
Total revenue$522,111 $499,991 
Net income attributable to the Company
$43,400 $50,935 

The pro forma financial information is based on the preliminary allocation of the purchase price of the Nova acquisition and is therefore subject to adjustment upon finalizing the purchase price allocation, as described above, during the measurement period. The net income tax impact was calculated at the effective tax rate, as Nova had been a subsidiary of the Company as of January 1, 2024.

Pro forma results were adjusted to exclude acquisition-related expenses incurred by the Company that are directly attributable to the transaction. These excluded costs primarily consist of legal, advisory, and transaction-related compensation expenses that are nonrecurring in nature and not reflective of the ongoing operations of the combined business.
XML 45 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Derivatives
 3 Months Ended
Mar. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments Derivative Instruments
The Company uses derivative instruments to manage its exposure to variable-rate debt indexed to 1-month Term SOFR, issued under its Tranche B-1 Term Loans drawn from the Company’s Credit Agreement.

Derivative

Certain information related to our derivatives contracts is presented below (in thousands):
Effective DateNotional AmountFixed RateCapFloorIndexActual Termination Date
Swap contracts3/3/2025$300,000 3.829 %USD-SOFR rate2/29/2028
Collar contracts3/3/2025$300,000 — 4.500 %3.001 %USD-SOFR rate2/29/2028
Cash Flow Hedge Coverage

The Company has entered into interest rate swap and collar agreements designated as cash flow hedges. These agreements are used to manage interest rate risk associated with a portion of the Company’s floating-rate debt for periods not exceeding the next three years.

Deferred Hedging Gains and Losses on Cash Flow Hedges

Based on our valuation at March 31, 2025 and assuming market rates remain constant through contract maturities, we expect transfers to earnings of the existing gains or losses reported in accumulated other comprehensive income on interest rate cash flow hedges during the next 12 months to correspond to the current and non-current assets and liabilities portion of the derivative as disclosed in Note 8—“Fair Value of Financial Instruments”.
Derivative Impact on the Statements of Comprehensive Income

The following table presents the pre-tax amounts of derivative gains or losses deferred into accumulated other comprehensive income and the income statement line item that will be affected when reclassified to earnings (in thousands):

Accumulated Other Comprehensive Income Component (OCI)Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging InstrumentsLocation of Gains/(Losses) When Reclassified to Net Income/(Loss)
Three Months Ended March 31, 2025
Cash flow hedges:
Swap contracts$(1,412)Interest expense
Collar contracts(884)Interest expense
Total (losses)/gains recognized in statements of comprehensive income
$(2,296)

Derivative Impact on the Statements of Income

The following tables present the pre-tax amounts of derivative gains or (losses) recorded to earnings and the affected income statement line items (in thousands):
Three Months Ended March 31, 2025
Interest expense
Total amounts presented in the condensed consolidated statements of income in which the following effects were recorded
Gains/(losses) related to derivatives designated as hedging instruments:
Cash flow hedges(1):
Swap contracts
$115 
Collar contracts(2)
— 
Total gains/(losses) recognized in statements of income$115 
____________________________________________
(1)    Represents the pre-tax amounts of derivative gains/(losses) reclassified from accumulated other comprehensive income to earnings.
(2)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, there are no payments required to be exchanged under this agreement.
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Accumulated Other Comprehensive Income
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income
The components of, and changes in, accumulated other comprehensive income, net of tax, were as follows (in thousands):

Net Cash Flow
Hedge Adjustments
Balance as of December 31, 2024$— 
Net deferred (losses)/gains on cash flow hedges
(1,808)
Net deferred gains/(losses) on cash flow hedges reclassified to net income
86 
Balance as of March 31, 2025$(1,722)
The gross amount and related tax benefit/(expense) recorded in, and associated with, each component of other comprehensive income were as follows (in thousands):

Three Months Ended March 31, 2025
Before Tax AmountTaxNet of Tax Amount
Net deferred (losses)/gains on cash flow hedges
$(2,411)$603 $(1,808)
Net deferred gains/(losses) on cash flow hedges reclassified to net income
$115 $(29)$86 
The amounts reclassified from accumulated other comprehensive income were as follows (in thousands):

Accumulated Other Comprehensive Income (OCI) ComponentReclassified from Accumulated OCI to Earnings for the Three Months Ended March 31, 2025Affected Line Item in the Statements of Income
Gains/(losses) on cash flow hedges:
Swap contract$115 Interest expense
Collar contract(1)
—Interest expense
Gains/(losses) on hedges before income taxes
$115 
Income tax expense(29)
Gains on hedges$86 
____________________________________________
(1)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, no amounts have been reclassified from OCI to earnings.
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent Events
 3 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Equity Purchase Agreement
On April 18, 2025, CHSI entered into an equity purchase agreement with Pivot Occupational Health, LLC to acquire all of the outstanding equity interests of Onsite Innovations, LLC (“Pivot Onsite Innovations”). The transaction values Pivot Onsite Innovations at $55 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. The transaction is expected to close in the second quarter of 2025 and is subject to customary closing conditions set forth in the purchase agreement.
CHSI currently expects to finance the transaction using a combination of cash on hand and available borrowing capacity under its existing Revolving Credit Facility.
Pivot Onsite Innovations operates approximately 200 onsite health clinics at employer locations in over 40 states, providing occupational health, wellness, prevention, and performance services. When combined with Concentra’s current onsite health clinic footprint, the acquisition will enable the Company to expand to more than 350 onsite health clinics at employer worksites.
Dividend
On May 6, 2025, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable May 29, 2025, to stockholders of record as of the close of business on May 20, 2025.
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net income attributable to the Company $ 38,911 $ 48,956
XML 49 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 50 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Basis of Presentation and Consolidation
Basis of Presentation and Consolidation
The Company operated as part of Select Medical Corporation (“Select”) until Select made a special stock distribution of 104,093,503 shares of the Company’s common stock to Select’s stockholders (the “Distribution”) on November 25, 2024. The Company’s consolidated financial statements prior to the Distribution have been prepared from Select’s historical accounting records and derived from the condensed consolidated financial statements of Select to present the Company as if it had been operating on a standalone basis. The unaudited condensed consolidated financial statements of the Company as of March 31, 2025, and for the three months ended March 31, 2025 and 2024, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods.
The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the full fiscal year ended December 31, 2025. These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (File No. 001-42188).
The condensed consolidated financial statements include the assets, liabilities, revenue, and expenses based on our legal entity structure as well as direct and indirect costs that are attributable to our operations. Indirect costs are the costs of support functions that are partially provided on a centralized basis by Select and its affiliates, which include finance, human resources, benefits administration, procurement support, information technology, legal, corporate governance and other professional services. Indirect costs were allocated to the Company, prior to the IPO, for the purposes of preparing the consolidated financial statements based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method, primarily based on headcount or other allocation methodologies that are considered to be a reasonable reflection of the utilization of services provided or the benefit received by the Company during the periods presented, depending on the nature of the services received. Subsequent to the IPO, the support services provided by Select have been billed to the Company pursuant to a transitional services agreement, as further described in Note 11—“Relationship with Select”.
The income tax amounts in these condensed consolidated financial statements prior to the Distribution have been calculated based on a separate return methodology and are presented as if our income gave rise to separate federal and state consolidated income tax return filing obligations in the respective jurisdictions in which we operate. Adjustments to income tax expense resulting from the application of the separate return methodology, as compared to tax obligations determined by the Company’s inclusion in Select’s consolidated income tax provision, were assumed to be immediately settled with Select through contributed capital/capital in excess of par as reflected on the condensed consolidated balance sheets, and reflected as a (distribution)/contribution to Select on the condensed consolidated statements of changes in stockholders’/members’ equity and the condensed consolidated statements of cash flows within financing activities.
The condensed consolidated financial statements include the accounts of the Company and the subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions within the Company are eliminated in consolidation. Transactions between the Company and Select have been included in these condensed consolidated financial statements. The transactions with Select are settled in cash, other than the assumed income tax settlement noted above, and are reflected within the condensed consolidated statement of cash flows as an operating or financing activity determined by the nature of the transaction.
Basis of Presentation and Consolidation
The condensed consolidated financial statements include the accounts of the Company and the subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions within the Company are eliminated in consolidation. Transactions between the Company and Select have been included in these condensed consolidated financial statements. The transactions with Select are settled in cash, other than the assumed income tax settlement noted above, and are reflected within the condensed consolidated statement of cash flows as an operating or financing activity determined by the nature of the transaction.
Derivatives and Hedging
Derivatives and Hedging
The Company is exposed to certain risks relating to its ongoing financial arrangements. The primary risk managed using derivative instruments is to reduce variability in interest cash flows on its variable-rate debt. Interest rate swaps and collars are entered into to manage interest rate risk associated with the Company’s variable-rate debt. As a matter of policy, we do not use highly leveraged derivative instruments, nor do we use financial instruments for speculative purposes.
ASC 815 requires entities to recognize all derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship.
Our designated derivative contracts include interest rate swap and collar agreements, which effectively modify the Company’s exposure to interest rate risk by converting the Company’s floating-rate debt to a fixed-rate basis (for interest rate swap arrangements) and capping and flooring the interest rates (for collar arrangements) for the next three years, thus reducing the impact of interest-rate changes on future interest expense. These agreements involve the receipt of floating-rate amounts in exchange of fixed-rate interest payments and the application of cap and floor rates over the term of the agreements without an exchange of the underlying principal amount.
Our derivatives are designated as cash flow hedges and qualify for hedge accounting treatment. Gains or losses on cash flow hedges are deferred as a component of accumulated other comprehensive income or losses and reclassified into earnings at the time the hedged item affects earnings, presented in the same income statement line item as the underlying hedged item (i.e., in “interest expense” when the hedged transactions are interest cash flows associated with floating-rate debt).
To qualify for hedge accounting, a specified level of hedge effectiveness between the hedging instrument and the hedged item must be achieved at inception and maintained throughout the hedged period. We formally document our risk management objectives, our strategies for undertaking the hedge transactions, the nature of and relationships between the hedging instruments and hedged items, and the method for assessing hedge effectiveness. Additionally, for qualified hedges of forecasted transactions, we specifically identify the significant characteristics and expected terms of the forecasted transactions.
If it becomes probable that a forecasted transaction will not occur, previously deferred gains and losses related to those forecasted transactions would be recognized in earnings in the current period.
Recent Accounting Guidance Not Yet Adopted
Recent Accounting Guidance Not Yet Adopted
Income Taxes
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.
The ASU is effective for the Company’s annual financial statements for the year ended December 31, 2025. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have on the disclosures in our consolidated financial statements.
Expense Disaggregation
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which is intended to improve the disclosures of expenses by providing more
detailed information about the types of expenses in commonly presented expense captions. The ASU requires entities to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption; as well as a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendment also requires disclosure of the total amount of selling expense and, in annual reporting periods, an entity’s definition of selling expenses.
The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2024-03 will have on the disclosures in our consolidated financial statements.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.
Redeemable Non-Controlling Interests Redeemable Non-Controlling InterestsThe Company’s redeemable non-controlling interests are comprised of membership interests held by equity holders other than the Company in five less than wholly-owned subsidiaries. These shares are subject to redemption rights.
Variable Interest Entities Variable Interest Entities
Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices that directly employ physicians and from exercising control over medical decisions by physicians. In these states, the Company enters into long-term management agreements with affiliated professional medical groups (referred to as “Managed PCs”) that are owned by licensed physicians which, in turn, employ or contract with physicians who provide professional medical services in its occupational health centers. The Company also enters into a stock transfer restriction agreement with the respective equity holders, which provide for the Company to direct the transfer of ownership of the Managed PCs to other licensed physicians at any time. The long-term management agreements provide for various administrative and management services to be provided by the Company to the Managed PCs, including, but not limited to, billing and collections, accounting, non-physician personnel, supplies, security and maintenance, and insurance. The Company has the right to receive income as an ongoing management fee, and effectively absorbs all of the residual interests of the Managed PCs. Based on the provisions of the management and stock transfer agreements, the Managed PCs are variable interest entities for which the Company is the primary beneficiary and consolidates the Managed PCs under the variable interest entity model. There are no restrictions on the use of the assets of the Managed PCs or on the settlement of its liabilities. Additionally, the Company fully indemnifies the licensed physician owners from all claims, demands, costs, damages, losses, liabilities, and other amounts arising from the ownership and operation of the medical practices, excluding gross negligence.
XML 51 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Redeemable Non-Controlling Interests (Tables)
 3 Months Ended
Mar. 31, 2025
Noncontrolling Interest [Abstract]  
Schedule of redeemable non-controlling interests The changes in redeemable non-controlling interests are as follows:
20252024
(in thousands)
Balance as of January 1$18,013 $16,477 
Net income attributable to redeemable non-controlling interests1,438 1,053 
Distributions to redeemable non-controlling interests
(842)(1,174)
Redemption value adjustment on redeemable non-controlling interests— 1,901 
Balance as of March 31$18,609 $18,257 
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2025
Leases [Abstract]  
Schedule of lease cost
The Company’s total lease cost is as follows:
Three Months Ended March 31,
20252024
(in thousands)
Operating lease cost$27,317 $24,790 
Finance lease cost:
Amortization of right-of-use assets58 211 
Interest on lease liabilities(2)55 
Variable lease cost5,615 5,256 
Total lease cost$32,988 $30,312 
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Long-Term Debt (Tables)
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
Schedule of long-term debt and notes payable
As of March 31, 2025, the Company’s long-term debt is as follows:
 Principal OutstandingUnamortized Premium (Discount)Unamortized Issuance CostsCarrying Value
(in thousands)
6.875% senior notes
$650,000 $— $(11,533)$638,467 
Credit facilities:
Revolving Credit Facility
50,000 — — 50,000 
Term Loan
950,000 (956)(12,126)936,918 
Other debt(1)
8,846 — — 8,846 
Total debt$1,658,846 $(956)$(23,659)$1,634,231 
____________________________________________
(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.
As of December 31, 2024, the Company’s long-term debt and notes payable are as follows:
 Principal OutstandingUnamortized Premium (Discount)Unamortized Issuance CostsCarrying Value
(in thousands)
6.875% senior notes
$650,000 $— $(11,925)$638,075 
Credit facilities:
Term Loan
847,875 (995)(11,468)835,412 
Other debt(1)
5,523 — — 5,523 
Total debt$1,503,398 $(995)$(23,393)$1,479,010 
____________________________________________
(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.
Schedule of principal maturities of long-term debt and notes payable
As of March 31, 2025, principal maturities of the Company’s long-term debt and notes payable are as follows:
 20252026202720282029ThereafterTotal
(in thousands)
6.875% senior notes
$— $— $— $— $— $650,000 $650,000 
Credit facilities:
Revolving Credit Facility
— — — — 50,000 — 50,000 
Term Loan
7,125 9,500 9,500 9,500 9,500 904,875 950,000 
Other debt, including finance leases5,369 1,311 467 483 151 1,065 8,846 
Total debt$12,494 $10,811 $9,967 $9,983 $59,651 $1,555,940 $1,658,846 
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued and Other Liabilities (Tables)
 3 Months Ended
Mar. 31, 2025
Payables and Accruals [Abstract]  
Components of accrued and other liabilities
The following table sets forth the components of accrued and other liabilities on the condensed consolidated balance sheets:
March 31, 2025December 31, 2024
(in thousands)
Accrued payroll$42,999 $75,657 
Accrued vacation43,909 43,647 
Accrued interest9,695 21,849 
Accrued other52,003 58,396 
Income taxes payable16,528 2,350 
Accrued and other liabilities$165,134 $201,899 
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value of Financial Instruments (Tables)
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of fair value measurements
The fair values and the levels within the fair value hierarchy of financial instruments recorded on the condensed consolidated balance sheets were (in thousands):
March 31, 2025December 31, 2024
Financial InstrumentLevel
Balance Sheet Classification
Carrying ValueFair ValueCarrying ValueFair Value
Derivatives designated as hedging instruments(in thousands)
Swap contracts
Level 2
Other current assets
$347 $347 $— $— 
Swap contractsLevel 2Non-current liability(1,759)(1,759)— — 
Total swap contracts
(1,412)(1,412)— — 
Collar contractsLevel 2Current liability(121)(121)— — 
Collar contractsLevel 2
Non-current liability
(763)(763)— — 
Total collar contracts
(884)(884)
Total fair value
$(2,296)$(2,296)$— $— 
6.875% senior notes
Level 2$638,467 $657,150 $638,075 $660,972 
Credit facilities:
Revolving Credit Facility
Level 2$50,000 $49,465 $— $— 
Term LoanLevel 2$936,918 $947,625 $835,412 $853,174 
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table disaggregates the Company’s revenue for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
(in thousands)
Occupational health centers:
Workers’ compensation$302,107 $279,866 
Employer services160,140 150,735 
Consumer health8,611 8,326 
Other occupational health center revenue2,064 2,145 
Total occupational health center revenue472,922 441,072 
Onsite health clinics16,550 15,857 
Other11,280 10,669 
Total revenue$500,752 $467,598 
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Earnings per Share (Tables)
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of computation of basic and diluted earnings per share
The following table sets forth the net income attributable to the Company, its shares, and its participating shares:
Basic and Diluted EPS
Three Months Ended March 31,
20252024
(in thousands)
Net income$40,642 $50,279 
Less: net income attributable to non-controlling interests
1,731 1,323 
Net income attributable to the Company38,911 48,956 
Less: distributed and undistributed income attributable to participating securities
455 — 
Distributed and undistributed income attributable to common shares
$38,456 $48,956 
The following table set forth the computation of EPS. For the three months ended March 31, 2025, the Company applied the two-class method.
Three Months Ended March 31, 2025
Three Months Ended March 31, 2024
Net Income Attributable to the Company
Shares(1)
Basic and Diluted EPSNet Income Attributable to the Company
Shares(1)
Basic and Diluted EPS
(in thousands, except for per share amounts)
Common shares$38,456 126,647 $0.30 $48,956 104,094 $0.47 
Participating securities
455 1,500 $0.30 — — $— 
Total Company
$38,911 $48,956 
____________________________________________
(1)    Represents the weighted average shares outstanding during the period.
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of selected financial data for reportable segments
The following table is representative of the significant categories, including significant expenses, regularly provided to the CODM when managing the Company’s single reporting segment.
Three Months Ended March 31,
20252024
(in thousands)
Revenue$500,752 $467,598 
Expenses:(1)
Personnel expenses
281,658 268,372 
Facility expenses
48,382 43,805 
Other expenses
68,053 59,279 
Total segment expenses398,093 371,456 
Segment Adjusted EBITDA$102,659 $96,142 
Total assets$2,729,238 $2,366,162 
Purchases of property and equipment$15,732 $17,231 
Depreciation and amortization$16,619 $18,485 
____________________________________________
(1)    Includes transaction services agreement fees of $3.7 million and shared services fees from a related party $3.8 million for the three months ended March 31, 2025 and 2024, respectively. See Note 11—“Relationship with Select”, for additional information.
Schedule of reconciliation of Adjusted EBITDA to income before income taxes
The following table reconciles Segment Adjusted EBITDA to income before income taxes for the periods indicated.
 Three Months Ended March 31,
 20252024
(in thousands)
Segment Adjusted EBITDA
$102,659 $96,142 
Interest expense(25,548)(111)
Interest expense on related party debt
— (9,971)
Loss on early retirement of debt
(875)— 
Stock compensation expense
(2,269)(166)
Depreciation and amortization
(16,619)(18,485)
Separation transaction costs(1)
(315)(1,993)
Nova acquisition costs
(3,137)— 
Income before income taxes
$53,896 $65,416 
____________________________________________
(1)    Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations.
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Acquisitions (Tables)
 3 Months Ended
Mar. 31, 2025
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of recognized identified assets acquired and liabilities assumed
The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):
Identifiable tangible assets
$45,667 
Identifiable intangible assets
38,471 
Goodwill
205,633 
Total assets
289,771 
Total liabilities
24,600 
Consideration given
$265,171 
Schedule of pro forma unaudited results of operations
The following unaudited consolidated pro forma financial results combine the historical results of Nova and the Company to present the results as if the Nova acquisition had occurred on January 1, 2024. The pro forma information is presented for illustration purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition occurred on that date, nor is it indicative of future results.
Three Months Ended March 31,
20252024
(unaudited)
(in thousands)
Total revenue$522,111 $499,991 
Net income attributable to the Company
$43,400 $50,935 
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Derivatives Instruments (Tables)
 3 Months Ended
Mar. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of derivative instruments
Certain information related to our derivatives contracts is presented below (in thousands):
Effective DateNotional AmountFixed RateCapFloorIndexActual Termination Date
Swap contracts3/3/2025$300,000 3.829 %USD-SOFR rate2/29/2028
Collar contracts3/3/2025$300,000 — 4.500 %3.001 %USD-SOFR rate2/29/2028
Schedule of derivative instruments, effect on other comprehensive income (loss)
The following table presents the pre-tax amounts of derivative gains or losses deferred into accumulated other comprehensive income and the income statement line item that will be affected when reclassified to earnings (in thousands):

Accumulated Other Comprehensive Income Component (OCI)Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging InstrumentsLocation of Gains/(Losses) When Reclassified to Net Income/(Loss)
Three Months Ended March 31, 2025
Cash flow hedges:
Swap contracts$(1,412)Interest expense
Collar contracts(884)Interest expense
Total (losses)/gains recognized in statements of comprehensive income
$(2,296)
Schedule of cash flow hedging instruments, statements of financial performance and financial position, location
The following tables present the pre-tax amounts of derivative gains or (losses) recorded to earnings and the affected income statement line items (in thousands):
Three Months Ended March 31, 2025
Interest expense
Total amounts presented in the condensed consolidated statements of income in which the following effects were recorded
Gains/(losses) related to derivatives designated as hedging instruments:
Cash flow hedges(1):
Swap contracts
$115 
Collar contracts(2)
— 
Total gains/(losses) recognized in statements of income$115 
____________________________________________
(1)    Represents the pre-tax amounts of derivative gains/(losses) reclassified from accumulated other comprehensive income to earnings.
(2)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, there are no payments required to be exchanged under this agreement.
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Accumulated Other Comprehensive Income (Tables)
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Schedule of accumulated other comprehensive income (loss)
The components of, and changes in, accumulated other comprehensive income, net of tax, were as follows (in thousands):

Net Cash Flow
Hedge Adjustments
Balance as of December 31, 2024$— 
Net deferred (losses)/gains on cash flow hedges
(1,808)
Net deferred gains/(losses) on cash flow hedges reclassified to net income
86 
Balance as of March 31, 2025$(1,722)
The gross amount and related tax benefit/(expense) recorded in, and associated with, each component of other comprehensive income were as follows (in thousands):

Three Months Ended March 31, 2025
Before Tax AmountTaxNet of Tax Amount
Net deferred (losses)/gains on cash flow hedges
$(2,411)$603 $(1,808)
Net deferred gains/(losses) on cash flow hedges reclassified to net income
$115 $(29)$86 
Schedule of reclassification out of accumulated other comprehensive income
The amounts reclassified from accumulated other comprehensive income were as follows (in thousands):

Accumulated Other Comprehensive Income (OCI) ComponentReclassified from Accumulated OCI to Earnings for the Three Months Ended March 31, 2025Affected Line Item in the Statements of Income
Gains/(losses) on cash flow hedges:
Swap contract$115 Interest expense
Collar contract(1)
—Interest expense
Gains/(losses) on hedges before income taxes
$115 
Income tax expense(29)
Gains on hedges$86 
____________________________________________
(1)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, no amounts have been reclassified from OCI to earnings.
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Organization (Details)
 3 Months Ended
Mar. 01, 2025
state
hospital
Mar. 31, 2025
state
clinic
health_center
Product Information [Line Items]    
Number of occupational health centers operated by entity 775 627
Number of states in which entity operates 42  
Number of onsite health clinics | clinic   160
Occupational Health Centers    
Product Information [Line Items]    
Number of states in which entity operates   41
Onsite health clinics    
Product Information [Line Items]    
Number of states in which entity operates   36
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Accounting Policies (Details) - shares
 3 Months Ended
Nov. 25, 2024
Mar. 31, 2025
Class of Stock [Line Items]    
Derivative, term of contract   3 years
Swap contracts    
Class of Stock [Line Items]    
Derivative, term of contract   3 years
Collar contracts    
Class of Stock [Line Items]    
Derivative, term of contract   3 years
Concentra Group Holdings Parent | Select Medical Corporation    
Class of Stock [Line Items]    
Select special stock distribution (in shares) 104,093,503  
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Redeemable Non-Controlling Interests - Narrative (Details)
Mar. 31, 2025
less_than_wholly_owned_subsidiary
Noncontrolling Interest [Abstract]  
Number of less than wholly owned subsidiaries 5
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Redeemable Non-Controlling Interests - Schedule of Redeemable Non-Controlling Interests (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Increase (Decrease) in Temporary Equity [Roll Forward]    
Balance, beginning $ 18,013 $ 16,477
Net income attributable to redeemable non-controlling interests 1,438 1,053
Distributions to redeemable non-controlling interests (842) (1,174)
Redemption value adjustment on redeemable non-controlling interests 0 1,901
Balance, ending $ 18,609 $ 18,257
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Variable Interest Entities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Variable Interest Entity [Line Items]      
Assets $ 2,729,238 $ 2,521,164 $ 2,366,162
Liabilities 2,398,177 2,222,440  
Variable Interest Entity, Primary Beneficiary      
Variable Interest Entity [Line Items]      
Assets 235,300 213,900  
Liabilities 51,800 57,500  
Variable Interest Entity, Primary Beneficiary | Related Party      
Variable Interest Entity [Line Items]      
Obligations payable $ 180,900 $ 157,000  
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Lease, Cost [Abstract]    
Operating lease cost $ 27,317 $ 24,790
Finance lease cost:    
Amortization of right-of-use assets 58 211
Interest on lease liabilities (2) 55
Variable lease cost 5,615 5,256
Total lease cost $ 32,988 $ 30,312
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Long-Term Debt - Components of Long-Term Debt And Notes Payable (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Instrument [Line Items]    
Principal Outstanding $ 1,658,846 $ 1,503,398
Unamortized Premium (Discount) (956) (995)
Unamortized Issuance Costs (23,659) (23,393)
Carrying Value $ 1,634,231 $ 1,479,010
Senior notes | 6.875% senior notes    
Debt Instrument [Line Items]    
Interest rate of debt (as a percent) 6.875% 6.875%
Principal Outstanding $ 650,000 $ 650,000
Unamortized Premium (Discount) 0 0
Unamortized Issuance Costs (11,533) (11,925)
Carrying Value 638,467 638,075
Term Loan | Term Loan    
Debt Instrument [Line Items]    
Principal Outstanding 950,000 847,875
Unamortized Premium (Discount) (956) (995)
Unamortized Issuance Costs (12,126) (11,468)
Carrying Value 936,918 835,412
Other debt    
Debt Instrument [Line Items]    
Principal Outstanding 8,846 5,523
Unamortized Premium (Discount) 0 0
Unamortized Issuance Costs 0 0
Carrying Value 8,846 $ 5,523
Revolving Credit Facility | Revolving Credit Facility    
Debt Instrument [Line Items]    
Principal Outstanding 50,000  
Unamortized Premium (Discount) 0  
Unamortized Issuance Costs 0  
Carrying Value $ 50,000  
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Long-Term Debt - Principal Maturities Of Long-Term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Instrument [Line Items]    
2025 $ 12,494  
2026 10,811  
2027 9,967  
2028 9,983  
2029 59,651  
Thereafter 1,555,940  
Total 1,658,846 $ 1,503,398
Revolving Credit Facility | Revolving Credit Facility    
Debt Instrument [Line Items]    
2025 0  
2026 0  
2027 0  
2028 0  
2029 50,000  
Thereafter 0  
Total 50,000  
Term Loan | Term Loan    
Debt Instrument [Line Items]    
2025 7,125  
2026 9,500  
2027 9,500  
2028 9,500  
2029 9,500  
Thereafter 904,875  
Total 950,000 847,875
Other debt, including finance leases    
Debt Instrument [Line Items]    
2025 5,369  
2026 1,311  
2027 467  
2028 483  
2029 151  
Thereafter 1,065  
Total $ 8,846 $ 5,523
6.875% senior notes | Senior notes    
Debt Instrument [Line Items]    
Interest rate of debt (as a percent) 6.875% 6.875%
2025 $ 0  
2026 0  
2027 0  
2028 0  
2029 0  
Thereafter 650,000  
Total $ 650,000 $ 650,000
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Long-Term Debt - Narrative (Details)
$ in Millions
 1 Months Ended
Feb. 28, 2025
USD ($)
Jul. 26, 2024
USD ($)
Mar. 31, 2025
USD ($)
Term Loan      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity   $ 850.0  
Revolving Credit Facility | Concentra Credit Facilities      
Line of Credit Facility [Line Items]      
Debt instrument, covenant, leverage ratio   6.50  
Revolving Credit Facility | Term Loan | Concentra Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Credit spread adjustment 2.25%   2.00%
Revolving Credit Facility | Term Loan | Concentra Term Loan      
Line of Credit Facility [Line Items]      
Increase in revolving credit facility     $ 102.1
Principal outstanding     $ 950.0
Debt Instrument, Basis Point Step Down     0.0025
Revolving Credit Facility | Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity   $ 400.0  
Revolving Credit Facility | Revolving Credit Facility | Concentra Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity $ 400.0   $ 450.0
Increase in revolving credit facility     $ 50.0
Credit spread adjustment 2.50%   2.00%
Debt instrument, covenant, leverage ratio     3.25
Available borrowing capacity     $ 386.4
Outstanding letters of credit     50.0
Revolving Credit Facility | Standby letters of credit      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity   $ 75.0  
Revolving Credit Facility | Letter of Credit | Concentra Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Outstanding letters of credit     $ 13.6
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued and Other Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Accrued payroll $ 42,999 $ 75,657
Accrued vacation 43,909 43,647
Accrued interest 9,695 21,849
Accrued other 52,003 58,396
Income taxes payable 16,528 2,350
Accrued and other liabilities $ 165,134 $ 201,899
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Level 2 | Carrying Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts $ (2,296) $ 0
Level 2 | Fair Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (2,296) 0
Level 2 | Swap contracts | Carrying Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (1,412) 0
Level 2 | Swap contracts | Carrying Value | Fair Value, Recurring | Other current assets    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts 347 0
Level 2 | Swap contracts | Carrying Value | Fair Value, Recurring | Non-current liability    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (1,759) 0
Level 2 | Swap contracts | Fair Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (1,412) 0
Level 2 | Swap contracts | Fair Value | Fair Value, Recurring | Other current assets    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts 347 0
Level 2 | Swap contracts | Fair Value | Fair Value, Recurring | Non-current liability    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (1,759) 0
Level 2 | Collar contracts | Carrying Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (884)
Level 2 | Collar contracts | Carrying Value | Fair Value, Recurring | Non-current liability    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (763) 0
Level 2 | Collar contracts | Carrying Value | Fair Value, Recurring | Current liability    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (121) 0
Level 2 | Collar contracts | Fair Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (884)
Level 2 | Collar contracts | Fair Value | Fair Value, Recurring | Non-current liability    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (763) 0
Level 2 | Collar contracts | Fair Value | Fair Value, Recurring | Current liability    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total collar contracts (121) 0
Senior notes | Level 2 | Carrying Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt fair value 638,467 638,075
Senior notes | Level 2 | Fair Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt fair value $ 657,150 $ 660,972
Senior notes | 6.875% senior notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest rate of debt (as a percent) 6.875% 6.875%
Revolving Credit Facility | Level 2 | Carrying Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt fair value $ 50,000 $ 0
Revolving Credit Facility | Level 2 | Fair Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt fair value 49,465 0
Term Loan | Level 2 | Carrying Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt fair value 936,918 835,412
Term Loan | Level 2 | Fair Value | Fair Value, Recurring    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt fair value $ 947,625 $ 853,174
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Revenue $ 500,752 $ 467,598
Total occupational health center revenue    
Disaggregation of Revenue [Line Items]    
Revenue 472,922 441,072
Onsite health clinics    
Disaggregation of Revenue [Line Items]    
Revenue 16,550 15,857
Other    
Disaggregation of Revenue [Line Items]    
Revenue 11,280 10,669
Workers’ compensation    
Disaggregation of Revenue [Line Items]    
Revenue 302,107 279,866
Employer services    
Disaggregation of Revenue [Line Items]    
Revenue 160,140 150,735
Consumer health    
Disaggregation of Revenue [Line Items]    
Revenue 8,611 8,326
Other occupational health center revenue    
Disaggregation of Revenue [Line Items]    
Revenue $ 2,064 $ 2,145
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Earnings per Share - Net Income Attributable to the Company, Units Outstanding, and Participating Units Outstanding (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Earnings Per Share [Abstract]    
Net income $ 40,642 $ 50,279
Less: net income attributable to non-controlling interests 1,731 1,323
Net income attributable to the Company 38,911 48,956
Basic EPS    
Less: Distributed and undistributed income attributable to participating shares - basic EPS 455 0
Distributed and undistributed income attributable to common shares 38,456 48,956
Diluted EPS    
Less: Distributed and undistributed income attributable to participating shares - diluted EPS 455 0
Distributed and undistributed income attributable to common shares $ 38,456 $ 48,956
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Earnings per Share - Computation of EPS Under the Two-Class Method (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Undistributed Earnings, Basic [Abstract]    
Net income allocated to common shares - basic $ 38,456 $ 48,956
Participating shares - basic 455 0
Net income allocated to common shares - diluted 38,456 48,956
Participating shares - diluted 455 0
Net income attributable to the Company $ 38,911 $ 48,956
Weighted average common shares outstanding, basic (in shares) 126,647 104,094
Weighted average common shares outstanding, diluted (in shares) 126,647 104,094
Weighted average participating shares outstanding (in shares) 1,500  
Basic EPS    
Basic EPS (in dollars per share) $ 0.30 $ 0.47
Diluted EPS    
Diluted EPS (in dollars per share) $ 0.30 $ 0.47
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Relationship with Select (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Related Party    
Related Party Transaction [Line Items]    
Shared service fee from related party $ 3.7 $ 3.8
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Mar. 31, 2025
class_action_lawsuit
Mar. 31, 2025
USD ($)
Mar. 31, 2024
class_action_lawsuit
Feb. 29, 2024
patient
Commitments and Contingencies        
Loss contingency, number of patients | patient       4,000,000
Loss contingency, new claims filed, number 5   6  
Number of putative class actions claims transferred     5  
Number of class action lawsuit pending     1  
Professional liability claims        
Commitments and Contingencies        
Total annual aggregate limit of insurance coverage | $   $ 29.0    
XML 78 R59.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Narrative (Details)
 3 Months Ended
Mar. 31, 2025
segment
Segment Reporting [Abstract]  
Number of operating segments 3
XML 79 R60.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Selected Financial Data (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Segment Reporting Information [Line Items]      
Revenue $ 500,752 $ 467,598  
Total costs and expenses 420,433 392,384  
Total assets 2,729,238 2,366,162 $ 2,521,164
Purchases of property and equipment 15,732 17,231  
Depreciation and amortization 16,619 18,485  
Related Party      
Segment Reporting Information [Line Items]      
Shared service fee from related party 3,700 3,800  
Reportable Segment      
Segment Reporting Information [Line Items]      
Revenue 500,752 467,598  
Personnel expenses 281,658 268,372  
Facility expenses 48,382 43,805  
Other expenses 68,053 59,279  
Total costs and expenses 398,093 371,456  
Segment Adjusted EBITDA 102,659 96,142  
Depreciation and amortization 16,619 18,485  
Reportable Segment | Related Party      
Segment Reporting Information [Line Items]      
Shared service fee from related party $ 3,700 $ 3,800  
XML 80 R61.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Interest expense $ (25,548) $ (111)
Loss on early retirement of debt (875) 0
Depreciation and amortization (16,619) (18,485)
Income before income taxes 53,896 65,416
Related Party    
Segment Reporting Information [Line Items]    
Interest expense on related party debt 0 (9,971)
Reportable Segment    
Segment Reporting Information [Line Items]    
Segment Adjusted EBITDA 102,659 96,142
Interest expense (25,548) (111)
Loss on early retirement of debt (875)  
Stock compensation expense (2,269) (166)
Depreciation and amortization (16,619) (18,485)
Separation transaction costs (315) (1,993)
Nova acquisition costs (3,137) 0
Income before income taxes 53,896 65,416
Reportable Segment | Related Party    
Segment Reporting Information [Line Items]    
Interest expense on related party debt $ 0 $ (9,971)
XML 81 R62.htm IDEA: XBRL DOCUMENT v3.25.1
Acquisitions - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
Mar. 01, 2025
USD ($)
hospital
state
Mar. 31, 2025
USD ($)
Mar. 31, 2025
USD ($)
health_center
Dec. 31, 2024
USD ($)
Business Combination, Separately Recognized Transactions [Line Items]        
Number of occupational health centers operated by entity 775   627  
Number of states in which entity operates | state 42      
Goodwill   $ 1,444,563 $ 1,444,563 $ 1,234,707
Nova Medical Centers        
Business Combination, Separately Recognized Transactions [Line Items]        
Number of occupational health centers operated by entity | hospital 67      
Number of states in which entity operates | state 5      
Nova Acquisition        
Business Combination, Separately Recognized Transactions [Line Items]        
Consideration transferred $ 265,171      
Cash paid to acquire business, term loan add-on 102,100      
Cash paid to acquire business, available borrowing capacity 50,000      
Goodwill $ 205,633      
Net revenues of acquiree   11,200    
Net income from acquiree   $ 1,200    
XML 82 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Acquisitions - Nova Purchase Price (Details) - USD ($)
$ in Thousands
Mar. 01, 2025
Mar. 31, 2025
Dec. 31, 2024
Business Combination, Separately Recognized Transactions [Line Items]      
Goodwill   $ 1,444,563 $ 1,234,707
Nova Acquisition      
Business Combination, Separately Recognized Transactions [Line Items]      
Identifiable tangible assets $ 45,667    
Identifiable intangible assets 38,471    
Goodwill 205,633    
Total assets 289,771    
Total liabilities 24,600    
Consideration transferred $ 265,171    
XML 83 R64.htm IDEA: XBRL DOCUMENT v3.25.1
Acquisitions - Pro Forma Information (Details) - Nova Acquisition - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Business Combination, Separately Recognized Transactions [Line Items]    
Total revenue $ 522,111 $ 499,991
Net income attributable to the Company $ 43,400 $ 50,935
XML 84 R65.htm IDEA: XBRL DOCUMENT v3.25.1
Derivatives Instruments - Schedule of Derivatives (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
Derivative [Line Items]  
Derivative, term of contract 3 years
Swap contracts  
Derivative [Line Items]  
Notional amount $ 300,000
Fixed Rate 3.829%
Derivative, term of contract 3 years
Collar contracts  
Derivative [Line Items]  
Notional amount $ 300,000
Cap 4.50%
Floor 3.001%
Derivative, term of contract 3 years
XML 85 R66.htm IDEA: XBRL DOCUMENT v3.25.1
Derivatives Instruments - Derivative Impact on Statements of Income and Comprehensive Income (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
Derivative [Line Items]  
Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging Instruments $ (2,296)
Gains/(losses) related to derivatives designated as hedging instruments: 115
Swap contracts  
Derivative [Line Items]  
Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging Instruments (1,412)
Gains/(losses) related to derivatives designated as hedging instruments: 115
Collar contracts  
Derivative [Line Items]  
Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging Instruments (884)
Gains/(losses) related to derivatives designated as hedging instruments: $ 0
XML 86 R67.htm IDEA: XBRL DOCUMENT v3.25.1
Accumulated Other Comprehensive Income - AOCI Rollforward (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance $ 280,711
Ending balance 312,452
Net Cash Flow Hedge Adjustments  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance 0
Net deferred (losses)/gains on cash flow hedges (1,808)
Net deferred gains/(losses) on cash flow hedges reclassified to net income 86
Ending balance $ (1,722)
XML 87 R68.htm IDEA: XBRL DOCUMENT v3.25.1
Accumulated Other Comprehensive Income - AOCI Tax Benefit/Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Net deferred (losses)/gains on cash flow hedges    
Before Tax Amount $ (2,411)  
Tax 603  
Net of Tax Amount (1,808) $ 0
Net deferred gains/(losses) on cash flow hedges reclassified to net income    
Before Tax Amount 115  
Tax (29)  
Net of Tax Amount $ 86 $ 0
XML 88 R69.htm IDEA: XBRL DOCUMENT v3.25.1
Accumulated Other Comprehensive Income - Reclassifications from ACOI (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Interest expense $ (25,548) $ (111)
Gains/(losses) on hedges before income taxes (53,896) (65,416)
Income tax expense (13,254) (15,137)
Gains on hedges (38,911) $ (48,956)
Reclassification out of Accumulated Other Comprehensive Income    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Income tax expense (29)  
Gains on hedges 86  
Reclassification out of Accumulated Other Comprehensive Income | Net Cash Flow Hedge Adjustments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Gains/(losses) on hedges before income taxes 115  
Swap contracts | Reclassification out of Accumulated Other Comprehensive Income | Net Cash Flow Hedge Adjustments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Interest expense 115  
Collar contracts | Reclassification out of Accumulated Other Comprehensive Income | Net Cash Flow Hedge Adjustments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Interest expense $ 0  
XML 89 R70.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent Events (Details)
$ / shares in Units, $ in Millions
 3 Months Ended
May 06, 2025
$ / shares
Apr. 18, 2025
USD ($)
hospital
state
clinic
Mar. 01, 2025
state
hospital
Mar. 31, 2025
clinic
health_center
$ / shares
Subsequent Event [Line Items]        
Number of occupational health centers operated by entity     775 627
Number of states in which entity operates | state     42  
Number of onsite health clinics | clinic       160
Cash dividend declared (in dollars per share) | $ / shares       $ 0.0625
Subsequent Event        
Subsequent Event [Line Items]        
Number of onsite health clinics | clinic   350    
Cash dividend declared (in dollars per share) | $ / shares $ 0.0625      
Subsequent Event | Onsite Innovations        
Subsequent Event [Line Items]        
Number of occupational health centers operated by entity | hospital   200    
Number of states in which entity operates | state   40    
Subsequent Event | Onsite Innovations Acquisition        
Subsequent Event [Line Items]        
Business combination, expected price of acquisition | $   $ 55    
EXCEL 90 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 92 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 157 271 1 true 52 0 false 12 false false R1.htm 0000001 - Document - Cover Sheet http://www.concentra.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnauditedParenthetical Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) Statements 7 false false R8.htm 9952157 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited Condensed Consolidated Statements of Changes in Equity (Unaudited) Statements 8 false false R9.htm 9952158 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnauditedParenthetical Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) Statements 9 false false R10.htm 9952159 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 10 false false R11.htm 9952160 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Statements 11 false false R12.htm 9952161 - Disclosure - Organization Sheet http://www.concentra.com/role/Organization Organization Notes 12 false false R13.htm 9952162 - Disclosure - Accounting Policies Sheet http://www.concentra.com/role/AccountingPolicies Accounting Policies Notes 13 false false R14.htm 9952163 - Disclosure - Redeemable Non-Controlling Interests Sheet http://www.concentra.com/role/RedeemableNonControllingInterests Redeemable Non-Controlling Interests Notes 14 false false R15.htm 9952164 - Disclosure - Variable Interest Entities Sheet http://www.concentra.com/role/VariableInterestEntities Variable Interest Entities Notes 15 false false R16.htm 9952165 - Disclosure - Leases Sheet http://www.concentra.com/role/Leases Leases Notes 16 false false R17.htm 9952166 - Disclosure - Long-Term Debt Sheet http://www.concentra.com/role/LongTermDebt Long-Term Debt Notes 17 false false R18.htm 9952167 - Disclosure - Accrued and Other Liabilities Sheet http://www.concentra.com/role/AccruedandOtherLiabilities Accrued and Other Liabilities Notes 18 false false R19.htm 9952168 - Disclosure - Fair Value of Financial Instruments Sheet http://www.concentra.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 19 false false R20.htm 9952169 - Disclosure - Revenue Sheet http://www.concentra.com/role/Revenue Revenue Notes 20 false false R21.htm 9952170 - Disclosure - Earnings per Share Sheet http://www.concentra.com/role/EarningsperShare Earnings per Share Notes 21 false false R22.htm 9952171 - Disclosure - Relationship with Select Sheet http://www.concentra.com/role/RelationshipwithSelect Relationship with Select Notes 22 false false R23.htm 9952172 - Disclosure - Commitments and Contingencies Sheet http://www.concentra.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 9952173 - Disclosure - Segment Information Sheet http://www.concentra.com/role/SegmentInformation Segment Information Notes 24 false false R25.htm 9952174 - Disclosure - Acquisitions Sheet http://www.concentra.com/role/Acquisitions Acquisitions Notes 25 false false R26.htm 9952175 - Disclosure - Derivatives Sheet http://www.concentra.com/role/Derivatives Derivatives Notes 26 false false R27.htm 9952176 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.concentra.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 27 false false R28.htm 9952177 - Disclosure - Subsequent Events Sheet http://www.concentra.com/role/SubsequentEvents Subsequent Events Notes 28 false false R29.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 29 false false R30.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 30 false false R31.htm 9955511 - Disclosure - Accounting Policies (Policies) Sheet http://www.concentra.com/role/AccountingPoliciesPolicies Accounting Policies (Policies) Policies http://www.concentra.com/role/AccountingPolicies 31 false false R32.htm 9955512 - Disclosure - Redeemable Non-Controlling Interests (Tables) Sheet http://www.concentra.com/role/RedeemableNonControllingInterestsTables Redeemable Non-Controlling Interests (Tables) Tables http://www.concentra.com/role/RedeemableNonControllingInterests 32 false false R33.htm 9955513 - Disclosure - Leases (Tables) Sheet http://www.concentra.com/role/LeasesTables Leases (Tables) Tables http://www.concentra.com/role/Leases 33 false false R34.htm 9955514 - Disclosure - Long-Term Debt (Tables) Sheet http://www.concentra.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.concentra.com/role/LongTermDebt 34 false false R35.htm 9955515 - Disclosure - Accrued and Other Liabilities (Tables) Sheet http://www.concentra.com/role/AccruedandOtherLiabilitiesTables Accrued and Other Liabilities (Tables) Tables http://www.concentra.com/role/AccruedandOtherLiabilities 35 false false R36.htm 9955516 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.concentra.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.concentra.com/role/FairValueofFinancialInstruments 36 false false R37.htm 9955517 - Disclosure - Revenue (Tables) Sheet http://www.concentra.com/role/RevenueTables Revenue (Tables) Tables http://www.concentra.com/role/Revenue 37 false false R38.htm 9955518 - Disclosure - Earnings per Share (Tables) Sheet http://www.concentra.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.concentra.com/role/EarningsperShare 38 false false R39.htm 9955519 - Disclosure - Segment Information (Tables) Sheet http://www.concentra.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.concentra.com/role/SegmentInformation 39 false false R40.htm 9955520 - Disclosure - Acquisitions (Tables) Sheet http://www.concentra.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.concentra.com/role/Acquisitions 40 false false R41.htm 9955521 - Disclosure - Derivatives Instruments (Tables) Sheet http://www.concentra.com/role/DerivativesInstrumentsTables Derivatives Instruments (Tables) Tables 41 false false R42.htm 9955522 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeTables Accumulated Other Comprehensive Income (Tables) Tables http://www.concentra.com/role/AccumulatedOtherComprehensiveIncome 42 false false R43.htm 9955523 - Disclosure - Organization (Details) Sheet http://www.concentra.com/role/OrganizationDetails Organization (Details) Details http://www.concentra.com/role/Organization 43 false false R44.htm 9955524 - Disclosure - Accounting Policies (Details) Sheet http://www.concentra.com/role/AccountingPoliciesDetails Accounting Policies (Details) Details http://www.concentra.com/role/AccountingPoliciesPolicies 44 false false R45.htm 9955525 - Disclosure - Redeemable Non-Controlling Interests - Narrative (Details) Sheet http://www.concentra.com/role/RedeemableNonControllingInterestsNarrativeDetails Redeemable Non-Controlling Interests - Narrative (Details) Details 45 false false R46.htm 9955526 - Disclosure - Redeemable Non-Controlling Interests - Schedule of Redeemable Non-Controlling Interests (Details) Sheet http://www.concentra.com/role/RedeemableNonControllingInterestsScheduleofRedeemableNonControllingInterestsDetails Redeemable Non-Controlling Interests - Schedule of Redeemable Non-Controlling Interests (Details) Details 46 false false R47.htm 9955527 - Disclosure - Variable Interest Entities (Details) Sheet http://www.concentra.com/role/VariableInterestEntitiesDetails Variable Interest Entities (Details) Details http://www.concentra.com/role/VariableInterestEntities 47 false false R48.htm 9955528 - Disclosure - Leases (Details) Sheet http://www.concentra.com/role/LeasesDetails Leases (Details) Details http://www.concentra.com/role/LeasesTables 48 false false R49.htm 9955529 - Disclosure - Long-Term Debt - Components of Long-Term Debt And Notes Payable (Details) Notes http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails Long-Term Debt - Components of Long-Term Debt And Notes Payable (Details) Details 49 false false R50.htm 9955530 - Disclosure - Long-Term Debt - Principal Maturities Of Long-Term Debt (Details) Sheet http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails Long-Term Debt - Principal Maturities Of Long-Term Debt (Details) Details 50 false false R51.htm 9955531 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://www.concentra.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 51 false false R52.htm 9955532 - Disclosure - Accrued and Other Liabilities (Details) Sheet http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails Accrued and Other Liabilities (Details) Details http://www.concentra.com/role/AccruedandOtherLiabilitiesTables 52 false false R53.htm 9955533 - Disclosure - Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details) Sheet http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details) Details 53 false false R54.htm 9955534 - Disclosure - Revenue (Details) Sheet http://www.concentra.com/role/RevenueDetails Revenue (Details) Details http://www.concentra.com/role/RevenueTables 54 false false R55.htm 9955535 - Disclosure - Earnings per Share - Net Income Attributable to the Company, Units Outstanding, and Participating Units Outstanding (Details) Sheet http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails Earnings per Share - Net Income Attributable to the Company, Units Outstanding, and Participating Units Outstanding (Details) Details 55 false false R56.htm 9955536 - Disclosure - Earnings per Share - Computation of EPS Under the Two-Class Method (Details) Sheet http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails Earnings per Share - Computation of EPS Under the Two-Class Method (Details) Details 56 false false R57.htm 9955537 - Disclosure - Relationship with Select (Details) Sheet http://www.concentra.com/role/RelationshipwithSelectDetails Relationship with Select (Details) Details http://www.concentra.com/role/RelationshipwithSelect 57 false false R58.htm 9955538 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.concentra.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.concentra.com/role/CommitmentsandContingencies 58 false false R59.htm 9955539 - Disclosure - Segment Information - Narrative (Details) Sheet http://www.concentra.com/role/SegmentInformationNarrativeDetails Segment Information - Narrative (Details) Details 59 false false R60.htm 9955540 - Disclosure - Segment Information - Selected Financial Data (Details) Sheet http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails Segment Information - Selected Financial Data (Details) Details 60 false false R61.htm 9955541 - Disclosure - Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) Sheet http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) Details 61 false false R62.htm 9955542 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.concentra.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 62 false false R63.htm 9955543 - Disclosure - Acquisitions - Nova Purchase Price (Details) Sheet http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails Acquisitions - Nova Purchase Price (Details) Details 63 false false R64.htm 9955544 - Disclosure - Acquisitions - Pro Forma Information (Details) Sheet http://www.concentra.com/role/AcquisitionsProFormaInformationDetails Acquisitions - Pro Forma Information (Details) Details 64 false false R65.htm 9955545 - Disclosure - Derivatives Instruments - Schedule of Derivatives (Details) Sheet http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails Derivatives Instruments - Schedule of Derivatives (Details) Details 65 false false R66.htm 9955546 - Disclosure - Derivatives Instruments - Derivative Impact on Statements of Income and Comprehensive Income (Details) Sheet http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails Derivatives Instruments - Derivative Impact on Statements of Income and Comprehensive Income (Details) Details 66 false false R67.htm 9955547 - Disclosure - Accumulated Other Comprehensive Income - AOCI Rollforward (Details) Sheet http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails Accumulated Other Comprehensive Income - AOCI Rollforward (Details) Details 67 false false R68.htm 9955548 - Disclosure - Accumulated Other Comprehensive Income - AOCI Tax Benefit/Expense (Details) Sheet http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails Accumulated Other Comprehensive Income - AOCI Tax Benefit/Expense (Details) Details 68 false false R69.htm 9955549 - Disclosure - Accumulated Other Comprehensive Income - Reclassifications from ACOI (Details) Sheet http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails Accumulated Other Comprehensive Income - Reclassifications from ACOI (Details) Details 69 false false R70.htm 9955550 - Disclosure - Subsequent Events (Details) Sheet http://www.concentra.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.concentra.com/role/SubsequentEvents 70 false false All Reports Book All Reports cghp-20250331.htm cghp-20250331.xsd cghp-20250331_cal.xml cghp-20250331_def.xml cghp-20250331_lab.xml cghp-20250331_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 96 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cghp-20250331.htm": { "nsprefix": "cghp", "nsuri": "http://www.concentra.com/20250331", "dts": { "inline": { "local": [ "cghp-20250331.htm" ] }, "schema": { "local": [ "cghp-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "cghp-20250331_cal.xml" ] }, "definitionLink": { "local": [ "cghp-20250331_def.xml" ] }, "labelLink": { "local": [ "cghp-20250331_lab.xml" ] }, "presentationLink": { "local": [ "cghp-20250331_pre.xml" ] } }, "keyStandard": 245, "keyCustom": 26, "axisStandard": 19, "axisCustom": 0, "memberStandard": 29, "memberCustom": 21, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 157, "entityCount": 1, "segmentCount": 52, "elementCount": 541, "unitCount": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 578, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.concentra.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R5": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical", "longName": "9952154 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ContractuallySpecifiedServicingFeesAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "longName": "9952155 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R7": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnauditedParenthetical", "longName": "9952156 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "longName": "9952157 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:CommonUnitOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:CommonUnitOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnauditedParenthetical", "longName": "9952158 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "9952159 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R11": { "role": "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "longName": "9952160 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "11", "firstAnchor": { "contextRef": "c-54", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": null }, "R12": { "role": "http://www.concentra.com/role/Organization", "longName": "9952161 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.concentra.com/role/AccountingPolicies", "longName": "9952162 - Disclosure - Accounting Policies", "shortName": "Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.concentra.com/role/RedeemableNonControllingInterests", "longName": "9952163 - Disclosure - Redeemable Non-Controlling Interests", "shortName": "Redeemable Non-Controlling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.concentra.com/role/VariableInterestEntities", "longName": "9952164 - Disclosure - Variable Interest Entities", "shortName": "Variable Interest Entities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.concentra.com/role/Leases", "longName": "9952165 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.concentra.com/role/LongTermDebt", "longName": "9952166 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.concentra.com/role/AccruedandOtherLiabilities", "longName": "9952167 - Disclosure - Accrued and Other Liabilities", "shortName": "Accrued and Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.concentra.com/role/FairValueofFinancialInstruments", "longName": "9952168 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.concentra.com/role/Revenue", "longName": "9952169 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.concentra.com/role/EarningsperShare", "longName": "9952170 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.concentra.com/role/RelationshipwithSelect", "longName": "9952171 - Disclosure - Relationship with Select", "shortName": "Relationship with Select", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.concentra.com/role/CommitmentsandContingencies", "longName": "9952172 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.concentra.com/role/SegmentInformation", "longName": "9952173 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.concentra.com/role/Acquisitions", "longName": "9952174 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.concentra.com/role/Derivatives", "longName": "9952175 - Disclosure - Derivatives", "shortName": "Derivatives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncome", "longName": "9952176 - Disclosure - Accumulated Other Comprehensive Income", "shortName": "Accumulated Other Comprehensive Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.concentra.com/role/SubsequentEvents", "longName": "9952177 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.concentra.com/role/AccountingPoliciesPolicies", "longName": "9955511 - Disclosure - Accounting Policies (Policies)", "shortName": "Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.concentra.com/role/RedeemableNonControllingInterestsTables", "longName": "9955512 - Disclosure - Redeemable Non-Controlling Interests (Tables)", "shortName": "Redeemable Non-Controlling Interests (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.concentra.com/role/LeasesTables", "longName": "9955513 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.concentra.com/role/LongTermDebtTables", "longName": "9955514 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.concentra.com/role/AccruedandOtherLiabilitiesTables", "longName": "9955515 - Disclosure - Accrued and Other Liabilities (Tables)", "shortName": "Accrued and Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.concentra.com/role/FairValueofFinancialInstrumentsTables", "longName": "9955516 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.concentra.com/role/RevenueTables", "longName": "9955517 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.concentra.com/role/EarningsperShareTables", "longName": "9955518 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.concentra.com/role/SegmentInformationTables", "longName": "9955519 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.concentra.com/role/AcquisitionsTables", "longName": "9955520 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.concentra.com/role/DerivativesInstrumentsTables", "longName": "9955521 - Disclosure - Derivatives Instruments (Tables)", "shortName": "Derivatives Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeTables", "longName": "9955522 - Disclosure - Accumulated Other Comprehensive Income (Tables)", "shortName": "Accumulated Other Comprehensive Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.concentra.com/role/OrganizationDetails", "longName": "9955523 - Disclosure - Organization (Details)", "shortName": "Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-138", "name": "cghp:NumberOfOccupationalHealthCentersOperatedByEntity", "unitRef": "hospital", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "unitRef": "state", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R44": { "role": "http://www.concentra.com/role/AccountingPoliciesDetails", "longName": "9955524 - Disclosure - Accounting Policies (Details)", "shortName": "Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R45": { "role": "http://www.concentra.com/role/RedeemableNonControllingInterestsNarrativeDetails", "longName": "9955525 - Disclosure - Redeemable Non-Controlling Interests - Narrative (Details)", "shortName": "Redeemable Non-Controlling Interests - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "cghp:NumberOfLessThanWhollyOwnedSubsidiaries", "unitRef": "less_than_wholly_owned_subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "cghp:NumberOfLessThanWhollyOwnedSubsidiaries", "unitRef": "less_than_wholly_owned_subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.concentra.com/role/RedeemableNonControllingInterestsScheduleofRedeemableNonControllingInterestsDetails", "longName": "9955526 - Disclosure - Redeemable Non-Controlling Interests - Schedule of Redeemable Non-Controlling Interests (Details)", "shortName": "Redeemable Non-Controlling Interests - Schedule of Redeemable Non-Controlling Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R47": { "role": "http://www.concentra.com/role/VariableInterestEntitiesDetails", "longName": "9955527 - Disclosure - Variable Interest Entities (Details)", "shortName": "Variable Interest Entities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R48": { "role": "http://www.concentra.com/role/LeasesDetails", "longName": "9955528 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "us-gaap:LeaseCostTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "us-gaap:LeaseCostTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "longName": "9955529 - Disclosure - Long-Term Debt - Components of Long-Term Debt And Notes Payable (Details)", "shortName": "Long-Term Debt - Components of Long-Term Debt And Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "cghp:LongTermDebtGrossAndFinanceLeaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R50": { "role": "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails", "longName": "9955530 - Disclosure - Long-Term Debt - Principal Maturities Of Long-Term Debt (Details)", "shortName": "Long-Term Debt - Principal Maturities Of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "cghp:LongTermDebtAndFinanceLeaseObligationRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "cghp:LongTermDebtAndFinanceLeaseObligationRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "longName": "9955531 - Disclosure - Long-Term Debt - Narrative (Details)", "shortName": "Long-Term Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-61", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails", "longName": "9955532 - Disclosure - Accrued and Other Liabilities (Details)", "shortName": "Accrued and Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "cghp:AccruedSalariesAccruedBonusesAndAccruedPayrollTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "cghp:AccruedSalariesAccruedBonusesAndAccruedPayrollTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "longName": "9955533 - Disclosure - Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-98", "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-98", "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.concentra.com/role/RevenueDetails", "longName": "9955534 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R55": { "role": "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails", "longName": "9955535 - Disclosure - Earnings per Share - Net Income Attributable to the Company, Units Outstanding, and Participating Units Outstanding (Details)", "shortName": "Earnings per Share - Net Income Attributable to the Company, Units Outstanding, and Participating Units Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "longName": "9955536 - Disclosure - Earnings per Share - Computation of EPS Under the Two-Class Method (Details)", "shortName": "Earnings per Share - Computation of EPS Under the Two-Class Method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R57": { "role": "http://www.concentra.com/role/RelationshipwithSelectDetails", "longName": "9955537 - Disclosure - Relationship with Select (Details)", "shortName": "Relationship with Select (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ContractuallySpecifiedServicingFeesAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://www.concentra.com/role/CommitmentsandContingenciesDetails", "longName": "9955538 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-129", "name": "cghp:LossContingencyNumberOfPatients", "unitRef": "patient", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-129", "name": "cghp:LossContingencyNumberOfPatients", "unitRef": "patient", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.concentra.com/role/SegmentInformationNarrativeDetails", "longName": "9955539 - Disclosure - Segment Information - Narrative (Details)", "shortName": "Segment Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails", "longName": "9955540 - Disclosure - Segment Information - Selected Financial Data (Details)", "shortName": "Segment Information - Selected Financial Data (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R61": { "role": "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "longName": "9955541 - Disclosure - Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details)", "shortName": "Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-131", "name": "us-gaap:InterestExpenseNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R62": { "role": "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "longName": "9955542 - Disclosure - Acquisitions - Narrative (Details)", "shortName": "Acquisitions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-138", "name": "cghp:NumberOfOccupationalHealthCentersOperatedByEntity", "unitRef": "hospital", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "cghp:NumberOfOccupationalHealthCentersOperatedByEntity", "unitRef": "hospital", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R63": { "role": "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails", "longName": "9955543 - Disclosure - Acquisitions - Nova Purchase Price (Details)", "shortName": "Acquisitions - Nova Purchase Price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-140", "name": "cghp:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R64": { "role": "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails", "longName": "9955544 - Disclosure - Acquisitions - Pro Forma Information (Details)", "shortName": "Acquisitions - Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-142", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-142", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails", "longName": "9955545 - Disclosure - Derivatives Instruments - Schedule of Derivatives (Details)", "shortName": "Derivatives Instruments - Schedule of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-144", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R66": { "role": "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails", "longName": "9955546 - Disclosure - Derivatives Instruments - Derivative Impact on Statements of Income and Comprehensive Income (Details)", "shortName": "Derivatives Instruments - Derivative Impact on Statements of Income and Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails", "longName": "9955547 - Disclosure - Accumulated Other Comprehensive Income - AOCI Rollforward (Details)", "shortName": "Accumulated Other Comprehensive Income - AOCI Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-146", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R68": { "role": "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails", "longName": "9955548 - Disclosure - Accumulated Other Comprehensive Income - AOCI Tax Benefit/Expense (Details)", "shortName": "Accumulated Other Comprehensive Income - AOCI Tax Benefit/Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "longName": "9955549 - Disclosure - Accumulated Other Comprehensive Income - Reclassifications from ACOI (Details)", "shortName": "Accumulated Other Comprehensive Income - Reclassifications from ACOI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } }, "R70": { "role": "http://www.concentra.com/role/SubsequentEventsDetails", "longName": "9955550 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-138", "name": "cghp:NumberOfOccupationalHealthCentersOperatedByEntity", "unitRef": "hospital", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-156", "name": "cghp:NumberOfOnsiteHealthClinicsOperatedByEntity", "unitRef": "clinic", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cghp-20250331.htm", "unique": true } } }, "tag": { "cghp_A6.875SeniorNotesDueJuly152032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "A6.875SeniorNotesDueJuly152032Member", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.875% senior notes", "label": "6.875% Senior Notes Due July 15, 2032 [Member]", "documentation": "6.875% Senior Notes Due July 15, 2032" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and Other Liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r418" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails", "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other liabilities", "totalLabel": "Accrued and other liabilities", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r91", "r704" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r840" ] }, "cghp_AccruedSalariesAccruedBonusesAndAccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "AccruedSalariesAccruedBonusesAndAccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll", "label": "Accrued Salaries, Accrued Bonuses, And Accrued Payroll Taxes, Current", "documentation": "Accrued Salaries, Accrued Bonuses, And Accrued Payroll Taxes, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedVacationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedVacationCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued vacation", "label": "Accrued Vacation, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r46", "r94" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Cash Flow Hedge Adjustments", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r187", "r195", "r196", "r444", "r660", "r816" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r194", "r195", "r480", "r482", "r483", "r484", "r485", "r486" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r17", "r18", "r110", "r181", "r536", "r573", "r574" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r194", "r195", "r480", "r482", "r483", "r484", "r485", "r486" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r12", "r18", "r452", "r455", "r501", "r569", "r570", "r816", "r817", "r818", "r829", "r830", "r831", "r832" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r758" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r104" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r588", "r829", "r830", "r831", "r832", "r868", "r931" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r771" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r771" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r771" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r771" ] }, "cghp_AdjustedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "AdjustedEbitda", "crdr": "credit", "calculation": { "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 7.0 }, "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Segment Adjusted EBITDA", "terseLabel": "Segment Adjusted EBITDA", "label": "Adjusted EBITDA", "documentation": "Measure of profit (loss) for reportable segments" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r47", "r48", "r388" ] }, "cghp_AdjustmentsToMembersContributedCapitalDistributionsToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "AdjustmentsToMembersContributedCapitalDistributionsToParent", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distribution to Parent", "negatedLabel": "Distribution to Parent", "label": "Adjustments To Member's Contributed Capital, Distributions To Parent", "documentation": "Adjustments To Member's Contributed Capital, Distributions To Parent" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r804" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r730", "r740", "r750", "r782" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r733", "r743", "r753", "r785" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r805" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r771" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r778" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r734", "r744", "r754", "r778", "r786", "r790", "r798" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r796" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r415", "r416" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount and issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r354", "r680", "r681", "r822", "r888" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails", "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "verboseLabel": "Assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r144", "r157", "r177", "r212", "r249", "r256", "r274", "r278", "r286", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r440", "r445", "r479", "r530", "r612", "r669", "r670", "r704", "r721", "r859", "r860", "r892" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r172", "r183", "r212", "r286", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r440", "r445", "r479", "r704", "r859", "r860", "r892" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r793" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r789" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r789" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r789" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r789" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r789" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r789" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r792" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r791" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r790" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r790" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r312", "r896", "r897" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r74", "r77", "r312", "r896", "r897" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Consolidation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails", "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r435", "r693", "r694" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails", "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r50", "r53", "r299", "r300", "r301", "r302", "r303", "r435", "r693", "r694" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.concentra.com/role/AcquisitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of pro forma unaudited results of operations", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r811", "r812" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to the Company", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r433", "r434" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r433", "r434" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Nova acquisition costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r49" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r11" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/Acquisitions" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r135", "r436" ] }, "us-gaap_BusinessCombinationPriceOfAcquisitionExpected": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationPriceOfAcquisitionExpected", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, expected price of acquisition", "label": "Business Combination, Price of Acquisition, Expected", "documentation": "Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition." } } }, "auth_ref": [ "r810" ] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income from acquiree", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r52" ] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenues of acquiree", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r52" ] }, "cghp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Including Goodwill", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Including Goodwill" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails": { "parentTag": "cghp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r54" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r54" ] }, "cghp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets", "crdr": "debit", "calculation": { "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails": { "parentTag": "cghp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identifiable tangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Tangible Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Tangible Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails", "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]", "label": "Business Combination, Separately Recognized Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails", "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Separately Recognized Transactions [Table]", "label": "Business Combination, Separately Recognized Transactions [Table]", "documentation": "Disclosure of information about transaction recognized separately from acquisition of asset and assumption of liability in business combination." } } }, "auth_ref": [ "r51" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r22", "r174", "r657" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r22", "r122", "r209" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r122" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r769" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r766" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r764" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r178", "r179", "r180", "r251", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r578", "r579", "r580", "r581", "r682", "r809", "r823" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r770" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r770" ] }, "cghp_CollarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "CollarMember", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails", "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collar contracts", "label": "Collar [Member]", "documentation": "Collar" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 12)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r100", "r147", "r534", "r599" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r127", "r315", "r316", "r654", "r846", "r850" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnauditedParenthetical", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividend declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r134" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r711", "r712", "r713", "r715", "r716", "r717", "r718", "r829", "r830", "r832", "r868", "r928", "r931" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r103" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r103", "r600" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r103" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r103", "r600", "r618", "r931", "r932" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value, 700,000,000 shares authorized, 128,171,952 and 128,125,952 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r103", "r535", "r704" ] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonUnitOutstanding", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Members' unit, beginning balance (in shares)", "periodEndLabel": "Members' unit, ending balance (in shares)", "label": "Common Unit, Outstanding", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r775" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r774" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r776" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r773" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to the Company", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r19", "r191", "r193", "r200", "r527", "r546", "r548" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Less: comprehensive income attributable to non-controlling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r58", "r69", "r191", "r193", "r199", "r526", "r546", "r547" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r69", "r138", "r191", "r193", "r198", "r525", "r546" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r109", "r197", "r524", "r545" ] }, "cghp_ConcentraCreditFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "ConcentraCreditFacilitiesMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentra Credit Facilities", "label": "Concentra Credit Facilities [Member]", "documentation": "Concentra Credit Facilities" } } }, "auth_ref": [] }, "cghp_ConcentraGroupHoldingsParentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "ConcentraGroupHoldingsParentMember", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentra Group Holdings Parent", "label": "Concentra Group Holdings Parent [Member]", "documentation": "" } } }, "auth_ref": [] }, "cghp_ConcentraRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "ConcentraRevolvingCreditFacilityMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentra Revolving Credit Facility", "label": "Concentra Revolving Credit Facility [Member]", "documentation": "Concentra Revolving Credit Facility" } } }, "auth_ref": [] }, "cghp_ConcentraTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "ConcentraTermLoanMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentra Term Loan", "label": "Concentra Term Loan [Member]", "documentation": "Concentra Term Loan" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r216", "r440", "r441", "r445", "r446", "r510", "r655", "r858", "r861", "r862" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r216", "r440", "r441", "r445", "r446", "r510", "r655", "r858", "r861", "r862" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r59", "r661" ] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Non-Controlling Interests", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r160" ] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": [ "r55", "r62", "r64" ] }, "us-gaap_ContractuallySpecifiedServicingFeesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractuallySpecifiedServicingFeesAmount", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical", "http://www.concentra.com/role/RelationshipwithSelectDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shared service fee from related party", "label": "Contractually Specified Servicing Fees, Amount", "documentation": "All amounts that, per contract, are due to the servicer in exchange for servicing the financial asset and would no longer be received by a servicer if the beneficial owners of the serviced assets (or their trustees or agents) were to exercise their actual or potential authority under the contract to shift the servicing to another servicer. Depending on the servicing contract, those fees may include some or all of the difference between the interest rate collected on the asset being serviced and the rate to be paid to the beneficial owners of the asset." } } }, "auth_ref": [ "r520" ] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services, exclusive of depreciation and amortization", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": [ "r814", "r815" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails": { "parentTag": "cghp_AdjustedEbitda", "weight": -1.0, "order": 1.0 }, "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r117" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r322", "r856" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r322", "r856", "r857" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/LongTermDebt" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-Term Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r128", "r211", "r307", "r308", "r309", "r310", "r311", "r321", "r322", "r332", "r338", "r339", "r340", "r341", "r342", "r343", "r348", "r355", "r356", "r358", "r488" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r16", "r93", "r94", "r145", "r146", "r216", "r333", "r334", "r335", "r336", "r337", "r339", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r677", "r678", "r679", "r680", "r681", "r702", "r824", "r847", "r848", "r849", "r887", "r889" ] }, "cghp_DebtInstrumentBasisPointStepDown": { "xbrltype": "pureItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "DebtInstrumentBasisPointStepDown", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Basis Point Step Down", "label": "Debt Instrument, Basis Point Step Down", "documentation": "Debt Instrument, Basis Point Step Down" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit spread adjustment", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 }, "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Outstanding", "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r16", "r146", "r359" ] }, "cghp_DebtInstrumentCovenantLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "DebtInstrumentCovenantLeverageRatio", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, leverage ratio", "label": "Debt Instrument, Covenant, Leverage Ratio", "documentation": "Debt Instrument, Covenant, Leverage Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal outstanding", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r333", "r488", "r489", "r678", "r679", "r702" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate of debt (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r96", "r334" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r333", "r334", "r335", "r336", "r337", "r339", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r357", "r677", "r678", "r679", "r680", "r681", "r702", "r824", "r887", "r889" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r16", "r216", "r333", "r334", "r335", "r336", "r337", "r339", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r677", "r678", "r679", "r680", "r681", "r702", "r824", "r847", "r848", "r849", "r887", "r889" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r16", "r41", "r44", "r89", "r132", "r133", "r216", "r333", "r334", "r335", "r336", "r337", "r339", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r357", "r677", "r678", "r679", "r680", "r681", "r702", "r824", "r887", "r889" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails": { "parentTag": "cghp_LongTermDebtAndFinanceLeaseObligation", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized Premium (Discount)", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r863", "r886", "r887", "r889" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails": { "parentTag": "cghp_LongTermDebtAndFinanceLeaseObligation", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized Issuance Costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r863", "r886", "r887", "r889" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r419", "r420", "r531" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r124" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r33" ] }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total collar contracts", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments." } } }, "auth_ref": [ "r9", "r871", "r872", "r873" ] }, "us-gaap_DerivativeCapInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCapInterestRate", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cap", "label": "Derivative, Cap Interest Rate", "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails", "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r590", "r591", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r614", "r615", "r616", "r630", "r631", "r632", "r633", "r636", "r637", "r638", "r639", "r648", "r649", "r650", "r652", "r711", "r713", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeFloorInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFloorInterestRate", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floor", "label": "Derivative, Floor Interest Rate", "documentation": "Floor rate on an interest rate derivative such as an interest rate floor or collar. If market rates falls below the floor rate, a payment or receipt is triggered on the contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains/(losses) related to derivatives designated as hedging instruments:", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r867" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails", "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r75", "r78", "r79", "r142", "r590", "r591", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r614", "r615", "r616", "r630", "r631", "r632", "r633", "r636", "r637", "r638", "r639", "r648", "r649", "r650", "r652", "r659", "r711", "r713", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/Derivatives" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r140", "r449", "r457" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails", "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r457" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r865", "r866" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails", "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r14", "r70", "r71", "r72", "r73", "r76", "r78", "r80", "r82", "r84", "r457" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, term of contract", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives and Hedging", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r14", "r70", "r71", "r73", "r81", "r215", "r230" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r379", "r683", "r684", "r685", "r686", "r687", "r688", "r689" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r379", "r683", "r684", "r685", "r686", "r687", "r688", "r689" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.concentra.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of disaggregation of revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r864" ] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends declared for common shareholders ($0.0625 per share)", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r5", "r134" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r94" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r725" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r757" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r768" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share (Note 10):", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic EPS (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r201", "r222", "r223", "r224", "r225", "r226", "r227", "r232", "r235", "r242", "r243", "r244", "r248", "r431", "r438", "r459", "r460", "r528", "r549", "r662" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic EPS", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted EPS (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r201", "r222", "r223", "r224", "r225", "r226", "r227", "r235", "r242", "r243", "r244", "r248", "r431", "r438", "r459", "r460", "r528", "r549", "r662" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted EPS", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.concentra.com/role/EarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r231", "r245", "r246", "r247" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r723" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r723" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r723" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r807" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r723" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r723" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r723" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r723" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r762" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r803" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r803" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r803" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r168", "r194", "r195", "r196", "r217", "r218", "r219", "r221", "r226", "r228", "r230", "r250", "r287", "r288", "r305", "r369", "r425", "r426", "r428", "r429", "r430", "r432", "r437", "r438", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r480", "r482", "r483", "r484", "r485", "r486", "r490", "r493", "r501", "r545", "r569", "r570", "r571", "r588", "r642" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r772" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r730", "r740", "r750", "r782" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r727", "r737", "r747", "r779" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r346", "r478", "r678", "r679" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r778" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value measurements", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r698", "r869", "r870", "r880" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r346", "r381", "r382", "r383", "r384", "r385", "r386", "r461", "r463", "r464", "r465", "r466", "r470", "r471", "r472", "r514", "r515", "r516", "r678", "r679", "r690", "r691", "r692", "r698", "r700" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r346", "r678", "r679" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r462", "r463", "r464", "r466", "r698", "r872", "r882" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r346", "r678", "r679" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r467", "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r476", "r522", "r698", "r701" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r346", "r381", "r386", "r463", "r464", "r471", "r515", "r678", "r679", "r690", "r691", "r692", "r698" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r462", "r463", "r464", "r466", "r698", "r872", "r882" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r346", "r381", "r382", "r383", "r384", "r385", "r386", "r461", "r463", "r464", "r465", "r466", "r470", "r471", "r472", "r514", "r515", "r516", "r678", "r679", "r690", "r691", "r692", "r698", "r700" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r698", "r869", "r870", "r871", "r872", "r873", "r882" ] }, "cghp_FinanceLeaseInterestExpenseNetOfBuyouts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "FinanceLeaseInterestExpenseNetOfBuyouts", "crdr": "debit", "calculation": { "http://www.concentra.com/role/LeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense, Net Of Buyouts", "documentation": "Finance Lease, Interest Expense, Net Of Buyouts" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.concentra.com/role/LeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r496", "r498", "r703" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r734", "r744", "r754", "r786" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r734", "r744", "r754", "r786" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r734", "r744", "r754", "r786" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r734", "r744", "r754", "r786" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r734", "r744", "r754", "r786" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r767" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss on sale of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r822" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on early retirement of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r8", "r35", "r36" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative, exclusive of depreciation and amortization", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r114", "r622" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails": { "parentTag": "cghp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 2.0 }, "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails", "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r175", "r289", "r523", "r670", "r675", "r699", "r704", "r843", "r844" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "negatedTerseLabel": "Gains/(losses) on hedges before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r111", "r151", "r156", "r529", "r541", "r664", "r669", "r834", "r836", "r837", "r838", "r839" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r159", "r166", "r229", "r230", "r249", "r264", "r278", "r421", "r422", "r427", "r550", "r695" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash (refund received) paid for taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r23", "r208", "r423", "r424" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of effects of business combinations:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r821" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r821" ] }, "us-gaap_IncreaseDecreaseInPartnersCapitalRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPartnersCapitalRollForward", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Partners' Capital [Roll Forward]", "label": "Increase (Decrease) in Partners' Capital [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://www.concentra.com/role/RedeemableNonControllingInterestsScheduleofRedeemableNonControllingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights", "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average participating shares outstanding (in shares)", "label": "Incremental Common Shares Attributable to Participating Nonvested Shares with Non-forfeitable Dividend Rights", "documentation": "This element represents nonvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid). Basic and dilutive earnings per share are generally disclosed for such shares using the two-class method." } } }, "auth_ref": [ "r24" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r734", "r744", "r754", "r778", "r786", "r790", "r798" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r796" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r726", "r802" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r726", "r802" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r726", "r802" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense on related party debt", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r116", "r352", "r361", "r680", "r681" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r260", "r820" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r203", "r206", "r207" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r94" ] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Personnel expenses", "label": "Labor and Related Expense", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r819" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.concentra.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r497", "r703" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": [ "http://www.concentra.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost [Abstract]", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.concentra.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of lease cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r890" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseDescriptionAbstract", "presentation": [ "http://www.concentra.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease cost:", "label": "Lessee, Finance Lease, Description [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.concentra.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r492" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.concentra.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r492" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r16", "r93", "r94", "r95", "r98", "r99", "r100", "r101", "r212", "r286", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r441", "r445", "r446", "r479", "r598", "r663", "r721", "r859", "r892", "r893" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r108", "r149", "r539", "r704", "r825", "r841", "r883" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r95", "r173", "r212", "r286", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r441", "r445", "r446", "r479", "r704", "r859", "r892", "r893" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding letters of credit", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r16", "r146", "r894" ] }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in revolving credit facility", "label": "Line of Credit Facility, Increase (Decrease), Net", "documentation": "Amount of increase (decrease) of the credit facility." } } }, "auth_ref": [ "r824" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r322", "r824", "r856" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r92", "r97" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r92", "r97", "r322" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r92", "r97", "r322", "r824", "r856" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carrying Value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r16", "r146", "r345", "r360", "r678", "r679", "r702", "r894" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current portion", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r16", "r532" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt and notes payable", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r94" ] }, "cghp_LongTermDebtAndFinanceLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligation", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carrying Value", "label": "Long-Term Debt And Finance Lease Obligation", "documentation": "Long-Term Debt And Finance Lease Obligation" } } }, "auth_ref": [] }, "cghp_LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalAfterYearFour", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "cghp_LongTermDebtGrossAndFinanceLeaseObligation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal After Year Four", "documentation": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal After Year Four" } } }, "auth_ref": [] }, "cghp_LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "cghp_LongTermDebtGrossAndFinanceLeaseObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Next Twelve Months", "documentation": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Next Twelve Months" } } }, "auth_ref": [] }, "cghp_LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "cghp_LongTermDebtGrossAndFinanceLeaseObligation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Four", "documentation": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Four" } } }, "auth_ref": [] }, "cghp_LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "cghp_LongTermDebtGrossAndFinanceLeaseObligation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Three", "documentation": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Three" } } }, "auth_ref": [] }, "cghp_LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "cghp_LongTermDebtGrossAndFinanceLeaseObligation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Two", "documentation": "Long-Term Debt And Finance Lease Obligation, Maturities, Repayments Of Principal In Year Two" } } }, "auth_ref": [] }, "cghp_LongTermDebtAndFinanceLeaseObligationRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtAndFinanceLeaseObligationRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "cghp_LongTermDebtGrossAndFinanceLeaseObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt And Finance Lease Obligation, Repayments Of Principal, Remainder Of Fiscal Year", "documentation": "Long-Term Debt And Finance Lease Obligation, Repayments Of Principal, Remainder Of Fiscal Year" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r869", "r871", "r872", "r873" ] }, "cghp_LongTermDebtGrossAndFinanceLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtGrossAndFinanceLeaseObligation", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails": { "parentTag": "cghp_LongTermDebtAndFinanceLeaseObligation", "weight": 1.0, "order": 1.0 }, "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Outstanding", "totalLabel": "Total", "label": "Long-Term Debt, Gross And Finance Lease Obligation", "documentation": "Long-Term Debt, Gross And Finance Lease Obligation" } } }, "auth_ref": [] }, "cghp_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-term Debt, Maturities, Repayments Of Principal After Year Four", "documentation": "Long-term Debt, Maturities, Repayments Of Principal After Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r216", "r350" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r216", "r350" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r216", "r350" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r216", "r350" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r16", "r847", "r848", "r849" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r16", "r34", "r847", "r848", "r849" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r417", "r676", "r851", "r852" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r417", "r676", "r851", "r852" ] }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNewClaimsFiledNumber", "calculation": { "http://www.concentra.com/role/CommitmentsandContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss contingency, new claims filed, number", "label": "Loss Contingency, New Claims Filed, Number", "documentation": "The total number of new claims filed pertaining to a loss contingency during the period." } } }, "auth_ref": [ "r851", "r852" ] }, "cghp_LossContingencyNumberOfClassActionLawsuitPending": { "xbrltype": "integerItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LossContingencyNumberOfClassActionLawsuitPending", "calculation": { "http://www.concentra.com/role/CommitmentsandContingenciesDetails": { "parentTag": "us-gaap_LossContingencyNewClaimsFiledNumber", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of class action lawsuit pending", "label": "Loss Contingency, Number of Class Action Lawsuit Pending", "documentation": "Loss Contingency, Number of Class Action Lawsuit Pending" } } }, "auth_ref": [] }, "cghp_LossContingencyNumberOfPatients": { "xbrltype": "integerItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LossContingencyNumberOfPatients", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, number of patients", "label": "Loss Contingency, Number Of Patients", "documentation": "Loss Contingency, Number Of Patients" } } }, "auth_ref": [] }, "cghp_LossContingencyNumberOfPutativeClassActionsClaimsTransferred": { "xbrltype": "integerItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "LossContingencyNumberOfPutativeClassActionsClaimsTransferred", "calculation": { "http://www.concentra.com/role/CommitmentsandContingenciesDetails": { "parentTag": "us-gaap_LossContingencyNewClaimsFiledNumber", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of putative class actions claims transferred", "label": "Loss Contingency, Number of Putative Class Actions Claims Transferred", "documentation": "Loss Contingency, Number of Putative Class Actions Claims Transferred" } } }, "auth_ref": [] }, "us-gaap_MalpracticeInsuranceAnnualCoverageLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MalpracticeInsuranceAnnualCoverageLimit", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total annual aggregate limit of insurance coverage", "label": "Malpractice Insurance, Annual Coverage Limit", "documentation": "Annual coverage limit provided by the insurance arrangement for malpractice claims." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r770" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r770" ] }, "us-gaap_MemberUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MemberUnitsMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Member Units", "label": "Member Units [Member]", "documentation": "Ownership interest in limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_MembersCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MembersCapital", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Members' unit, beginning balance", "periodEndLabel": "Members' unit, ending balance", "label": "Members' Capital", "documentation": "Amount of member capital in limited liability company (LLC)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r107", "r148", "r212", "r286", "r323", "r325", "r326", "r327", "r330", "r331", "r479", "r538", "r602" ] }, "us-gaap_MinorityInterestChangeInRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestChangeInRedemptionValue", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "http://www.concentra.com/role/RedeemableNonControllingInterestsScheduleofRedeemableNonControllingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption value adjustment on non-controlling interests", "negatedTerseLabel": "Redemption value adjustment on redeemable non-controlling interests", "label": "Noncontrolling Interest, Change in Redemption Value", "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest." } } }, "auth_ref": [ "r38", "r45", "r130", "r131" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributions to and purchases of non-controlling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r134" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/RedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Non-Controlling Interests", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r137" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r789" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r797" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r771" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r205" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r205" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r122", "r123", "r124" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to the Company", "terseLabel": "Net income attributable to the Company", "negatedLabel": "Gains on hedges", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r113", "r124", "r152", "r171", "r189", "r192", "r196", "r212", "r220", "r222", "r223", "r224", "r225", "r226", "r229", "r230", "r240", "r286", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r431", "r438", "r460", "r479", "r544", "r620", "r640", "r641", "r719", "r859" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: net income attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r68", "r139", "r189", "r192", "r226", "r229", "r230", "r543", "r818" ] }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net income attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest." } } }, "auth_ref": [ "r112" ] }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/RedeemableNonControllingInterestsScheduleofRedeemableNonControllingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to redeemable non-controlling interests", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest." } } }, "auth_ref": [ "r112" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Distributed and undistributed income attributable to common shares", "verboseLabel": "Net income allocated to common shares - basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r202", "r222", "r223", "r224", "r225", "r232", "r233", "r241", "r244", "r438" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Distributed and undistributed income attributable to common shares", "terseLabel": "Net income allocated to common shares - diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r202", "r234", "r236", "r237", "r238", "r239", "r241", "r244" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Guidance Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r770" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r734", "r744", "r754", "r778", "r786" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r761" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r760" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r778" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r797" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r797" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Abstract]", "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "cghp_NoncontrollingInterestDistributionstoRedeemableNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "NoncontrollingInterestDistributionstoRedeemableNoncontrollingInterests", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/RedeemableNonControllingInterestsScheduleofRedeemableNonControllingInterestsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to redeemable non-controlling interests", "label": "Noncontrolling Interest, Distributions to Redeemable Noncontrolling Interests", "documentation": "Noncontrolling Interest, Distributions to Redeemable Noncontrolling Interests" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r56", "r369", "r829", "r830", "r831", "r832", "r931" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income and expense:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r826", "r827" ] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other debt", "terseLabel": "Other debt, including finance leases", "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "cghp_NovaAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "NovaAcquisitionMember", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/AcquisitionsNovaPurchasePriceDetails", "http://www.concentra.com/role/AcquisitionsProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nova Acquisition", "label": "Nova Acquisition [Member]", "documentation": "Nova Acquisition" } } }, "auth_ref": [] }, "cghp_NovaMedicalCentersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "NovaMedicalCentersMember", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nova Medical Centers", "label": "Nova Medical Centers [Member]", "documentation": "Nova Medical Centers" } } }, "auth_ref": [] }, "cghp_NumberOfLessThanWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "NumberOfLessThanWhollyOwnedSubsidiaries", "presentation": [ "http://www.concentra.com/role/RedeemableNonControllingInterestsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of less than wholly owned subsidiaries", "label": "Number Of Less Than Wholly Owned Subsidiaries", "documentation": "Number Of Less Than Wholly Owned Subsidiaries" } } }, "auth_ref": [] }, "cghp_NumberOfOccupationalHealthCentersOperatedByEntity": { "xbrltype": "integerItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "NumberOfOccupationalHealthCentersOperatedByEntity", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/OrganizationDetails", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of occupational health centers operated by entity", "label": "Number of Occupational Health Centers Operated by Entity", "documentation": "Number of Occupational Health Centers Operated by Entity" } } }, "auth_ref": [] }, "cghp_NumberOfOnsiteHealthClinicsOperatedByEntity": { "xbrltype": "integerItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "NumberOfOnsiteHealthClinicsOperatedByEntity", "presentation": [ "http://www.concentra.com/role/OrganizationDetails", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of onsite health clinics", "label": "Number of Onsite Health Clinics Operated by Entity", "documentation": "Number of Onsite Health Clinics Operated by Entity" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.concentra.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r670", "r835" ] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails", "http://www.concentra.com/role/OrganizationDetails", "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states in which entity operates", "label": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OccupancyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OccupancyNet", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility expenses", "label": "Occupancy, Net", "documentation": "Amount of net occupancy expense that may include items, such as depreciation of facilities and equipment, lease expenses, property taxes and property and casualty insurance expense." } } }, "auth_ref": [ "r115", "r150", "r158" ] }, "cghp_OccupationalHealthCenterConsumerHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OccupationalHealthCenterConsumerHealthMember", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumer health", "label": "Occupational Health Center, Consumer Health [Member]", "documentation": "Occupational Health Center, Consumer Health" } } }, "auth_ref": [] }, "cghp_OccupationalHealthCenterEmployerServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OccupationalHealthCenterEmployerServicesMember", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer services", "label": "Occupational Health Center, Employer Services [Member]", "documentation": "Occupational Health Center, Employer Services" } } }, "auth_ref": [] }, "cghp_OccupationalHealthCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OccupationalHealthCenterMember", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total occupational health center revenue", "label": "Occupational Health Center [Member]", "documentation": "Occupational Health Center" } } }, "auth_ref": [] }, "cghp_OccupationalHealthCenterOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OccupationalHealthCenterOtherMember", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other occupational health center revenue", "label": "Occupational Health Center, Other [Member]", "documentation": "Occupational Health Center, Other" } } }, "auth_ref": [] }, "cghp_OccupationalHealthCenterWorkersCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OccupationalHealthCenterWorkersCompensationMember", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Workers\u2019 compensation", "label": "Occupational Health Center, Workers Compensation [Member]", "documentation": "Occupational Health Center, Workers Compensation" } } }, "auth_ref": [] }, "cghp_OccupationalHealthCentersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OccupationalHealthCentersMember", "presentation": [ "http://www.concentra.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Occupational Health Centers", "label": "Occupational Health Centers [Member]", "documentation": "Occupational Health Centers" } } }, "auth_ref": [] }, "cghp_OnsiteHealthClinicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OnsiteHealthClinicsMember", "presentation": [ "http://www.concentra.com/role/OrganizationDetails", "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Onsite health clinics", "label": "Onsite Health Clinics [Member]", "documentation": "Onsite Health Clinics" } } }, "auth_ref": [] }, "cghp_OnsiteInnovationsAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OnsiteInnovationsAcquisitionMember", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Onsite Innovations Acquisition", "label": "Onsite Innovations Acquisition [Member]", "documentation": "Onsite Innovations Acquisition" } } }, "auth_ref": [] }, "cghp_OnsiteInnovationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OnsiteInnovationsMember", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Onsite Innovations", "label": "Onsite Innovations [Member]", "documentation": "Onsite Innovations" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r156", "r664", "r834", "r836", "r837", "r838", "r839" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.concentra.com/role/LeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r499", "r703" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r495" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r495" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r494" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r90", "r137", "r575", "r576" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r94" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r182", "r704" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r176" ] }, "cghp_OtherBusinessesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "OtherBusinessesMember", "presentation": [ "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Businesses [Member]", "documentation": "Other Businesses" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred (losses)/gains on cash flow hedges", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r15", "r18", "r195", "r480", "r483", "r486", "r545", "r816" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r184", "r185", "r545" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging Instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax", "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r184", "r185", "r545" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnauditedParenthetical" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit on components of other comprehensive income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r186" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": 1.0, "order": 1.0 }, "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on derivatives", "totalLabel": "Net of Tax Amount", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r184", "r185" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Before Tax Amount", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r184", "r185", "r447", "r448", "r450" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "calculation": { "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r186" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": -1.0, "order": 2.0 }, "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustment for gains included in net income", "negatedTotalLabel": "Net of Tax Amount", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r185", "r188" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Before Tax Amount", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r165", "r185", "r188" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "calculation": { "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r186" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r13", "r15", "r190", "r193", "r197", "r226", "r480", "r481", "r486", "r524", "r545", "r816", "r817" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred (losses)/gains on cash flow hedges", "label": "Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCITaxBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred gains/(losses) on cash flow hedges reclassified to net income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r74", "r83" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current liability", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other identifiable intangible assets, net", "label": "Other Intangible Assets, Net", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obligations payable", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r94", "r704" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r99" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r124" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liability", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r770" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r732", "r742", "r752", "r784" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r735", "r745", "r755", "r787" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r735", "r745", "r755", "r787" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stockholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "crdr": "debit", "calculation": { "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Distributed and undistributed income attributable to participating shares - basic EPS", "verboseLabel": "Participating shares - basic", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic", "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r241", "r808" ] }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "crdr": "debit", "calculation": { "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Distributed and undistributed income attributable to participating shares - diluted EPS", "verboseLabel": "Participating shares - diluted", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted", "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r241" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r759" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDistributionsToAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDistributionsToAffiliates", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to Select", "label": "Payments of Distributions to Affiliates", "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership." } } }, "auth_ref": [ "r120" ] }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsMinorityInterest", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributions to and purchases of non-controlling interests", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests." } } }, "auth_ref": [ "r120" ] }, "cghp_PaymentsToAcquireBusinessesGrossAvailableBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "PaymentsToAcquireBusinessesGrossAvailableBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid to acquire business, available borrowing capacity", "label": "Payments To Acquire Businesses, Gross, Available Borrowing Capacity", "documentation": "Payments To Acquire Businesses, Gross, Available Borrowing Capacity" } } }, "auth_ref": [] }, "cghp_PaymentsToAcquireBusinessesGrossTermLoanAddOn": { "xbrltype": "monetaryItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "PaymentsToAcquireBusinessesGrossTermLoanAddOn", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid to acquire business, term loan add-on", "label": "Payments To Acquire Businesses, Gross, Term Loan Add-On", "documentation": "Payments To Acquire Businesses, Gross, Term Loan Add-On" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Business combinations, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r20" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r119" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r769" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r769" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r761" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r778" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r771" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r760" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r762" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r806" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r761" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r477" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r658", "r674", "r842" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from term loans, net of issuance costs", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings on revolving facilities and related party revolving promissory note", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r21", "r824" ] }, "us-gaap_ProceedsFromOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromOtherDebt", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings of other debt", "label": "Proceeds from Other Debt", "documentation": "Amount of cash inflow from debt classified as other." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of assets", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r118" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [ "http://www.concentra.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Information [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.concentra.com/role/OrganizationDetails", "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r281", "r521", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r656", "r683", "r705", "r706", "r707", "r709", "r710", "r853", "r854", "r864", "r895", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.concentra.com/role/OrganizationDetails", "http://www.concentra.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r281", "r521", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r656", "r683", "r705", "r706", "r707", "r709", "r710", "r853", "r854", "r864", "r895", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Separation transaction costs", "label": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r669", "r719", "r929", "r930" ] }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalMalpracticeLiabilityMember", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional liability claims", "label": "Professional Malpractice Liability Insurance [Member]", "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/EarningsperShareNetIncomeAttributabletotheCompanyUnitsOutstandingandParticipatingUnitsOutstandingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r171", "r189", "r192", "r204", "r212", "r220", "r226", "r229", "r230", "r286", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r431", "r438", "r439", "r442", "r443", "r460", "r479", "r529", "r542", "r587", "r620", "r640", "r641", "r696", "r697", "r720", "r818", "r859" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r813", "r845" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r759" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r759" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net deferred gains/(losses) on cash flow hedges reclassified to net income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r15", "r18", "r195", "r480", "r485", "r486", "r545", "r816" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r196" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r196" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r196" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of reclassification out of accumulated other comprehensive income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.concentra.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of reconciliation of Adjusted EBITDA to income before income taxes", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r31", "r32" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r727", "r737", "r747", "r779" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.concentra.com/role/RedeemableNonControllingInterestsScheduleofRedeemableNonControllingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable non-controlling interests", "periodStartLabel": "Balance, beginning", "periodEndLabel": "Balance, ending", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r37", "r38", "r130", "r131" ] }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestTableTextBlock", "presentation": [ "http://www.concentra.com/role/RedeemableNonControllingInterestsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of redeemable non-controlling interests", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical", "http://www.concentra.com/role/RelationshipwithSelectDetails", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails", "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r285", "r387", "r505", "r506", "r533", "r540", "r593", "r594", "r595", "r596", "r597", "r617", "r619", "r647" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical", "http://www.concentra.com/role/RelationshipwithSelectDetails", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails", "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r213", "r214", "r505", "r506", "r507", "r508", "r533", "r540", "r593", "r594", "r595", "r596", "r597", "r617", "r619", "r647" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.concentra.com/role/RelationshipwithSelectDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r285", "r623", "r624", "r627" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical", "http://www.concentra.com/role/RelationshipwithSelectDetails", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails", "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r285", "r387", "r505", "r506", "r533", "r540", "r593", "r594", "r595", "r596", "r597", "r617", "r619", "r647", "r891" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/RelationshipwithSelect" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship with Select", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r502", "r503", "r504", "r506", "r509", "r583", "r584", "r585", "r625", "r626", "r627", "r645", "r646" ] }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on other debt", "label": "Repayments of Debt and Lease Obligation", "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on related party revolving promissory note", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r121" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on term loans", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r121" ] }, "cghp_ReportableSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "ReportableSegmentMember", "presentation": [ "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable Segment", "label": "Reportable Segment [Member]", "documentation": "Reportable Segment" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r728", "r738", "r748", "r780" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r729", "r739", "r749", "r781" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r736", "r746", "r756", "r788" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r105", "r134", "r537", "r572", "r574", "r582", "r601", "r704" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r168", "r217", "r218", "r219", "r221", "r226", "r228", "r230", "r287", "r288", "r305", "r425", "r426", "r428", "r429", "r430", "r432", "r437", "r438", "r451", "r453", "r454", "r456", "r458", "r490", "r493", "r569", "r571", "r588", "r931" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails": { "parentTag": "cghp_AdjustedEbitda", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/RevenueDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r154", "r155", "r249", "r257", "r258", "r272", "r278", "r281", "r283", "r284", "r378", "r379", "r521" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.concentra.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r167", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r380" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r797" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r797" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of accrued and other liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of accumulated other comprehensive income (loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r18", "r884", "r885" ] }, "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of cash flow hedging instruments, statements of financial performance and financial position, location", "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.concentra.com/role/LongTermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of long-term debt and notes payable", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r16", "r41", "r44", "r89", "r132", "r133", "r678", "r680", "r828", "r887" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of derivative instruments, effect on other comprehensive income (loss)", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.concentra.com/role/DerivativesInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of derivative instruments", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r14", "r70", "r71", "r72", "r73", "r76", "r78", "r80", "r82" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.concentra.com/role/EarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of computation of basic and diluted earnings per share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r833" ] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Type and Tier Identifier [Axis]", "label": "Insurance Type and Tier Identifier [Axis]", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r153" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.concentra.com/role/LongTermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of principal maturities of long-term debt and notes payable", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.concentra.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Operation, Product Information, Concentration of Risk [Table]", "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.concentra.com/role/AcquisitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of recognized identified assets acquired and liabilities assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r136" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.concentra.com/role/RelationshipwithSelectDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r87", "r88", "r623", "r624", "r627" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r28", "r29", "r30" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.concentra.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of selected financial data for reportable segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r28", "r29", "r30" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r39", "r40", "r41", "r42", "r43", "r44", "r129", "r132", "r133", "r134", "r178", "r179", "r180", "r251", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r578", "r579", "r580", "r581", "r682", "r809", "r823" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": [ "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities [Table]", "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": [ "r60", "r61", "r63", "r65", "r66", "r440", "r441", "r445", "r446", "r517", "r518", "r519" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": [ "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtNarrativeDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Term Loan", "terseLabel": "Term Loan", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r722" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r724" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.concentra.com/role/RevenueDetails", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r154", "r155", "r156", "r157", "r249", "r253", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r284", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r304", "r313", "r314", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r666", "r669", "r670", "r675", "r708", "r895", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": [ "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of property and equipment", "label": "Segment, Expenditure, Addition to Long-Lived Assets", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": [ "r249", "r267", "r278", "r669", "r670" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r157", "r249", "r252", "r253", "r254", "r255", "r256", "r268", "r270", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r665", "r667", "r668", "r669", "r671", "r672", "r673" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "calculation": { "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expenses", "label": "Segment Reporting, Other Segment Item, Amount", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": [ "r249", "r270", "r271", "r278", "r669" ] }, "cghp_SelectMedicalCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "SelectMedicalCorporationMember", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Select Medical Corporation", "label": "Select Medical Corporation [Member]", "documentation": "Select Medical Corporation [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails", "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.concentra.com/role/AccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r125", "r210" ] }, "us-gaap_StandbyLettersOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandbyLettersOfCreditMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standby letters of credit", "label": "Standby Letters of Credit [Member]", "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation." } } }, "auth_ref": [ "r0", "r855", "r926", "r927" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.concentra.com/role/RevenueDetails", "http://www.concentra.com/role/SegmentInformationReconciliationofAdjustedEBITDAtoIncomeBeforeTaxesDetails", "http://www.concentra.com/role/SegmentInformationSelectedFinancialDataDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r154", "r155", "r156", "r157", "r170", "r249", "r253", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r284", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r304", "r306", "r313", "r314", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r666", "r669", "r670", "r675", "r708", "r895", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r103", "r106", "r107", "r168", "r194", "r195", "r196", "r217", "r218", "r219", "r221", "r226", "r228", "r230", "r250", "r287", "r288", "r305", "r369", "r425", "r426", "r428", "r429", "r430", "r432", "r437", "r438", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r480", "r482", "r483", "r484", "r485", "r486", "r490", "r493", "r501", "r545", "r569", "r570", "r571", "r588", "r642" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r217", "r218", "r219", "r250", "r493", "r521", "r577", "r589", "r592", "r593", "r594", "r595", "r596", "r597", "r600", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r614", "r615", "r616", "r617", "r619", "r621", "r622", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r642", "r714" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofOperationsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r217", "r218", "r219", "r250", "r285", "r493", "r521", "r577", "r589", "r592", "r593", "r594", "r595", "r596", "r597", "r600", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r614", "r615", "r616", "r617", "r619", "r621", "r622", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r642", "r714" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r731", "r741", "r751", "r783" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of LLC to Corporation and Impact of Reverse Stock Split (in shares)", "terseLabel": "Select special stock distribution (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r13", "r41", "r102", "r103", "r134" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r13", "r134" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of LLC to Corporation and impact of reverse stock split", "terseLabel": "Conversion of LLC to Corporation and impact of reverse stock split", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r13", "r103", "r106", "r107", "r134" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r13", "r102", "r103", "r134" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r103", "r106", "r107", "r126", "r602", "r618", "r643", "r644", "r704", "r721", "r825", "r841", "r883", "r931" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeAOCIRollforwardDetails", "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.concentra.com/role/CondensedConsolidatedStatementsofChangesinEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r56", "r57", "r67", "r168", "r169", "r195", "r217", "r218", "r219", "r221", "r226", "r228", "r287", "r288", "r305", "r369", "r425", "r426", "r428", "r429", "r430", "r432", "r437", "r438", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r480", "r482", "r486", "r491", "r501", "r570", "r571", "r586", "r602", "r618", "r643", "r644", "r653", "r720", "r825", "r841", "r883", "r931" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r487", "r512" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r487", "r512" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r487", "r512" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r487", "r512" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.concentra.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r487", "r512" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.concentra.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r511", "r513" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SwapMember", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesDetails", "http://www.concentra.com/role/AccumulatedOtherComprehensiveIncomeReclassificationsfromACOIDetails", "http://www.concentra.com/role/DerivativesInstrumentsDerivativeImpactonStatementsofIncomeandComprehensiveIncomeDetails", "http://www.concentra.com/role/DerivativesInstrumentsScheduleofDerivativesDetails", "http://www.concentra.com/role/FairValueofFinancialInstrumentsScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swap contracts", "label": "Swap [Member]", "documentation": "A forward-based contract in which two parties agree to swap streams of payments over a specified period. The payment streams are based on an agreed-upon (or notional) principal amount. The term notional is used because swap contracts generally involve no exchange of principal at either inception or maturity. Rather, the notional amount serves as a basis for calculation of the payment streams to be exchanged." } } }, "auth_ref": [ "r141", "r607", "r611", "r616", "r633", "r639", "r651", "r652", "r713" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r777" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.concentra.com/role/AccruedandOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r93", "r94" ] }, "cghp_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.concentra.com/20250331", "localname": "TermLoanMember", "presentation": [ "http://www.concentra.com/role/LongTermDebtComponentsofLongTermDebtAndNotesPayableDetails", "http://www.concentra.com/role/LongTermDebtPrincipalMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r769" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r776" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r796" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r798" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.concentra.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r799" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r800" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r800" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r798" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r798" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r801" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r799" ] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeAndTierIdentifierDomain", "presentation": [ "http://www.concentra.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type and Tier Identifier [Domain]", "label": "Type and Tier Identifier [Domain]", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r153" ] }, "us-gaap_UndistributedEarningsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsAbstract", "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undistributed Earnings, Basic [Abstract]", "label": "Undistributed Earnings, Basic [Abstract]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r795" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.concentra.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r161", "r162", "r163", "r164" ] }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": [ "http://www.concentra.com/role/VariableInterestEntities" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Variable Interest Entity Disclosure [Text Block]", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": [ "r137" ] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation": [ "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r440", "r441", "r445", "r446", "r517", "r518", "r519" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.concentra.com/role/VariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r60", "r440", "r441", "r445", "r446" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.concentra.com/role/LeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.concentra.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r500", "r703" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r765" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r234", "r244" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.concentra.com/role/EarningsperShareComputationofEPSUndertheTwoClassMethodDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r232", "r244" ] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "calculation": { "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.concentra.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on extinguishment of debt", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r116" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r763" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "68B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-68B" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Paragraph": "2AA", "Subparagraph": "(a)", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481161/840-30-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r808": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60" }, "r809": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479455/805-10-15-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 97 0002014596-25-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0002014596-25-000022-xbrl.zip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�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�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cghp-20250331_htm.xml IDEA: XBRL DOCUMENT 0002014596 2025-01-01 2025-03-31 0002014596 2025-04-30 0002014596 2025-03-31 0002014596 2024-12-31 0002014596 2024-01-01 2024-03-31 0002014596 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0002014596 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0002014596 us-gaap:CommonStockMember 2024-12-31 0002014596 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002014596 us-gaap:RetainedEarningsMember 2024-12-31 0002014596 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0002014596 us-gaap:ParentMember 2024-12-31 0002014596 us-gaap:NoncontrollingInterestMember 2024-12-31 0002014596 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0002014596 us-gaap:ParentMember 2025-01-01 2025-03-31 0002014596 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0002014596 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0002014596 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0002014596 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0002014596 us-gaap:CommonStockMember 2025-03-31 0002014596 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0002014596 us-gaap:RetainedEarningsMember 2025-03-31 0002014596 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0002014596 us-gaap:ParentMember 2025-03-31 0002014596 us-gaap:NoncontrollingInterestMember 2025-03-31 0002014596 us-gaap:MemberUnitsMember 2023-12-31 0002014596 us-gaap:RetainedEarningsMember 2023-12-31 0002014596 us-gaap:ParentMember 2023-12-31 0002014596 us-gaap:NoncontrollingInterestMember 2023-12-31 0002014596 2023-12-31 0002014596 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0002014596 us-gaap:ParentMember 2024-01-01 2024-03-31 0002014596 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0002014596 us-gaap:MemberUnitsMember 2024-01-01 2024-03-31 0002014596 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0002014596 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0002014596 us-gaap:CommonStockMember 2024-03-31 0002014596 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0002014596 us-gaap:RetainedEarningsMember 2024-03-31 0002014596 us-gaap:ParentMember 2024-03-31 0002014596 us-gaap:NoncontrollingInterestMember 2024-03-31 0002014596 2024-03-31 0002014596 us-gaap:NonrelatedPartyMember 2025-01-01 2025-03-31 0002014596 us-gaap:NonrelatedPartyMember 2024-01-01 2024-03-31 0002014596 cghp:OccupationalHealthCentersMember 2025-03-31 0002014596 cghp:OnsiteHealthClinicsMember 2025-03-31 0002014596 cghp:ConcentraGroupHoldingsParentMember cghp:SelectMedicalCorporationMember 2024-11-25 2024-11-25 0002014596 us-gaap:SwapMember 2025-01-01 2025-03-31 0002014596 cghp:CollarMember 2025-01-01 2025-03-31 0002014596 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-03-31 0002014596 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-12-31 0002014596 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:RelatedPartyMember 2025-03-31 0002014596 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:RelatedPartyMember 2024-12-31 0002014596 cghp:A6.875SeniorNotesDueJuly152032Member us-gaap:SeniorNotesMember 2025-03-31 0002014596 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-03-31 0002014596 cghp:TermLoanMember us-gaap:SecuredDebtMember 2025-03-31 0002014596 us-gaap:NotesPayableOtherPayablesMember 2025-03-31 0002014596 cghp:A6.875SeniorNotesDueJuly152032Member us-gaap:SeniorNotesMember 2024-12-31 0002014596 cghp:TermLoanMember us-gaap:SecuredDebtMember 2024-12-31 0002014596 us-gaap:NotesPayableOtherPayablesMember 2024-12-31 0002014596 us-gaap:SecuredDebtMember 2024-07-26 0002014596 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-07-26 0002014596 us-gaap:StandbyLettersOfCreditMember us-gaap:LineOfCreditMember 2024-07-26 0002014596 us-gaap:RevolvingCreditFacilityMember cghp:ConcentraRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-03-01 2025-03-31 0002014596 us-gaap:RevolvingCreditFacilityMember cghp:ConcentraRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-02-28 0002014596 us-gaap:RevolvingCreditFacilityMember cghp:ConcentraRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-03-31 0002014596 us-gaap:RevolvingCreditFacilityMember cghp:ConcentraRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-02-28 2025-02-28 0002014596 us-gaap:SecuredDebtMember cghp:ConcentraTermLoanMember us-gaap:LineOfCreditMember 2025-03-01 2025-03-31 0002014596 us-gaap:SecuredDebtMember cghp:ConcentraTermLoanMember us-gaap:LineOfCreditMember 2025-03-31 0002014596 us-gaap:SecuredDebtMember cghp:ConcentraRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-02-28 2025-02-28 0002014596 us-gaap:SecuredDebtMember cghp:ConcentraRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-03-01 2025-03-31 0002014596 us-gaap:LetterOfCreditMember cghp:ConcentraRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-03-31 0002014596 cghp:ConcentraCreditFacilitiesMember us-gaap:LineOfCreditMember 2024-07-26 2024-07-26 0002014596 us-gaap:OtherCurrentAssetsMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherCurrentAssetsMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherCurrentAssetsMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:OtherCurrentAssetsMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:SwapMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:OtherCurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherCurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherCurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:OtherCurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:OtherNoncurrentLiabilitiesMember cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 cghp:CollarMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeniorNotesMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:LineOfCreditMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:LineOfCreditMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:LineOfCreditMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:LineOfCreditMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2025-03-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2024-12-31 0002014596 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:SecuredDebtMember 2024-12-31 0002014596 cghp:OccupationalHealthCenterWorkersCompensationMember 2025-01-01 2025-03-31 0002014596 cghp:OccupationalHealthCenterWorkersCompensationMember 2024-01-01 2024-03-31 0002014596 cghp:OccupationalHealthCenterEmployerServicesMember 2025-01-01 2025-03-31 0002014596 cghp:OccupationalHealthCenterEmployerServicesMember 2024-01-01 2024-03-31 0002014596 cghp:OccupationalHealthCenterConsumerHealthMember 2025-01-01 2025-03-31 0002014596 cghp:OccupationalHealthCenterConsumerHealthMember 2024-01-01 2024-03-31 0002014596 cghp:OccupationalHealthCenterOtherMember 2025-01-01 2025-03-31 0002014596 cghp:OccupationalHealthCenterOtherMember 2024-01-01 2024-03-31 0002014596 cghp:OccupationalHealthCenterMember 2025-01-01 2025-03-31 0002014596 cghp:OccupationalHealthCenterMember 2024-01-01 2024-03-31 0002014596 cghp:OnsiteHealthClinicsMember 2025-01-01 2025-03-31 0002014596 cghp:OnsiteHealthClinicsMember 2024-01-01 2024-03-31 0002014596 cghp:OtherBusinessesMember 2025-01-01 2025-03-31 0002014596 cghp:OtherBusinessesMember 2024-01-01 2024-03-31 0002014596 us-gaap:ProfessionalMalpracticeLiabilityMember 2025-01-01 2025-03-31 0002014596 2024-02-29 0002014596 2025-03-01 2025-03-31 0002014596 cghp:ReportableSegmentMember 2025-01-01 2025-03-31 0002014596 cghp:ReportableSegmentMember 2024-01-01 2024-03-31 0002014596 us-gaap:RelatedPartyMember cghp:ReportableSegmentMember 2025-01-01 2025-03-31 0002014596 us-gaap:RelatedPartyMember cghp:ReportableSegmentMember 2024-01-01 2024-03-31 0002014596 cghp:NovaAcquisitionMember 2025-03-01 2025-03-01 0002014596 cghp:NovaMedicalCentersMember 2025-03-01 2025-03-01 0002014596 cghp:NovaMedicalCentersMember 2025-03-01 0002014596 2025-03-01 2025-03-01 0002014596 2025-03-01 0002014596 cghp:NovaAcquisitionMember 2025-03-01 0002014596 cghp:NovaAcquisitionMember 2025-03-01 2025-03-31 0002014596 cghp:NovaAcquisitionMember 2025-01-01 2025-03-31 0002014596 cghp:NovaAcquisitionMember 2024-01-01 2024-03-31 0002014596 us-gaap:SwapMember 2025-03-31 0002014596 cghp:CollarMember 2025-03-31 0002014596 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0002014596 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0002014596 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-03-31 0002014596 us-gaap:SwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0002014596 cghp:CollarMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0002014596 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-31 0002014596 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0002014596 cghp:OnsiteInnovationsAcquisitionMember us-gaap:SubsequentEventMember 2025-04-18 2025-04-18 0002014596 us-gaap:SubsequentEventMember cghp:OnsiteInnovationsMember 2025-04-18 2025-04-18 0002014596 us-gaap:SubsequentEventMember cghp:OnsiteInnovationsMember 2025-04-18 0002014596 us-gaap:SubsequentEventMember 2025-04-18 2025-04-18 0002014596 us-gaap:SubsequentEventMember 2025-05-06 2025-05-06 shares iso4217:USD iso4217:USD shares cghp:health_center cghp:state cghp:clinic cghp:less_than_wholly_owned_subsidiary pure cghp:patient cghp:class_action_lawsuit cghp:segment cghp:hospital 0002014596 false --12-31 2025 Q1 10-Q true 2025-03-31 false 001-42188 CONCENTRA GROUP HOLDINGS PARENT, INC. DE 30-1006613 5080 Spectrum Drive Suite 1200W Addison TX 75001 972 364-8000 Common Stock, par value $0.01 per share CON NYSE Yes Yes Non-accelerated Filer false false false 128171952 52109000 183255000 258128000 217719000 1392000 1544000 39960000 34689000 351589000 437207000 463032000 435595000 207271000 197930000 1444563000 1234707000 249788000 204725000 12995000 11000000 2729238000 2521164000 96301000 75442000 15758000 10093000 35188000 19752000 8010000 0 165134000 201899000 320391000 307186000 405914000 396914000 1618473000 1468917000 24362000 25380000 29037000 24043000 2398177000 2222440000 18609000 18013000 0.01 0.01 700000000 700000000 128171952 128171952 128125952 128125952 1282000 1281000 263105000 260837000 44454000 13553000 -1722000 0 307119000 275671000 5333000 5040000 312452000 280711000 2729238000 2521164000 500752000 467598000 357101000 336990000 46713000 36909000 16619000 18485000 420433000 392384000 0 284000 80319000 75498000 -875000 0 25548000 111000 0 9971000 53896000 65416000 13254000 15137000 40642000 50279000 1731000 1323000 38911000 48956000 0.30 0.30 0.47 0.47 3700000 3800000 40642000 50279000 -1808000 0 -86000 0 -574000 -1722000 0 38920000 50279000 1731000 1323000 37189000 48956000 128126000 1281000 260837000 13553000 0 275671000 5040000 280711000 38911000 38911000 38911000 0 -293000 -293000 0.0625 8010000 8010000 8010000 46000 1000 -1000 0 0 2269000 2269000 2269000 -1722000 -1722000 -1722000 128172000 1282000 263105000 44454000 -1722000 307119000 5333000 312452000 447081000 470303000 685293000 1155596000 5366000 1160962000 48956000 48956000 48956000 0 -270000 -270000 6891000 6891000 6891000 0 369000 369000 -1901000 -1901000 -1901000 -447081000 -463412000 104094000 1041000 462371000 0 0 104094000 1041000 462371000 732348000 1195760000 5267000 1201027000 40642000 50279000 16619000 18485000 51000 0 1000 -43000 2269000 166000 976000 0 -1028000 -2521000 -11000 -12000 21145000 13505000 2753000 7315000 -902000 -722000 -24844000 -1744000 11699000 44622000 279018000 5144000 15732000 17231000 1000 23000 -294749000 -22352000 50000000 0 0 10000000 0 10000000 948848000 0 847875000 0 6468000 6618000 4695000 2276000 842000 1543000 0 6891000 151904000 -4092000 -131146000 18178000 183255000 31374000 52109000 49552000 38137000 9958000 -48000 34000 Organization<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentra Group Holdings Parent, Inc., a Delaware corporation, conducts substantially all of its business through Concentra Health Services, Inc. (“CHSI”) and its subsidiaries. As the context may require, the “Company,” “we,” “our” or similar words in this report refer collectively to Concentra and its subsidiaries.</span></div>The Company is the largest provider of occupational health services in the United States based on number of locations. As of March 31, 2025, we operated 627 stand-alone occupational health centers in 41 states and 160 onsite health clinics at employer worksites in 36 states. The Company provides a diverse and comprehensive array of occupational health services, including workers’ compensation and employers services, and consumer health services. 627 41 160 36 Accounting Policies<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operated as part of Select Medical Corporation (“Select”) until Select made a special stock distribution of 104,093,503 shares of the Company’s common stock to Select’s stockholders (the “Distribution”) on November 25, 2024. The Company’s consolidated financial statements prior to the Distribution have been prepared from Select’s historical accounting records and derived from the condensed consolidated financial statements of Select to present the Company as if it had been operating on a standalone basis. The unaudited condensed consolidated financial statements of the Company as of March 31, 2025, and for the three months ended March 31, 2025 and 2024, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the full fiscal year ended December 31, 2025. These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (File No. 001-42188).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the assets, liabilities, revenue, and expenses based on our legal entity structure as well as direct and indirect costs that are attributable to our operations. Indirect costs are the costs of support functions that are partially provided on a centralized basis by Select and its affiliates, which include finance, human resources, benefits administration, procurement support, information technology, legal, corporate governance and other professional services. Indirect costs were allocated to the Company, prior to the IPO, for the purposes of preparing the consolidated financial statements based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method, primarily based on headcount or other allocation methodologies that are considered to be a reasonable reflection of the utilization of services provided or the benefit received by the Company during the periods presented, depending on the nature of the services received. Subsequent to the IPO, the support services provided by Select have been billed to the Company pursuant to a transitional services agreement, as further described in Note 11—“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationship with Select”.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax amounts in these condensed consolidated financial statements prior to the Distribution have been calculated based on a separate return methodology and are presented as if our income gave rise to separate federal and state consolidated income tax return filing obligations in the respective jurisdictions in which we operate. Adjustments to income tax expense resulting from the application of the separate return methodology, as compared to tax obligations determined by the Company’s inclusion in Select’s consolidated income tax provision, were assumed to be immediately settled with Select through contributed capital/capital in excess of par as reflected on the condensed consolidated balance sheets, and reflected as a (distribution)/contribution to Select on the condensed consolidated statements of changes in stockholders’/members’ equity and the condensed consolidated statements of cash flows within financing activities. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and the subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions within the Company are eliminated in consolidation. Transactions between the Company and Select have been included in these condensed consolidated financial statements. The transactions with Select are settled in cash, other than the assumed income tax settlement noted above, and are reflected within the condensed consolidated statement of cash flows as an operating or financing activity determined by the nature of the transaction.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks relating to its ongoing financial arrangements. The primary risk managed using derivative instruments is to reduce variability in interest cash flows on its variable-rate debt. Interest rate swaps and collars are entered into to manage interest rate risk associated with the Company’s variable-rate debt. As a matter of policy, we do not use highly leveraged derivative instruments, nor do we use financial instruments for speculative purposes.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 815 requires entities to recognize all derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our designated derivative contracts include interest rate swap and collar agreements, which effectively modify the Company’s exposure to interest rate risk by converting the Company’s floating-rate debt to a fixed-rate basis (for interest rate swap arrangements) and capping and flooring the interest rates (for collar arrangements) for the next three years, thus reducing the impact of interest-rate changes on future interest expense. These agreements involve the receipt of floating-rate amounts in exchange of fixed-rate interest payments and the application of cap and floor rates over the term of the agreements without an exchange of the underlying principal amount.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivatives are designated as cash flow hedges and qualify for hedge accounting treatment. Gains or losses on cash flow hedges are deferred as a component of accumulated other comprehensive income or losses and reclassified into earnings at the time the hedged item affects earnings, presented in the same income statement line item as the underlying hedged item (i.e., in “interest expense” when the hedged transactions are interest cash flows associated with floating-rate debt).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for hedge accounting, a specified level of hedge effectiveness between the hedging instrument and the hedged item must be achieved at inception and maintained throughout the hedged period. We formally document our risk management objectives, our strategies for undertaking the hedge transactions, the nature of and relationships between the hedging instruments and hedged items, and the method for assessing hedge effectiveness. Additionally, for qualified hedges of forecasted transactions, we specifically identify the significant characteristics and expected terms of the forecasted transactions. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it becomes probable that a forecasted transaction will not occur, previously deferred gains and losses related to those forecasted transactions would be recognized in earnings in the current period.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU is effective for the Company’s annual financial statements for the year ended December 31, 2025. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have on the disclosures in our consolidated financial statements. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense Disaggregation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve the disclosures of expenses by providing more </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">detailed information about the types of expenses in commonly presented expense captions. The ASU requires entities to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption; as well as a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendment also requires disclosure of the total amount of selling expense and, in annual reporting periods, an entity’s definition of selling expenses.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2024-03 will have on the disclosures in our consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.</span></div> <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operated as part of Select Medical Corporation (“Select”) until Select made a special stock distribution of 104,093,503 shares of the Company’s common stock to Select’s stockholders (the “Distribution”) on November 25, 2024. The Company’s consolidated financial statements prior to the Distribution have been prepared from Select’s historical accounting records and derived from the condensed consolidated financial statements of Select to present the Company as if it had been operating on a standalone basis. The unaudited condensed consolidated financial statements of the Company as of March 31, 2025, and for the three months ended March 31, 2025 and 2024, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the full fiscal year ended December 31, 2025. These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (File No. 001-42188).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the assets, liabilities, revenue, and expenses based on our legal entity structure as well as direct and indirect costs that are attributable to our operations. Indirect costs are the costs of support functions that are partially provided on a centralized basis by Select and its affiliates, which include finance, human resources, benefits administration, procurement support, information technology, legal, corporate governance and other professional services. Indirect costs were allocated to the Company, prior to the IPO, for the purposes of preparing the consolidated financial statements based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method, primarily based on headcount or other allocation methodologies that are considered to be a reasonable reflection of the utilization of services provided or the benefit received by the Company during the periods presented, depending on the nature of the services received. Subsequent to the IPO, the support services provided by Select have been billed to the Company pursuant to a transitional services agreement, as further described in Note 11—“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationship with Select”.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax amounts in these condensed consolidated financial statements prior to the Distribution have been calculated based on a separate return methodology and are presented as if our income gave rise to separate federal and state consolidated income tax return filing obligations in the respective jurisdictions in which we operate. Adjustments to income tax expense resulting from the application of the separate return methodology, as compared to tax obligations determined by the Company’s inclusion in Select’s consolidated income tax provision, were assumed to be immediately settled with Select through contributed capital/capital in excess of par as reflected on the condensed consolidated balance sheets, and reflected as a (distribution)/contribution to Select on the condensed consolidated statements of changes in stockholders’/members’ equity and the condensed consolidated statements of cash flows within financing activities. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and the subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions within the Company are eliminated in consolidation. Transactions between the Company and Select have been included in these condensed consolidated financial statements. The transactions with Select are settled in cash, other than the assumed income tax settlement noted above, and are reflected within the condensed consolidated statement of cash flows as an operating or financing activity determined by the nature of the transaction.</span></div> 104093503 <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and the subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions within the Company are eliminated in consolidation. Transactions between the Company and Select have been included in these condensed consolidated financial statements. The transactions with Select are settled in cash, other than the assumed income tax settlement noted above, and are reflected within the condensed consolidated statement of cash flows as an operating or financing activity determined by the nature of the transaction.</span></div> <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks relating to its ongoing financial arrangements. The primary risk managed using derivative instruments is to reduce variability in interest cash flows on its variable-rate debt. Interest rate swaps and collars are entered into to manage interest rate risk associated with the Company’s variable-rate debt. As a matter of policy, we do not use highly leveraged derivative instruments, nor do we use financial instruments for speculative purposes.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 815 requires entities to recognize all derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our designated derivative contracts include interest rate swap and collar agreements, which effectively modify the Company’s exposure to interest rate risk by converting the Company’s floating-rate debt to a fixed-rate basis (for interest rate swap arrangements) and capping and flooring the interest rates (for collar arrangements) for the next three years, thus reducing the impact of interest-rate changes on future interest expense. These agreements involve the receipt of floating-rate amounts in exchange of fixed-rate interest payments and the application of cap and floor rates over the term of the agreements without an exchange of the underlying principal amount.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivatives are designated as cash flow hedges and qualify for hedge accounting treatment. Gains or losses on cash flow hedges are deferred as a component of accumulated other comprehensive income or losses and reclassified into earnings at the time the hedged item affects earnings, presented in the same income statement line item as the underlying hedged item (i.e., in “interest expense” when the hedged transactions are interest cash flows associated with floating-rate debt).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for hedge accounting, a specified level of hedge effectiveness between the hedging instrument and the hedged item must be achieved at inception and maintained throughout the hedged period. We formally document our risk management objectives, our strategies for undertaking the hedge transactions, the nature of and relationships between the hedging instruments and hedged items, and the method for assessing hedge effectiveness. Additionally, for qualified hedges of forecasted transactions, we specifically identify the significant characteristics and expected terms of the forecasted transactions. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it becomes probable that a forecasted transaction will not occur, previously deferred gains and losses related to those forecasted transactions would be recognized in earnings in the current period.</span></div> P3Y P3Y <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU is effective for the Company’s annual financial statements for the year ended December 31, 2025. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have on the disclosures in our consolidated financial statements. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense Disaggregation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve the disclosures of expenses by providing more </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">detailed information about the types of expenses in commonly presented expense captions. The ASU requires entities to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption; as well as a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendment also requires disclosure of the total amount of selling expense and, in annual reporting periods, an entity’s definition of selling expenses.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2024-03 will have on the disclosures in our consolidated financial statements.</span></div> <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.</span></div> Redeemable Non-Controlling Interests<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s redeemable non-controlling interests are comprised of membership interests held by equity holders other than the Company in five less than wholly-owned subsidiaries. These shares are subject to redemption rights. The changes in redeemable non-controlling interests are as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to redeemable non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to redeemable non-controlling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemption value adjustment on redeemable non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,257 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> Redeemable Non-Controlling InterestsThe Company’s redeemable non-controlling interests are comprised of membership interests held by equity holders other than the Company in five less than wholly-owned subsidiaries. These shares are subject to redemption rights. 5 The changes in redeemable non-controlling interests are as follows:<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to redeemable non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to redeemable non-controlling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemption value adjustment on redeemable non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,257 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 18013000 16477000 1438000 1053000 842000 1174000 0 -1901000 18609000 18257000 Variable Interest Entities<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices that directly employ physicians and from exercising control over medical decisions by physicians. In these states, the Company enters into long-term management agreements with affiliated professional medical groups (referred to as “Managed PCs”) that are owned by licensed physicians which, in turn, employ or contract with physicians who provide professional medical services in its occupational health centers. The Company also enters into a stock transfer restriction agreement with the respective equity holders, which provide for the Company to direct the transfer of ownership of the Managed PCs to other licensed physicians at any time. The long-term management agreements provide for various administrative and management services to be provided by the Company to the Managed PCs, including, but not limited to, billing and collections, accounting, non-physician personnel, supplies, security and maintenance, and insurance. The Company has the right to receive income as an ongoing management fee, and effectively absorbs all of the residual interests of the Managed PCs. Based on the provisions of the management and stock transfer agreements, the Managed PCs are variable interest entities for which the Company is the primary beneficiary and consolidates the Managed PCs under the variable interest entity model. There are no restrictions on the use of the assets of the Managed PCs or on the settlement of its liabilities. Additionally, the Company fully indemnifies the licensed physician owners from all claims, demands, costs, damages, losses, liabilities, and other amounts arising from the ownership and operation of the medical practices, excluding gross negligence.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, and December 31, 2024, the total assets of the Company’s variable interest entities were $235.3 million and $213.9 million, respectively, and are principally comprised of accounts receivable. As of March 31, 2025, and December 31, 2024, the total liabilities of the Company’s variable interest entities were $51.8 million and $57.5 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of $180.9 million and $157.0 million as of March 31, 2025, and December 31, 2024, respectively. These intercompany balances are eliminated in consolidation.</span></div> Variable Interest Entities<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices that directly employ physicians and from exercising control over medical decisions by physicians. In these states, the Company enters into long-term management agreements with affiliated professional medical groups (referred to as “Managed PCs”) that are owned by licensed physicians which, in turn, employ or contract with physicians who provide professional medical services in its occupational health centers. The Company also enters into a stock transfer restriction agreement with the respective equity holders, which provide for the Company to direct the transfer of ownership of the Managed PCs to other licensed physicians at any time. The long-term management agreements provide for various administrative and management services to be provided by the Company to the Managed PCs, including, but not limited to, billing and collections, accounting, non-physician personnel, supplies, security and maintenance, and insurance. The Company has the right to receive income as an ongoing management fee, and effectively absorbs all of the residual interests of the Managed PCs. Based on the provisions of the management and stock transfer agreements, the Managed PCs are variable interest entities for which the Company is the primary beneficiary and consolidates the Managed PCs under the variable interest entity model. There are no restrictions on the use of the assets of the Managed PCs or on the settlement of its liabilities. Additionally, the Company fully indemnifies the licensed physician owners from all claims, demands, costs, damages, losses, liabilities, and other amounts arising from the ownership and operation of the medical practices, excluding gross negligence.</span></div> 235300000 213900000 51800000 57500000 180900000 157000000.0 Leases<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s total lease cost is as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> Leases<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s total lease cost is as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s total lease cost is as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,988 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 27317000 24790000 58000 211000 -2000 55000 5615000 5256000 32988000 30312000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Term Debt</span><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company’s long-term debt is as follows:</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Premium (Discount)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,658,846 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(956)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,659)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634,231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, principal maturities of the Company’s long-term debt and notes payable are as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt, including finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,811 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,967 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,983 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,555,940 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,658,846 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company’s long-term debt and notes payable are as follows:</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Premium (Discount)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">847,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(995)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,503,398 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(995)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,393)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,479,010 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.</span></div><div style="margin-bottom:1pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2024, Concentra Health Services, Inc. (“CHSI”), a wholly-owned subsidiary of Concentra, entered into a senior secured credit agreement (the “Credit Agreement”) that provides for an $850.0 million term loan (the “Term Loan”), and a $400.0 million revolving credit facility, including a $75.0 million sublimit for the issuance of standby letters of credit (the “Revolving Credit Facility” and, together with the Term Loan, the “Credit Facilities”). In March 2025, the Company completed an amendment to the Credit Agreement to increase our Revolving Credit Facility by $50.0 million from $400.0 million to $450.0 million. The interest rate for the Revolving Credit Facility has been reduced from Term SOFR plus 2.50% to Term SOFR plus 2.00%, subject to a leverage-based pricing grid. In addition, the amendment to the Credit Agreement also added new debt through an incremental term loan of $102.1 million, which provides an updated Term Loan of $950.0 million. The Term Loan interest rate has been reduced from Term SOFR plus 2.25% down to Term SOFR plus 2.00%, subject to a leverage-based pricing grid including 25-basis point step down at a net leverage ratio of ≤3.25x. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2025, the Company had $386.4 million of availability under its Revolving Credit Facility after giving effect to $50.0 million of borrowings under the Revolving Credit Facility and $13.6 million of outstanding letters of credit. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities require CHSI to maintain a leverage ratio (as defined in the Credit Agreement), which is tested quarterly and currently must not be greater than 6.50 to 1.00. As of March 31, 2025, the Company was in compliance with all debt covenants.</span></div> <div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company’s long-term debt is as follows:</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Premium (Discount)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,658,846 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(956)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,659)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634,231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company’s long-term debt and notes payable are as follows:</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Premium (Discount)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">847,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(995)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,503,398 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(995)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,393)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,479,010 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)        Other debt is primarily comprised of insurance financing arrangements, promissory notes executed in connection with business combinations, and finance leases.</span></div> 0.06875 650000000 0 11533000 638467000 50000000 0 0 50000000 950000000 956000 12126000 936918000 8846000 0 0 8846000 1658846000 956000 23659000 1634231000 <div style="margin-bottom:9pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, principal maturities of the Company’s long-term debt and notes payable are as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt, including finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,811 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,967 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,983 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,555,940 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,658,846 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.06875 0 0 0 0 0 650000000 650000000 0 0 0 0 50000000 0 50000000 7125000 9500000 9500000 9500000 9500000 904875000 950000000 5369000 1311000 467000 483000 151000 1065000 8846000 12494000 10811000 9967000 9983000 59651000 1555940000 1658846000 0.06875 650000000 0 11925000 638075000 847875000 995000 11468000 835412000 5523000 0 0 5523000 1503398000 995000 23393000 1479010000 850000000 400000000 75000000 50000000 400000000 450000000 0.0250 0.0200 102100000 950000000 0.0225 0.0200 0.0025 3.25 386400000 50000000 13600000 6.50 Accrued and Other Liabilities<div style="margin-bottom:9pt;margin-top:9pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of accrued and other liabilities on the condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,134 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,899 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> <div style="margin-bottom:9pt;margin-top:9pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of accrued and other liabilities on the condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:22.5pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,134 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,899 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 42999000 75657000 43909000 43647000 9695000 21849000 52003000 58396000 16528000 2350000 165134000 201899000 Fair Value of Financial Instruments<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 1 – inputs are based upon quoted prices for identical instruments in active markets. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s derivative instruments are based on quotes from the market makers that derive fair values from market data, and therefore, are classified as Level 2.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the Credit Facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the Concentra senior notes is based on quoted market prices. The carrying value of the Company’s other debt, as disclosed in Note 6—“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”, approximates fair value. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any Level 3 financial assets or liabilities in any period presented.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values and the levels within the fair value hierarchy of financial instruments recorded on the condensed consolidated balance sheets were (in thousands):</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collar contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collar contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current liability</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total collar contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947,625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company’s other financial instruments, which primarily consist of cash, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values and the levels within the fair value hierarchy of financial instruments recorded on the condensed consolidated balance sheets were (in thousands):</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collar contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collar contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current liability</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total collar contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.875% senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947,625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 347000 347000 0 0 -1759000 -1759000 0 0 -1412000 -1412000 0 0 -121000 -121000 0 0 -763000 -763000 0 0 -884000 -884000 -2296000 -2296000 0 0 0.06875 638467000 657150000 638075000 660972000 50000000 49465000 0 0 936918000 947625000 835412000 853174000 Revenue <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s revenue for the three months ended March 31, 2025 and 2024: </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Occupational health centers:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Workers’ compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employer services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other occupational health center revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total occupational health center revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472,922 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,072 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onsite health clinics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s revenue for the three months ended March 31, 2025 and 2024: </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Occupational health centers:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Workers’ compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employer services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other occupational health center revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total occupational health center revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472,922 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,072 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onsite health clinics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 302107000 279866000 160140000 150735000 8611000 8326000 2064000 2145000 472922000 441072000 16550000 15857000 11280000 10669000 500752000 467598000 Earnings per Share<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the three months ended March 31, 2025, the Company applied the two-class method because its unvested restricted shares were participating securities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company’s capital structure consists of common stock and there were no participating shares or securities outstanding. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net income attributable to the Company, its shares, and its participating shares: </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and Diluted EPS</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to non-controlling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to the Company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: distributed and undistributed income attributable to participating securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributed and undistributed income attributable to common shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,456 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table set forth the computation of EPS. For the three months ended March 31, 2025, the Company applied the two-class method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to the Company</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and Diluted EPS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to the Company</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and Diluted EPS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Participating securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,911 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Represents the weighted average shares outstanding during the period.</span></div> <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net income attributable to the Company, its shares, and its participating shares: </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and Diluted EPS</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to non-controlling interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to the Company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: distributed and undistributed income attributable to participating securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributed and undistributed income attributable to common shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,456 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table set forth the computation of EPS. For the three months ended March 31, 2025, the Company applied the two-class method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to the Company</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and Diluted EPS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to the Company</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and Diluted EPS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Participating securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,911 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,956 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Represents the weighted average shares outstanding during the period.</span></div> 40642000 50279000 1731000 1323000 38911000 48956000 455000 455000 455000 455000 0 0 38456000 38456000 48956000 48956000 38456000 38456000 126647000 126647000 0.30 0.30 48956000 48956000 104094000 104094000 0.47 0.47 455000 455000 455000 455000 1500000 0.30 0.30 38911000 48956000 Relationship with Select<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, Concentra became a fully independent company upon the completion of the Distribution and Select ceased to be a related party on that date. The Company continues to have material agreements with Select, including a separation agreement, a transition services agreement, a tax matters agreement and an employee matters agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shared Services Agreement and Transition Services Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays Select a fee for the shared support functions provided on a centralized basis by Select and its affiliates. Prior to the IPO, the shared services fee was governed by a shared services agreement between the Company and Select which was reassessed and adjusted annually. The transition services agreement, which became effective concurrent with the IPO, now provides the framework for the services provided by Select and the applicable fee for such services. For the three months ended March 31, 2025, the transaction services agreement fees were $3.7 million, and for the three months ended March 31, 2024, the shared service fees from a related party were $3.8 million.</span></div> 3700000 3800000 Commitments and Contingencies<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various legal actions, proceedings, and claims, and regulatory and other governmental audits and investigations in the ordinary course of its business, including, but not limited to, legal actions and claims alleging professional malpractice, general liability for property damage, personal and bodily injury, violations of federal and state employment laws, often in the form of wage and hour class action lawsuits, and liability for data breaches. Many of these actions involve large claims and significant defense costs and sometimes, as in the case of wage and hour class actions, are not covered by insurance. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating. The Company currently maintains insurance coverages under a combination of policies with a total annual per claim aggregate limit of $29.0 million for professional malpractice liability insurance and general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. In addition, the Company purchases additional primary care limits in certain patient compensation fund states, including Indiana, Kansas, Louisiana, Nebraska, Pennsylvania and Wisconsin. The Company also maintains additional types of liability insurance covering claims that, due to their nature or amount, are not covered by or not fully covered by the applicable professional malpractice and general liability insurance policies, including workers compensation, property and casualty, directors and officers, cyber liability, and employment practices liability insurance coverages. Our insurance policies generally are silent with respect to punitive damages so coverage is available to the extent insurable under the law of any applicable jurisdiction, and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Department of Insurance Investigation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company received a subpoena from the California Department of Insurance relating to an investigation under the California Insurance Frauds Prevention Act, Cal. Ins. Code § 1871.7 et seq., which allows a whistleblower to file a false claims lawsuit based on the submission of false or fraudulent claims to insurance companies. The subpoena seeks documentation relating mainly to the Company’s billing and coding for physical therapy claims submitted to commercial insurers and workers’ compensation carriers located or doing business in California. The Company has produced data and other documents requested by the California Department of Insurance and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Perry Johnson &amp; Associates, Inc. Data Breach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On November 10, 2023, Perry Johnson &amp; Associates, Inc., a third-party vendor of health information technology solutions that provides medical transcription services (“PJ&amp;A”), notified CHSI that certain information related to particular Concentra patients was potentially affected by a cybersecurity event. In February 2024, </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentra sent notices to almost four million patients who may have been impacted by the data breach. During the first quarter of 2024, Concentra became aware of six putative class action lawsuits filed against PJ&amp;A and Concentra related to the data breach. Five of the putative class action lawsuits have been transferred to the U.S. District Court for the Eastern District of New York and consolidated with the one class action lawsuit pending there. Plaintiffs filed a Consolidated Class Action Complaint on August 19, 2024 against PJ&amp;A, Concentra, Select Medical Holdings Corporation and other unrelated defendants under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Perry Johnson &amp; Associates Medical Transcription Data Security Breach Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“Consolidated Complaint”). The Consolidated Complaint alleges that the plaintiffs have suffered injuries and damages under theories of negligence, breach of contract, and failure to comply with statutory duties, including duties under HIPAA, FTC guidelines and industry standards, and various state consumer protection and deceptive trade practice laws. In March 2025, pursuant to a Case Management Order (“Court Order”), five of the named plaintiffs in the Consolidated Complaint filed an amended Direct-Filed Class Action Complaint in the U.S. District Court for the Eastern District of New York. Pursuant to this Court Order, the Direct-Filed Class Action Complaint will be remanded to the United States District Court for the Northern District of Texas after the conclusion of pretrial proceedings. The Company is working with its cybersecurity risk insurance policy carrier and does not believe that the data breach or the lawsuits will have a material impact on its operations or financial performance. However, at this time, the Company is unable to predict the timing and outcome of these matters.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physical Therapy Billing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2021, Select Medical Corporation (“Select”), the former parent of the Company, received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services (“HHS”), is investigating Select in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, et seq. The letter specified that the investigation relates to Select’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from Select. Although the DOJ’s initial requests involved Select’s outpatient therapy clinics, in 2022 and 2023, the DOJ sought and the Company produced additional data and documents relating to the physical therapy services furnished by the Company. In May 2024, by order of the U.S. District Court for the Middle District of Florida, a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit that is related to the DOJ’s investigation was unsealed after the U.S. filed a notice declining to intervene in the case. The lawsuit, filed in May 2021 and amended in October 2021, was brought by Kathleen Kane, a physical therapist formerly employed in Select’s outpatient division, against Select Medical Corporation, Select Physical Therapy Holdings, Inc. and Select Employment Services, Inc., but does not name the Company as a defendant. The amended complaint alleges that the defendants billed Federally funded health programs for one-on-one therapy services when group therapy was performed or overbilled for one-on-one therapy services, billed for unreimbursable unskilled physical therapy services, and submitted claims containing signatures of therapists who did not provide the billed services. The Company is fully cooperating on this investigation, but at this time, is unable to predict the timing and outcome of this matter.</span></div> 29000000.0 4000000 6 5 1 5 <div style="margin-bottom:9pt;margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.    Segment Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is organized into three operating segments based primarily on the type or location of occupational health services provided: (i) occupational health centers, (ii) onsite health clinics, and (iii) other businesses. All three operating segments are aggregated into a single reportable segment in our consolidated financial statements based on similar services provided, service delivery process involved, target customers, and similar economic characteristics. Across our operating segments, we offer a diverse and comprehensive array of services, which includes workers’ compensation, employer services and consumer health. Our patients are generally employed by our main customers - employers across the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Occupational health services are focused on the diagnosis and treatment of work-related injuries and illnesses (workers’ compensation services) and employer services such as examinations, physicals, tests and screenings, vaccinations, and a range of consulting services designed to protect employees from workplace hazards.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chief operating decision maker (“CODM”) is our Chief Executive Officer. The CODM uses Segment Adjusted EBITDA in the annual budgeting and forecasting process, in the review of budget-to-actual and prior year variances to make decisions about the allocation of operating and capital resources, and to establish management’s compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is representative of the significant categories, including significant expenses, regularly provided to the CODM when managing the Company’s single reporting segment.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facility expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,093 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,659 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,729,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,366,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Includes transaction services agreement fees of $3.7 million and shared services fees from a related party $3.8 million for the three months ended March 31, 2025 and 2024, respectively. See Note 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Relationship with Select</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">”, for additional information. </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment Adjusted EBITDA is calculated as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, acquisition costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles Segment Adjusted EBITDA to income before income taxes for the periods indicated.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,548)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense on related party debt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on early retirement of debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nova acquisition costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,416 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations.</span></div> 3 3 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is representative of the significant categories, including significant expenses, regularly provided to the CODM when managing the Company’s single reporting segment.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facility expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398,093 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,659 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,729,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,366,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Includes transaction services agreement fees of $3.7 million and shared services fees from a related party $3.8 million for the three months ended March 31, 2025 and 2024, respectively. See Note 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Relationship with Select</span>”, for additional information. 500752000 467598000 281658000 268372000 48382000 43805000 68053000 59279000 398093000 371456000 102659000 96142000 2729238000 2366162000 15732000 17231000 16619000 18485000 3700000 3800000 <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles Segment Adjusted EBITDA to income before income taxes for the periods indicated.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,548)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense on related party debt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on early retirement of debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nova acquisition costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,416 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, and system implementation costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations.</span></div> 102659000 96142000 25548000 111000 0 9971000 -875000 0 2269000 166000 16619000 18485000 315000 1993000 3137000 0 53896000 65416000 <div style="margin-bottom:9pt;margin-top:9pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.    Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nova Acquisition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective March 1, 2025, the Company acquired Nova Medical Centers (“Nova”). CHSI entered into an equity purchase agreement to acquire all of the outstanding membership interests for a purchase price of approximately $265 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. We financed the transaction using a combination of $102.1 million of new debt financing under the Credit Agreement, $50.0 million of available borrowing capacity under our existing Revolving Credit Facility, and the remaining with cash on hand. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nova operates 67 occupational health centers in five states, providing workers’ compensation injury care services, physical therapy, drug and alcohol screening, and pre-employment physicals as part of their full suite of occupational health services. The acquisition enabled the Company to expand to more than 775 occupational health centers and onsite health clinics at employer worksites in 42 states.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nova acquisition met the definition of a business pursuant to Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, and the acquisition was accounted for as a business combination under the acquisition method of accounting. The Company allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary estimated fair values. The fair values are based on inputs that are unobservable in the market and therefore represent Level 3 inputs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of completing its assessment of the acquisition-date fair values of the assets acquired and liabilities assumed and determining the estimated useful lives of long-lived assets and finite-lived intangible assets; therefore, the values set forth are subject to adjustment during the measurement period. The amount of these potential adjustments could be significant. The Company expects to complete its purchase price allocation activities by December 31, 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to ASC Topic 810, Consolidation, certain Nova affiliated entities were determined to be a variable interest entity, and the Company was determined to be their primary beneficiary. As a result, the Company obtained a controlling financial interest and Nova has been consolidated into the Company's financial results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable tangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,771 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration given</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,171 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary estimate for goodwill of $205.6 million has been recognized for the business combination, representing the excess of the consideration given over the fair value of identifiable net assets acquired. The value of goodwill is derived from Nova’s future earnings potential and its assembled workforce. The amount of goodwill is expected to be deductible for tax purposes. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period March 1, 2025 through March 31, 2025, Nova had total revenue and net income of $11.2 million and $1.2 million, respectively, which was included in the condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro Forma Results</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited consolidated pro forma financial results combine the historical results of Nova and the Company to present the results as if the Nova acquisition had occurred on January 1, 2024. The pro forma information is presented for illustration purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition occurred on that date, nor is it indicative of future results. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:58.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">499,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to the Company</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma financial information is based on the preliminary allocation of the purchase price of the Nova acquisition and is therefore subject to adjustment upon finalizing the purchase price allocation, as described above, during the measurement period. The net income tax impact was calculated at the effective tax rate, as Nova had been a subsidiary of the Company as of January 1, 2024. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma results were adjusted to exclude acquisition-related expenses incurred by the Company that are directly attributable to the transaction. These excluded costs primarily consist of legal, advisory, and transaction-related compensation expenses that are nonrecurring in nature and not reflective of the ongoing operations of the combined business.</span></div> 265000000 102100000 50000000 67 5 775 42 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable tangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,771 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration given</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,171 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 45667000 38471000 205633000 289771000 24600000 265171000 205600000 11200000 1200000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited consolidated pro forma financial results combine the historical results of Nova and the Company to present the results as if the Nova acquisition had occurred on January 1, 2024. The pro forma information is presented for illustration purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition occurred on that date, nor is it indicative of future results. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:58.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">499,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to the Company</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 522111000 499991000 43400000 50935000 Derivative Instruments<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company uses derivative instruments to manage its exposure to variable-rate debt indexed to 1-month Term SOFR, issued under its Tranche B-1 Term Loans drawn from the Company’s Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information related to our derivatives contracts is presented below (in thousands):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cap</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Floor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Actual Termination Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Swap contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3/3/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">300,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3.829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">USD-SOFR rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2/29/2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Collar contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3/3/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3.001 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">USD-SOFR rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2/29/2028</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedge Coverage</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into interest rate swap and collar agreements designated as cash flow hedges. These agreements are used to manage interest rate risk associated with a portion of the Company’s floating-rate debt for periods not exceeding the next three years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Hedging Gains and Losses on Cash Flow Hedges</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our valuation at March 31, 2025 and assuming market rates remain constant through contract maturities, we expect transfers to earnings of the existing gains or losses reported in accumulated other comprehensive income on interest rate cash flow hedges during the next 12 months to correspond to the current and non-current assets and liabilities portion of the derivative as disclosed in Note 8—“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Impact on the Statements of Comprehensive Income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of derivative gains or losses deferred into accumulated other comprehensive income and the income statement line item that will be affected when reclassified to earnings (in thousands):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Accumulated Other Comprehensive Income Component (OCI)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Location of Gains/(Losses) When Reclassified to Net Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Three Months Ended March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:5.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:5.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Collar contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Total (losses)/gains recognized in statements of comprehensive income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2,296)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Impact on the Statements of Income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the pre-tax amounts of derivative gains or (losses) recorded to earnings and the affected income statement line items (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total amounts presented in the condensed consolidated statements of income in which the following effects were recorded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains/(losses) related to derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collar contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains/(losses) recognized in statements of income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Represents the pre-tax amounts of derivative gains/(losses) reclassified from accumulated other comprehensive income to earnings.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, there are no payments required to be exchanged under this agreement.</span></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information related to our derivatives contracts is presented below (in thousands):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cap</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Floor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Actual Termination Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Swap contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3/3/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">300,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3.829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">USD-SOFR rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2/29/2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Collar contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3/3/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3.001 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">USD-SOFR rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2/29/2028</span></td></tr></table></div> 300000000 0.03829 300000000 0.04500 0.03001 P3Y <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the pre-tax amounts of derivative gains or losses deferred into accumulated other comprehensive income and the income statement line item that will be affected when reclassified to earnings (in thousands):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Accumulated Other Comprehensive Income Component (OCI)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Gains/(Losses) Recognized in OCI Related to Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Location of Gains/(Losses) When Reclassified to Net Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Three Months Ended March 31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:5.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:5.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Collar contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Total (losses)/gains recognized in statements of comprehensive income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2,296)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> -1412000 -884000 -2296000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the pre-tax amounts of derivative gains or (losses) recorded to earnings and the affected income statement line items (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total amounts presented in the condensed consolidated statements of income in which the following effects were recorded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains/(losses) related to derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collar contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains/(losses) recognized in statements of income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Represents the pre-tax amounts of derivative gains/(losses) reclassified from accumulated other comprehensive income to earnings.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, there are no payments required to be exchanged under this agreement.</span></div> 115000 0 115000 Accumulated Other Comprehensive Income<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of, and changes in, accumulated other comprehensive income, net of tax, were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Net Cash Flow </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Hedge Adjustments</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred (losses)/gains on cash flow hedges</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred gains/(losses) on cash flow hedges reclassified to net income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount and related tax benefit/(expense) recorded in, and associated with, each component of other comprehensive income were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Before Tax Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net of Tax Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Net deferred (losses)/gains on cash flow hedges</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Net deferred gains/(losses) on cash flow hedges reclassified to net income</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">86 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified from accumulated other comprehensive income were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (OCI) Component</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassified from Accumulated OCI to Earnings for the Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Statements of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Gains/(losses) on cash flow hedges:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Swap contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Collar contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Gains/(losses) on hedges before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Gains on hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">86 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">____________________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, no amounts have been reclassified from OCI to earnings.</span></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of, and changes in, accumulated other comprehensive income, net of tax, were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Net Cash Flow </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Hedge Adjustments</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred (losses)/gains on cash flow hedges</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred gains/(losses) on cash flow hedges reclassified to net income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount and related tax benefit/(expense) recorded in, and associated with, each component of other comprehensive income were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Before Tax Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net of Tax Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Net deferred (losses)/gains on cash flow hedges</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Net deferred gains/(losses) on cash flow hedges reclassified to net income</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">86 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 0 -1808000 -86000 -1722000 -2411000 -603000 -1808000 -115000 -29000 -86000 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified from accumulated other comprehensive income were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (OCI) Component</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassified from Accumulated OCI to Earnings for the Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Statements of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Gains/(losses) on cash flow hedges:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Swap contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Collar contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Gains/(losses) on hedges before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Gains on hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">86 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">____________________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    As of the reporting date, the 1-month Term SOFR remains within the specified cap strike and floor strike bands. Consequently, no amounts have been reclassified from OCI to earnings.</span></div> -115000 0 -115000 29000 -86000 Subsequent Events <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Purchase Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2025, CHSI entered into an equity purchase agreement with Pivot Occupational Health, LLC to acquire all of the outstanding equity interests of Onsite Innovations, LLC (“Pivot Onsite Innovations”). The transaction values Pivot Onsite Innovations at $55 million, subject to adjustment in accordance with the terms and conditions set forth in the purchase agreement. The transaction is expected to close in the second quarter of 2025 and is subject to customary closing conditions set forth in the purchase agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHSI currently expects to finance the transaction using a combination of cash on hand and available borrowing capacity under its existing Revolving Credit Facility.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pivot Onsite Innovations operates approximately 200 onsite health clinics at employer locations in over 40 states, providing occupational health, wellness, prevention, and performance services. When combined with Concentra’s current onsite health clinic footprint, the acquisition will enable the Company to expand to more than 350 onsite health clinics at employer worksites. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2025, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable May 29, 2025, to stockholders of record as of the close of business on May 20, 2025.</span></div> 55000000 200 40 350 0.0625 false false false false Includes transaction services agreement fees of $3.7 million for the three months ended March 31, 2025, and shared service fees from a related party of $3.8 million for the three months ended March 31, 2024. See Note 11—“Relationship with Select”, for additional information.

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�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